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Abstract 
Background. Knee osteoarthritis (OA) can result in considerable pain 
and disability for some people. Inflammation within the joint may be 
partly responsible for the pain associated with OA and a link between 
inflammation and disease progression has been suggested.  Ultrasound 
(US) imaging has been successfully employed in the evaluation of knee 
joint effusion, synovial hypertrophy and power doppler signal (PDS) 
which are said to represent joint inflammation. The associations 
between US features of inflammation, knee pain and radiographic OA 
have yet to be firmly established. 
Objectives. The objectives of this thesis were to compare the 
frequency of US features of inflammation in 4 groups from a community 
sample, [1] those with normal knees (controls) [2] knee pain - without 
radiographic OA (KP) [3] radiographic OA (without pain)  (ROA) and [4] 
symptomatic OA (SOA). Associations between US features,  knee pain, 
radiographic change and clinical signs of inflammation could then be 
explored. Secondary objectives were to determine if US features 
change in tandem with fluctuations in knee pain (1) over time and (2) 
with improved pain following a therapeutic intervention in people with 
SOA.  
Methods.  In a cross-sectional multiple group comparison study, 243 
participants were divided into 4 groups based on the presence of 
absence of knee pain and ROA. All underwent an US examination for 
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effusion, synovial hypertrophy, peri-articular cysts and PDS. The 
presence or absence of features, absolute measures (millimetres) and 
grade of PDS (0-3) was recorded for both knees. Radiographs and 
clinical evaluation of knee pain, biomechanical stiffness and function 
were also undertaken.  
Follow-up examination of control and SOA groups was undertaken at 3 
months. Participants with SOA were then invited to take part in a 
randomised placebo-controlled study of intra-articular (IA) cortico-
steroid and a saline placebo. 
Results.  The frequency of US features in the control group (effusions 
(29%) synovial hypertrophy (8%), popliteal cysts (12%) and PD signal 
(2%)) was not significantly different from those in the KP group. US 
features were more common in ROA and higher again in SOA (effusion 
81% and 92% respectively, synovial hypertrophy 41% and 82%, 
popliteal cysts 22% and 39%). PDS was not significantly different 
between ROA (6.3%) and SOA (16%). 
Synovial hypertrophy was the only US feature independently associated 
with knee pain after adjusting for ROA (aOR 6.6; 95% CI 2.85, 15.11).  
All grey-scale features were strongly associated with ROA and 
remained so after adjusting for pain (effusion
 
aOR 13.39, 95%CI 6.14, 
29.02; synovial hypertrophy
 
aOR 14.39, 95%CI 6.28, 32.94; popliteal 
cysts
 
aOR 2.82, 95%CI 0.76, 10.43). PDS was not association with 
either knee pain or radiographic OA. 
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Change in pain severity was not found to correlate with and change in 
US measures among the participants followed up at 3 months or 
following improved pain among participants in the intervention study.  
Conclusion.  These findings show that US features suggestive of 
inflammation are higher in participants with SOA but was only 
significant for synovial hypertrophy. Synovial hypertrophy was 
confirmed as an independent risk factor for knee pain but was not found 
to be responsive to temporal changes in pain or improved pain following 
an IA cortico-steroid or placebo injection. Further studies to understand 
the contribution of US features of inflammation to pain in knee OA are 
warranted.   
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1 Introduction 
This chapter lays out the rationale for the studies undertaken for this 
PhD. The chapter commences with a description of osteoarthritis (OA) 
and describes the current burden of the disease in the United Kingdom 
and worldwide. Risk factors for the development and progression of the 
disease are outlined, and the pathology of the disease is described and 
current theories regarding the patho-aetiology, particularly that of joint 
inflammation are discussed. The use of ultrasound (US) as a measure 
for evaluating joint inflammation is discussed in terms of the metrics of 
a good outcome measure, the prevalence of ultrasound features in 
patient populations and the relationships between ultrasound features, 
clinical symptoms and structural pathology. An overview of current 
guidelines on the management of OA is presented. Finally the aims and 
objectives of this current work are presented. 
 
1.1 Osteoarthritis (OA)  
Arthritis is a large and growing public health burden throughout the 
world and OA is the major source of that burden (Brooks 2006). 
Lifetime risk for the development of symptomatic OA suggests that 
nearly 1 in 2 people are at risk of painful knee OA (Murphy, Schwartz et 
al. 2008) and 1 in 4  for painful hip OA (Murphy, Helmick et al. 2006).  
In the United States it is estimated that some 27 million adults have 
clinical OA in one or more joints (Lawrence, Felson et al. 2008) and in 
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the UK 10% of all musculoskeletal consultations with GPs reportedly 
are for OA (Parsons and Symmons 2010).  
To many, OA is recognised as an age-related painful joint condition 
affecting the hips, knees or  hands that is accompanied by structural 
changes on x-rays resulting in loss of function and ultimately ending in 
joint replacement (in the case of hip and knee joints) (Figure 1-1).  
However, although the prevalence and incidence of OA certainly 
increases with age, it is not an inevitable consequence of aging and 
while pain and disability can be devastating for some, structural 
changes can occur without symptoms in others. 
Figure 1-1 Tibio-femoral x-ray showing osteophytes and joint space narrowing 
(JSN) of the medial tibio-femoral compartment 
 
 
Despite its associations with loss of function and disability, OA has 
been conserved throughout our evolutionary history and is also present 
in other animals with synovial joints (Hutton 1987; Rogers and Dieppe 
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1994). Clinically OA is now recognised as a syndrome of joint pain, 
rather than a single disease entity, that presents with a variety of signs 
and symptoms triggered by an initial mechanical or biological insult 
(Table 1-1).  
Table 1-1 Common symptoms and signs of OA 
Symptoms Signs 
Pain Crepitus 
Stiffness Restricted movement 
Functional Impairment Tenderness 
Anxiety, depression Bony swelling 
 Deformity 
 Muscle wasting/weakness 
 Soft tissue swelling 
 Increased joint temperature 
 Joint instability 
 
OA can affect any synovial joint but typically affects the large weight-
bearing joints in the lower limb and the interphalangeal joints of the 
hand.  Prevalence rates for OA vary in their estimates but all rise with 
age, are higher in women than men and are higher for radiographic OA 
compared to symptomatic OA.  Radiographic hand OA has been 
reported in as many as 67% of women over 55 years but symptomatic 
disease is present in around just 9% (Arden and Nevitt 2006).  Knee 
OA is less frequent, with around 42% of women and 31% of  men 
showing radiographic changes and pain affecting around half of these 
(Peat, McCarney et al. 2001; Arden and Nevitt 2006; Dillon, Rasch et 
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al. 2006).  Hip OA is less common again with rates of 3-5% in the 
elderly (Arden and Nevitt 2006).  
Incidence rates for radiographic and symptomatic OA also increase with 
age and are higher for women. Most published data has been on the 
knee joint where the incidence of new radiographic OA is around 2%, 
symptomatic OA around 1% and progression in around 2.5-3% per year 
(Felson, Zhang et al. 1995; Cooper, Snow et al. 2000). Incidence rates 
are higher in those with knee pain at baseline and are higher in the 
patello-femoral joint (9.6%) than the tibio-femoral joint (7.2%) (Duncan, 
Peat et al. 2011). 
 
1.2 Knee OA  
Defining knee OA has been dogged by the common discordance 
between symptoms and radiographic evidence of the condition. Clinical 
criteria for the classification of knee OA have been published by the 
American College of Rheumatology (Altman, Asch et al. 1986). Pain is 
the major inclusion factor and is required on most days of the previous 
month. Other symptoms include crepitus on movement, morning 
stiffness of less than 30 minutes, age over 50, bony tenderness, bony 
enlargement and no palpable warmth of which 3 items are required. 
However, these criteria have been criticised for reflecting more 
advanced disease and poor agreement with radiographic OA, therefore 
under-estimating the true prevalence of the condition. This has been 
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borne out by several epidemiological studies. The Chingford study, for 
example, reported the prevalence of clinical symptomatic OA to be 
2.3% in a cohort of women aged between 45 and 65, but 
radiographically defined OA was present in 17% (Hart, Spector et al. 
1991). A later cross-sectional study of adults with knee pain found that 
only 41% of people with symptomatic radiographic OA fulfilled the ACR 
clinical criteria for knee OA (Peat, Thomas et al. 2006). 
Radiographs remain the cornerstone of defining knee OA in most 
population studies and are usually considered alongside the absence or 
presence of symptoms leading to the use of the separate terms 
radiographic OA (ROA) and symptomatic OA (SOA) respectively. 
However controversies also exist in the use of radiographs particularly 
with respect to the scoring methods employed. The most widely used is 
the Kellgren and Lawrence (K&L) grading scheme which awards a 
global score from 0 to 4 based on the presence of several features as 
listed in Table 1-2 (Ball, Jeffrey et al. 1963).  
However, it has been criticised for several reasons. Firstly, it gives 
emphasis to the presence of osteophytes over joint space narrowing 
and secondly, assumes a fixed sequence of development and hierarchy 
of change. Importantly the original atlas also omits the patello-femoral 
joint, a compartment with a reported prevalence of isolated SOA of 8% 
in women and 2% in men (McAlindon, Snow et al. 1992) and the site in 
which it is suggested that knee OA is most likely to start (Duncan, Peat 
et al. 2011).  Furthermore, differences between grades tend to be gross 
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reducing the ability to detect early radiographic features and 
responsiveness over time.  
Table 1-2 Kellgren & Lawrence grading system for OA  
Grade  Description 
Grade 0 Normal 
Grade 1 Doubtful narrowing of joint space, possible osteophyte 
Grade 2 Definite osteophyte, possible narrowing 
Grade 3 Moderate multiple osteophytes, definite narrowing, some sclerosis, 
possible deformity of bone ends 
Grade 4 Large osteophytes, marked narrowing, severe sclerosis, definite 
deformity of bone ends 
 
Efforts to improve on this have been made with the development of 
photographic atlases (Altman, Hochberg et al. 1995) but these have 
also had  issues in terms of using an ordinal and not interval grading of 
features and a lack of  skyline views for the patello-femoral joint. More 
recently an atlas of logically devised line drawings has been developed 
(LDA) (Nagaosa, Mateus et al. 2000; Wilkinson, Carr et al. 2005). 
Advantages over other grading systems include illustrations for normal 
shape and joint space width for men and women, maximum osteophyte 
representation and mathematically calculated intervals for joint space 
width and size of osteophyte.  Despite this, the K&L system with various 
adjustments remains the most widely used and reported. However, lack 
of a universally agreed consistent method for scoring and defining 
radiographic knee OA remains an issue. 
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Although most epidemiological studies focus on the prevalence of ROA 
it has been suggested that prevalence of knee pain is more important 
for healthcare planning and delivery (Peat, McCarney et al. 2001). In 
the UK, 1 in 3 people over the age of 40 years old develops significant 
knee pain within 12 years and the annual incidence is about 3% 
(Ingham, Zhang et al. 2011).  The estimated prevalence of knee pain in 
WKH RYHU ¶V LV EHWZHHQ % and 28% with around half of these 
reporting a resulting disability and a similar proportion showing ROA 
(McAlindon, Cooper et al. 1992; Tennant, Fear et al. 1995; O'Reilly, 
Muir et al. 1996). The prevalence staircase shown in Figure 1-2 
summarises the UK estimates of knee pain, ROA and disability for older 
adults (Peat, McCarney et al. 2001). Prevalence of disability is 50% 
higher in those with bilateral compared to unilateral symptoms (White, 
Zhang et al. 2010).  
Figure 1-2 Prevalence staircase (Peat G et al 2001; permission granted). 
 
Shading represents the proportion in each category with radiographic evidence 
of knee osteoarthritis. *The proportion with radiographic evidence in this 
category is not known, though seems likely to be high. 
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1.3 Risk factors for knee OA and knee pain 
Large scale population studies have identified risk factors for both the 
development and progression of knee OA. They can be broadly 
categorised into systemic factors which increase an individual¶s 
susceptibility to OA, and mechanical factors that interfere with the joint 
integrity and function (Figure 1-3) (Arden and Nevitt 2006). In reality, 
however, these factors are not always discrete from each other and 
frequently interact to modify overall risk. Risk factors for the 
development of structural knee OA may differ from those for 
progression of structural change and these are outlined in Table 1-3 
(Doherty M. 2001). The complexity of the disease is further 
compounded  by the fact that knee pain and the resultant  disability also 
have a number of different risk factors, including poor self-efficacy, 
depression and anxiety (McAlindon, Cooper et al. 1992; McAlindon, 
Cooper et al. 1993; Odding, Valkenburg et al. 1998; Sharma, Cahue et 
al. 2003). 
Figure 1-3 Risk factors for Knee OA 
 
 
 
 
 
Susceptibility           Mechanical factors 
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Table 1-3 Risk factors for development and progression of knee OA 
Development Progression 
Heredity (unidentified genetic factors) Obesity 
Ageing Low bone density 
Female sex Low intake of vitamins C and D 
Heberden's node/hand OA Indomethacin (possibly other non-
steroidal anti-inflammatory drugs)  
Obesity  
High bone density  
Trauma/meniscectomy/ligament rupture Instability 
Varus/valgus laxity Varus/valgus malalignment 
Occupation/sports 
3URIHVVLRQDOVRFFHUPLQLQJ 
5epetitive knee bending (especially   
     carrying loads) 
Chondrocalcinosis/calcium 
pyrophosphate crystal deposition  
Quadriceps weakness Knee effusion/warmth  
 
1.3.1 Systemic risk factors  
Increasing age, female gender and obesity are well recognised as risk 
factors for the onset of knee OA.  Age and gender were first confirmed 
as risk factors by the Framingham cohort study (Felson, Naimark et al. 
1987) and later the associations with obesity were recognised 
(Anderson and Felson 1988; Felson, Anderson et al. 1988).  More 
recently a systematic review and meta-analysis has confirmed these as 
important risk factors for the onset of OA (Blagojevic, Jinks et al. 2010). 
Pooled odds ratio (OR) for knee OA conferred an increased risk for 
women of 1.81 (95% CI, 1.32 -2.55). Pooled OR for age was not 
possible due to the varied categorisation used to report age but the 
methodological quality of the studies and overall agreement in the 
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direction of risk led the authors to conclude that older age was an 
important risk factor (Blagojevic, Jinks et al. 2010). 
Increased BMI imparts its risk for knee OA primarily as a mechanical 
factor. Pooled OR for BMI >30 compared to a normal BMI were 2.63 
(95% CI, 2.28-3.05 (Blagojevic, Jinks et al. 2010). The result was 
supported by a more recent meta-analysis, where pooled OR was 3.91 
(95%CI 3.32 ± 4.56) with more studies included (Muthuri, Hui et al. 
2011). Furthermore it was estimated that about 50% of knee OA in the 
US and 42% in the UK may be avoided should obesity be prevented in 
the population. Obesity is also associated with hand OA which would 
suggest that its mechanism of action is not entirely biomechanical.  
Obesity is known to contribute to an inflammatory systemic environment 
which has a catabolic effect on cartilage metabolism. The presence of 
circulating cytokines and adipokines are elevated in obese individuals 
and are associated with cartilage degeneration (Lee and Kean 2012).  
Odds ratios for the onset of knee OA for those with hand OA is 1.49 
(95% CI, 1.05- 2.10) (Blagojevic, Jinks et al. 2010). 
Other reported systemic factors include genetics, hormonal status in 
women and nutrition. Familial clustering of knee and hand OA has long 
been recognised and siblings of people with symptomatic knee OA are 
almost 3 times more likely to have the condition compared to age and 
sex matched individuals from the community (Neame, Muir et al. 2005). 
Multiple genes are likely to contribute to the overall susceptibility and 
environmental factors will also interact and modulate their effects 
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(Spector and MacGregor 2004).  Polymorphisms of certain common 
genes are now being identified, and most of those identified significant 
associations by genome wide studies, such as growth differentiation 
factor 5 (GDF5), may influence early development and growth of the 
musculoskeletal system suggesting that variation in growth and shape 
of bones and joints biomechanically may help explain some of the 
recognised heritability of OA (Sandell 2012).  
The rise of incident OA in women after menopausal age is suggestive 
of a role for reduced sex hormones as a risk factor (Arden and Nevitt 
2006) and this is strengthened by studies which report that hormone 
replacement therapy confers a negative effect on the risk of incident 
ROA (Spector, Nandra et al. 1997) and increased cartilage volumes on 
MRI (Wluka, Davis et al. 2001). 
The role of nutrition in the development of OA is also an area of 
growing interest.  While poor nutrition from an unhealthy diet is often 
associated with obesity which imparts an increased risk of OA, the 
potentially beneficial effects of specific nutritional components are less 
clear. Vitamins C and E are thought to protect against oxidative stress 
which has been proposed to prevent the normal division of 
chondrocytes during cartilage turnover (McAlindon and Biggee 2005). 
This in turn may contribute to the incidence and progression of OA. 
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1.3.2 Mechanical risk factors 
As previously stated obesity is perhaps the most convincing risk factor 
for knee OA. Its primary mechanism is via the overloading of the joint 
during weight-bearing activities and this is evident from the dose-
response increase in risk for the development of knee OA. Pooled odds 
ratios for risk increase from  2.18 (95 CI, 1.86-2.55) for BMI > 25 
(overweight) to 2.63 (95% CI, 2.28-3.05) for  BMI > 30 (obese) 
compared to a normal BMI (Blagojevic, Jinks et al. 2010). 
Joint injury is also widely accepted as a risk factor for knee OA. The 
disruption of normal joint biomechanics, joint stability, proprioceptive 
sensibility and muscle strength can all lead to abnormal loading on the 
joint and recurrent micro trauma which may contribute to the risk of 
onset of OA. One study reported the risk of OA as nearly five times 
higher for those with a history of previous knee injury (OR 4.8 (95% CI 
1.0-24)) (Cooper, Snow et al. 2000). The results were confirmed by a 
recent meta-analysis of 24 observational studies (7 cohort studies, 5 
cross-sectional studies and 12 case controlled studies).  Pooled OR 
was 4.20 (95%CI 3.11-5.66), with 3.74 (95%CI 2.16-6.74) for cohort 
studies, 3.34 (5%CI 1.95-5.75) for cross sectional studies and 5.34 
(95%CI 3.16-9.02) for case control studies respectively (Muthuri, 
McWilliams et al. 2011). 
Mechanical mal-alignment of the knee in the frontal plane results in 
either a varus or valgus deformity. Whilst it has not been demonstrated 
that mal-alignment is an independent risk factor for onset of OA 
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(Hunter, Niu et al. 2007) it has been demonstrated as a  risk factor in 
the overweight and obese (Brouwer, Tol et al. 2007). It has also been 
reported as a risk for disease progression in which a four-fold increase 
was observed in individuals with varus mal-alignment  and an almost 
fivefold increase for those with valgus mal-alignment (Sharma 2001). 
However, a later study reported a smaller risk for varus alignment (OR 
2.9 (95% CI 1.07-8.88) and no increased risk for valgus alignment 
(Brouwer, Tol et al. 2007). More recently an association has been found 
between self-reported varus or valgus knee malalignment during young 
adulthood was and  subsequent development of knee OA in later life 
(McWilliams, Doherty et al. 2010). A higher risk was found for varus 
knee alignment (aOR= 5.16, 95%CI 2.87, 9.41) which was associated 
with medial tibiofemoral OA than valgus alignment (aOR 3.16, 95%CI 
1.04, 9.64) which was associated with lateral tibiofemoral and lateral 
patellofemoral OA.  
Studies of muscle strength agree that quadriceps weakness is 
associated with knee OA and knee pain but it is unclear to what extent 
this is an independent risk factor. A decrease in overall strength occurs 
with normal aging from as early as the third decade but is accelerated 
by as much as 30% per decade after the age of 60 (Murray, Gardner et 
al. 1980). A further decrease in quadriceps strength by as much as 30% 
has been reported in SOA (Messier, Glasser et al. 2002). Whether 
strong quadriceps muscles can negate the risk of OA is not clear.  One 
study reported that although strength was not protective against the 
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development of ROA, it was protective for SOA in women (Segal, 
Torner et al. 2009). 
Occupational loading and leisure activity are also known to be risk 
factors for both incidence and progression. Regular kneeling (OR 3.4, 
95% CI 1.3-9.1) or squatting (OR 6.9, 95% CI 1.8-26.4) for more than 
30  minutes per day, or climbing more than ten flights of stairs per day 
(OR 2.7, 95% CI 1.2-6.1) confer significant risks even after adjusting for 
BMI and hand OA (Cooper, McAlindon et al. 1994). Mixed results have 
been reported for leisure or sports participation. Regular participation in 
sports has been reported as a risk for onset but not for progression 
(Cooper, Snow et al. 2000; Chapple, Nicholson et al. 2011) whereas 
regular physical activity (as opposed to sport) was not found to 
influence the risk in either direction (Felson, Niu et al. 2007). A recent 
meta-analysis which examined a variety of occupational factors from 51 
studies reported the risk of knee OA increased by 60% for all 
occupational risks (McWilliams, Leeb et al. 2011). Any risks associated 
with occupation and leisure activity are likely to be confounded by other 
risk factors, particularly previous injury, muscle strength, BMI and mal-
alignment (McWilliams, Doherty et al. 2010). 
 
1.4 Pathology of OA  
While OA is typically characterised by the degradation and loss of 
articular cartilage, it is now widely appreciated that the processes 
leading to the pathological end point are active, dynamic and involve all 
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the tissues that comprise the organ of the joint (Figure 1-4). What was 
RQFHGHVFULEHGDVDµZHDUDQGWHDU¶SURFHVVLVQRZPRUHDSSURSULDWHO\
UHIHUUHGWRDV³WHDUIODUHDQGUHSDLU´embodying the aetiological role of 
the initial biomechanical insult to the joint, the role of inflammation in 
pain and progression, and the mechanical adaptations of the joint 
tissues to compensate for the initial insult  (Birrell, Howells et al. 2011). 
Figure 1-4 OA joint showing involvement of all joint tissues 
 
The natural history of the condition is slow allowing what is now 
considered an inherent repair process to occur. The remodelling and 
production of new bone and the mechanical adaptations of the joint 
tissue often compensate for the initial insult that triggered the need for 
WKH MRLQW WR UHSDLU ³FRPSHQVDWHG 2$´ For some however, the 
PHGLDWLQJ HIIHFW RI RQH¶V LQGLYLGXDO ULVN IDFWRUV FRXSOHG ZLWK the 
overwhelming insult(s) or continued microtrauma in the joint means  the 
joint cannot compensate effectively and then more commonly may 
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DVVRFLDWHZLWKV\PSWRPVDQGORVVRIIXQFWLRQ³GHFRPSHQVDWHG2$´RU
³MRLQWIDLOXUH´Figure 1-5).  
Figure 1-5 Osteoarthritis as an inherent repair process 
 
1.4.1 Articular cartilage 
Articular cartilage is subject to turnover throughout our lifespan. 
Maintenance of this is controlled by chondrocytes which are both 
mechano-sensitive and osmo-sensitive (Abramson and Attur 2009). 
Under normal conditions they produce aggregan, type II collagen and 
other components that comprise the cartilage matrix and release 
anabolic factors responsible for the growth or stimulation of cartilage 
repair. Under abnormal mechanical stresses, they become stimulated 
to produce a range of catabolic and inflammatory mediators which lead 
to its degradation (Martel-Pelletier, Boileau et al. 2008). This is further 
enhanced by pathological changes in the subchondral bone and 
synovium. 
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The degradation of articular cartilage predominantly affects focal areas 
of cartilage subjected to abnormal mechanical force, with other areas 
remaining intact (Figure 1-6). Progressive changes can then be 
observed in adjacent areas until in advanced OA more of the joint 
surface may be involved (Pritzker, Gay et al. 2006). Histologically, 
oedema and fibrillation of the superficial layers of the cartilage are the 
earliest changes to be seen. Focal lesions within the superficial layer 
and flaking of small fragments of cartilage into the synovial fluid then 
appear as the superficial matrix is exposed to shearing forces across 
the joint. Vertical fissures begin to extend into the mid layers of the 
cartilage which can branch and extend into deeper zones as it 
progresses. Cell death and proliferation can be observed adjacent to 
the fissures. Matrix loss is progressive until the non-mineralised 
articular cartilage is eroded exposing mineralised cartilage or bone.  
Figure 1-6 Medial compartment knee OA showing articular cartilage loss. 
  
Photograph shows medial compartment (MC) OA with loss of articular cartilage 
exposing the underlying bone (thick arrow). Note the normal cartilage at the 
lateral compartment (LC) and trochlea (T). 
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1.4.2 Bony changes 
Osteophyte formation and subchondral sclerosis are the key 
pathological features of the bone in OA (Error! Not a valid bookmark 
self-reference.). The development of osteophytes, bony outgrowths 
capped by fibro-cartilage, may be due a number of processes. 
Osteophytes can be induced by mechanical instability in animal studies 
and it is proposed that they are simply features of remodelling in an 
attempt to stabilise the joint (Aspden 2008). Other theories include the 
abnormal repair of stress fractures in the subchondral bone near the 
joint margins (Abramson and Attur 2009) or as a mechanical response 
to increased loading of the bone at the joint margins transmitted via 
biochemical signalling (Aspden 2008).  
 
Figure 1-7 Bony features of OA  
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Sclerosis describes the radiographic appearance of dense bone tissue 
at the joint margin which may extend into the deeper subchondral bone. 
Sequentially it is detectable after loss of joint space and eburnation of 
the exposed subchondral bone and is thought to represent bone 
remodelling in response to increased stress and micro-fractures. 
Bone marrow lesions (BMLs) represent further pathology of bone in OA.  
These lesions, which are observable on magnetic resonance imaging 
(MRI) represent areas of abnormal bone with excessive fibrosis, focal 
osteonecrosis and remodelling and are consistent with bony trauma 
such as micro-fractures and chronic abnormal loading (Figure 1-8). The 
presence of BMLs is associated with painful knee OA having been 
found in over 75% of persons with symptomatic OA compared to 30% 
of those with asymptomatic disease, and their frequency increases with 
radiographic severity (Felson, Chaisson et al. 2001; Felson, McLaughlin 
et al. 2003). Joint mal-alignment which results in increased abnormal 
loading of the joint is also associated with BMLs in the corresponding 
joint compartment and with progressive joint space narrowing (Felson, 
McLaughlin et al. 2003). The sequence of bony pathology in OA is not 
clear and while many theories suggest they occur in response to 
changes in the articular cartilage they may occur concurrently or even 
precede it (Aspden 2008). 
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Figure 1-8 MRI showing subchondral bone marrow lesion in OA knee (white 
arrowheads). (Roemer, Frobell et al. 2009) permission granted. 
 
 
1.4.3 Synovial and peri-articular pathology 
In addition to the pathological changes occurring within the cartilage 
and bone, changes in other tissues may also contribute to the disease 
process and associated symptoms and disability. The synovium and its 
outer layer the capsule undergo hyperplasia and thickening, excess 
synovial fluid produced by the activated synovium leads to capsular 
swelling. This can cause pain, stiffness and lead to arthrogenic 
inhibition of the quadriceps muscle which in turn can progress to 
muscle weakness and atrophy (Stokes and Young 1984; Hurley and 
Newham 1993). 
Enthesitis has also gained some attention as a possible 
pathoetiological mechanism for OA. Enthesis are the insertion sites of 
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tendons, ligaments, fascia or articular capsule into bone, and their 
function is largely to dissipate biomechanical forces between the joint 
and bone. Pathological changes at the enthesis and adjacent tissues 
are recognised as a common feature within the spondylarthritides, but 
modest changes have also been demonstrated in hand and knee OA. 
Histological changes including synovial villus formation and 
inflammatory cell infiltration were commonly observed in elderly 
cadaveric specimens (Benjamin and McGonagle 2007). Whilst in an 
MRI study, Tan et al (2008) reported enthesopathy almost universally in 
the joints of early and established hand OA, the most common of which 
were changes in the joint collateral ligaments. Subtle ligamentous 
changes were also common in asymptomatic adjacent joints and in the 
joints of older control subjects, which the authors and others suggest 
may play an initiating or modulating role in the pathogenesis of OA or 
represent a subset of OA patients with systemic enthesopathy (Tan, 
Grainger et al. 2005; McGonagle, Tan et al. 2008).  
In SOA knees, MRI scans have found central BMLs adjacent to the 
insertion of the anterior cruciate ligament (ACL) which are highly 
prevalent (54%) and strongly related to ligament pathology, though 
many knees with central BMLs showed no evidence of ACL tear (58%) 
(Hernández-Molina, Guermazi et al. 2008). A subsequent study by 
Gibson et al (2012) was unable to demonstrate an association between 
enthesopathy at the hand and central BMLs at the knee, questioning 
the theory that OA maybe a systemic enthospathic disease and 
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supporting the belief that enthesopathy in OA is  biomechanically 
induced (Gibson, Guermazi et al. 2012; Haugen 2012). 
A recent review also suggested that the infra-patellar fat pad should be 
considered as an active joint tissue in knee OA which is capable of 
influencing the degradation of cartilage by stimulating the production of 
pro-inflammatory mediators (Clockaerts, Bastiaansen-Jenniskens et al. 
2010).  
 
1.5 Inflammation in OA 
1.5.1 Synovitis 
Over the past decade or so, there has been an increasing interest in 
the pathological changes occurring in the synovium and its possible 
role in the onset and progression of the disease. Though not as florid 
as the synovitis observed in rheumatoid arthritis, the synovium and 
outer layer the capsule undergo hyperplasia and thickening and excess 
synovial fluid produced by the activated synovium leads to capsular 
swelling Figure 1-9.  Synovitis is often localised to areas adjacent to 
damaged cartilage, bone or entheses and is generally regarded as a 
secondary response to cartilage and biomechanical insults and 
represents the flare component  in the µWHDU IODUHDQG UHSDLU¶analogy 
(Porcheret, Healey et al. 2011). 
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However, the detection of elevated cytokines early in the disease 
process has led to the suggestion that there may be an underlying 
primary inflammatory process (Aspden, 2008). It has also been 
demonstrated that the synovium itself produces some of the 
chemokines that degrade cartilage (Samuels et al., 2008).  
Arthroscopic evidence of synovitis has been reported in around half of 
patients with symptomatic knee OA and may be predictive of structural 
progression. A prospective study of 422 patients with primary 
symptomatic OA found that those with synovitis on arthroscopy at 
baseline showed greater deterioration in cartilage, compared to those 
with none or mild synovitis after 12 months (Ayral, Pickering et al. 
2005).  
Figure 1-9 Arthroscopic image of synovitis in the knee joint 
 
 
Histological evaluation has demonstrated features of mild synovitis in 
OA including hyperplasia of the synovial lining, increased vascular 
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density and higher density of proliferating cells compared to normal 
controls. The outer layer, the fibrous capsule, shows hyperplasia and 
overall thickening (Pessler, Chen et al. 2008). Synovial biopsies from 
patients with early OA  (defined as knee pain < 1 year, normal 
radiographs and early but defined chondropathy on arthroscopy) 
showed greater evidence of synovitis than  patients with late stage OA 
(undergoing knee joint arthroplasty) (Benito, Veale et al. 2005) 
suggesting that inflammation may be more important in early disease 
and contribute to disease progression in some patients. 
  
1.5.2 Biomarkers 
Biochemical biomarkers are molecules of connective tissue matrices 
released during the process of tissue turnover (Garnero, Piperno et al. 
2001). They hold promise of being useful clinical tools to aid in the 
diagnosis of disease and disease prognosis, monitoring of disease 
progression and response to treatment, as well as helping our 
understanding of the underlying disease mechanisms, particularly 
inflammation.  A range of biochemical markers of bone, synovium and 
cartilage have been measured and reported in OA (Figure 1-10) though 
no definitive markers have yet been identified which could be 
successfully used in research or clinical practice (Doherty, Jones et al. 
2004). 
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Figure 1-10 Potential biomarkers in the osteoarthritis process.(Doherty, Jones 
et al. 2004) 
 
 
Hyaluronic acid (HA) is most commonly associated with synovial tissue. 
It is a glycosaminoglycan produced by fibroblasts and other cells within 
connective tissue. It has a structural role in the connective tissue matrix 
and is involved in intercellular communication and increased levels are 
considered to reflect increased synovial activity (Attur, Samuels et al. 
2010). Increased serum HA levels can be found in patients with a wide 
range of conditions including liver disease, cancer, hypothyroidism and 
a variety of arthropathies (Turan, Bal et al. 2007). 
An early study of serum HA levels in OA found that they were twice that 
found in healthy age-matched controls and showed a correlation with 
JURVV IXQFWLRQ 6WHLQEURFNHU¶V FODVVLILFDWLRQ DQG DQ DUWLFXODU LQGH[
representing the amount of cartilage involved (Goldberg, Huff et al. 
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1991). Further indications that serum HA was linked with structural 
damage was demonstrated by a correlation with disease duration (p = 
0.036) (Sharif, George et al. 1995; Turan, Bal et al. 2007), minimum 
joint space width (p = 0.049) and medial joint space width (Sharma, 
Hurwitz et al. 1998). No direct association has been found with 
radiographic grade (Turan, Bal et al. 2007), though patients whose 
disease had progressed over a five year period, were shown to have 
significantly higher levels of HA at baseline compared with those whose 
disease had not progressed (p=.019) (Sharif, George et al. 1995). 
However the confounding effects of co-morbidities were not fully 
explored. 
Though not a specific tissue biomarker, serum C-reactive protein (CRP) 
levels rise in response to inflammation. CRP is the most sensitive 
available routine test for the acute phase response and is often used to 
help GLIIHUHQWLDWH EHWZHHQ ³LQIODPPDWRU\´ FRQGLWLRQV VXFK DV
rheumatoid arthritis (RA) DQG ³QRQ-LQIODPPDWRU\´ FRQGLWLRQV VXFK DV
OA. However more sensitive testing techniques have showed low 
elevated levels in conditions with low-grade inflammation (Pearle, 
Scanzello et al. 2007). Several studies have reported modest but 
significantly higher CRP concentrations in patients with knee OA 
compared to those without (Sharif, George et al. 1995; Spector, Hart et 
al. 1997; Sharif, Shepstone et al. 2000; Sowers, Jannausch et al. 
2002). It was also reported that raised CRP could be predictive of 
disease progression over 4  (Spector, Hart et al. 1997) and 8 years 
27 
 
(Sharif, Shepstone et al. 2000). However, low levels of CRP failed to 
show a correlation with histological grading of synovial infiltration for 
patients undergoing hip or knee arthroplasty (Pearle, Scanzello et al. 
2007) and the most recent and convincing evidence on this has shown 
that the association between knee OA and CRP is completely driven by 
BMI (Kerkhof, Bierma-Zeinstra et al. 2010). 
 
1.5.3 Clinical signs and symptoms 
Clinical signs and symptoms indicative of inflammation can be observed 
in OA.  Pain, tenderness, mild swelling and self-reported stiffness are 
common and warmth and synovial thickening can be apparent in some 
patients, some of the time. 
1.5.3.1 Effusion  
Whilst small joint effusions in OA are not uncommon, substantial 
effusions are infrequent and their presence would usually raise 
concerns of associated synovitis, for example gout or OA with calcium 
pyrophosphate crystal deposition.  
Under normal conditions the volume of synovial fluid in the joint is 
balanced by articular flux, that is, it is controlled by the concentration of 
solutes within the synovial fluid and its rate of clearance. Clearance 
from the joint occurs via a combination of the microvascular network 
and by the synovial lymphatic system. In the normal turnover of articular 
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cartilage, smaller molecules from the cartilage matrix pass into draining 
blood vessels as well as lymph but larger molecules such as aggrecan 
are cleared more slowly by the lymphatic system (Levick and McDonald 
1995; Simkin and Bassett 1995).  
Acute injury or insult to the cartilage results in an increase in the 
catabolic and inflammatory mediators accelerating the normal turnover 
of the cartilage matrix which is cleared in the main by the lymphatic 
system. The subsequent effusion is an attempt to restore equilibrium to 
the synovial fluid solutes and resolution of the insult usually sees a 
return to normal in the balance and volume of synovial fluid. Where 
resolution fails to occur such as in inflammatory joint disease or with 
repeated micro-trauma, this can lead to an elevated level of flux and 
chronic effusion. Levels of lymphatic clearance in knees with 
rheumatoid arthritis (RA) has been reported as almost twice that in 
knee joints with OA, reflecting the high  turnover (Wallis, Simkin et al. 
1987).  
1.5.3.2 Stiffness 
Joint stiffness of limited duration is a common complaint in people with 
knee OA and one of 6 criteria used for clinical diagnosis of knee OA 
(Altman 1991). Patient reported stiffness is associated with decreased 
function (Odding, Valkenburg et al. 1998; Hall, Mockett et al. 2006) yet 
its evaluation is often limited to patient reporting and scoring on the 
WOMAC Index (Bellamy, Buchanan et al. 1988). The underlying basis 
for joint stiffness is not clear though its prolonged duration in RA 
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compared to OA would suggest that the underlying inflammation is a 
major contributing factor. 
The use of the term stiffness is open to a variety of interpretations but 
for use in a clinical situation Thompson et al suggests that stiffness  is 
WKH³UHVLVWDQFHWRSDVVLYHPRWLRQDWDMRLQWWKURXJKRXWWKHQRUPDOUDQJH
RIPRWLRQ LQ D IXQFWLRQDO SODQH´  as opposed to a restricted range of 
movement (Thompson, Wright et al. 1978). Other terminology, such as 
flexibility, elasticity, plasticity and viscosity have specific characteristics 
and definitions that are related to stiffness but do not always translate 
easily  to the clinical interpretation of stiffness. 
A method of quantifying joint stiffness by calculating stiffness and 
damping co-efficient during a pendulum test (a relaxed swinging of the 
knee joint in sitting) has been described by Oatis et al (1993). This 
method utilises a mechanical spring-damper system to model the 
behaviour of a joint.  The stiffness of the spring represents behaviour of 
the joint as it deforms or bends and the peri-articular structures 
represent the damper.  The effect of a damper is to reduce the 
amplitude of oscillations. Mathematically it is modelled as a force 
synchronous with the velocity of the object but opposite in direction to it.  
During the pendulum test the angular displacement of the knee is 
measured using motion analysis equipment while the relaxed lower-leg 
is released from a position of joint extension and allowed to oscillate 
freely until it comes to a resting state (Figure 1-11). Stiffness and 
damping co-efficients can then be calculated using displacement data 
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and anthropometric measures of the participant. Stiffness is the force or 
moment needed to produce a rotational deformation and is expressed 
in newton-meter/radian. A higher stiffness co-efficient indicate greater 
forces are required to produce a movement and are synonymous 
increased stiffness of a joint. The damping co-efficient reflects the time-
dependent nature of the moment expressed in newton-meter-
second/radian. Larger damping co-efficients indicate larger moments 
required to produce more rapid movement (Oatis, Wolff et al. article in 
press 2013). 
 
Figure 1-11 Knee joint displacement during the pendulum test. (Adapted from 
(Valle, Casabona et al. 2006).   
 
The solid line represents the leg at the starting position (knee extended) and at 
the final position (knee flexed). 3-D motion analysis systems are most 
commonly used to capture displacements data from the positions of small 
reference markers attached to the anatomical reference points. The numbers 
represent the positions of the markers: 1, greater trochanter; 2, head of fibula; 
3, lateral malleolus. 
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These co-efficients represent the passive resistance resulting from the 
articular cartilage, viscosity of the synovial fluid, thickening of the joint 
capsule and the surrounding ligaments and musculature. While they do 
not enable the source of the resistance to be determined, a previous 
animal study reported that the joint capsule contributes almost half of 
the overall resistance, the muscles around 40% and tendons 10% 
(Johns and Wright 1962). The contribution of viscous and frictional 
stiffness from within the joint is thought to be much smaller, around 1% 
and 10% respectively (Wright and Johns 1960). 
A number of small pilot studies have utilised the pendulum test to 
explore biomechanical stiffness in patients with knee joint disease. In 
one study (Oatis, Wolff et al. 2006) participants with knee OA were 
shown to have significantly higher damping co-efficients when 
compared to age and sex-matched controls (p=.035) but the difference 
in mean stiffness co-efficients was not significant (Oatis, Wolff et al. 
2006). A type II error was highly probable and a power calculation 
established that 50 participants with knee OA would be required to 
show a significant difference between controls and cases. Furthermore, 
OA was self-reported by participants and so correlation with 
radiographic severity could not be examined, and confounding 
variables such as muscle strength were not measured. However, 
damping co-efficients were found to be associated with patient reported 
stiffness using the WOMAC (r= 0.85, p=.003) and it was suggested that 
this measure may reflect the SDWLHQWV¶SHUFHSWLRQRIMRLQWVWLIIQHVV 
32 
 
In contrast, a study by Burks et al (2206) reported a small but significant 
correlation between the WOMAC stiffness subscale and the stiffness 
co-efficient (r=0.36, p=0.05). However, the analysis for this study was 
limited and no data was presented for the measures of stiffness or 
damping to infer any differences between participants with and without 
knee OA (Burks and Keegan 2006).  
A similar method was used in a study evaluating stiffness in knees 
affected by RA compared to healthy controls (Valle, Casabona et al. 
2006). This study found that the amplitude of limb oscillations was 
reduced in RA knees and that this coincided with a significant increase 
in knee joint stiffness (p<.0001) which correlated to disease severity 
(R2=0.68). Damping co-efficients were lower in the RA group but not 
significantly so.  
The use of an objective measure of knee joint stiffness has been limited 
to small studies which have been unable to draw any firm conclusions 
regarding the relationship of stiffness and damping co-efficients 
measures with either structural joint change or symptoms. The 
application of this novel technique could help draw inferences as to the 
role of inflammation in joint stiffness in knee OA. 
1.5.4 Imaging 
Radiographs are the usual imaging technique of choice in the study of 
OA but do not allow for the evaluation of soft tissue pathology or 
inflammation. Other imaging techniques have been utilised in this 
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pursuit, though by far the most robust technique is magnetic resonance 
imaging (MRI). 
Infra-red thermography has demonstrated differences in temperature 
between OA and non-OA hand joints. A decline in joint temperature 
with increasing K&L score was noted and led the authors to suggest 
that early OA may  represent an inflammatory phase of the disease 
(Varju, Pieper et al. 2004). A decrease in knee temperature associated 
with decreasing knee pain was also demonstrated by thermography 
following intra-articular steroid injection for knee OA (Dieppe, 
Sathapatayavongs et al. 1980).   
Abnormal bone scintigraphic uptake patterns around the subchondral 
bone (early phase indicating increased bone perfusion and late phase 
indicating increased bone turnover) have been shown to correspond to 
increased signal on MRI scans in both chronic knee pain (Boegård, 
Rudling et al. 1999) and knee OA (McAlindon, Watt et al. 1991). It has 
been suggested that this may reflect abnormal perfusion in areas of 
active subchondral bone as well as in areas of synovitis (McCrae, 
Shouls et al. 1992). Increased uptake on bone scans was also found to 
be correlated with serum levels of cartilage oligomeric peptide (COMP) 
a marker of cartilage turnover) (r=0.56, p=0.002) (Petersson, Boegård 
et al. 1998). 
MRI is the gold standard for the imaging of synovitis, particularly when it 
is gadolinium contrast enhanced which allows the thickened synovium 
to be distinguished from fluid within the joint. Good correlations have 
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been demonstrated between synovitis on MRI and findings on 
arthroscopy and subsequent histological examination in patients with 
OA knees (Fernandez-Madrid, Karvonen et al. 1995; Loeuille, Chary-
Valckenaere et al. 2005). 
Synovitis on MRI has been reported in 50% or more of knees with SOA 
(Baker, Grainger et al. 2010). Findings agree that synovial hypertrophy 
is more common in those with SOA than ROA (p=0.002) (Hill, Gale et 
al. 2001) and that increased synovitis correlates with radiographic 
severity (Torres, Dunlop et al. 2006; Pelletier, Raynauld et al. 2008). 
However synovitis has also been observed in knees with mild or no 
radiographic changes. The association with knee pain has been 
demonstrated using pain severity scales and pain scores derived from 
the WOMAC index where extensive synovitis conferred a 9 fold 
increased odds for knee pain (p<0.001) (Fernandez-Madrid, Karvonen 
et al. 1995; Hill, Gale et al. 2001; Torres, Dunlop et al. 2006; Baker, 
Grainger et al. 2010).   
Longitudinal changes in synovitis and knee pain have shown a modest 
but direct correlation between increased synovitis and  increased pain 
severity (r=0.21, p<0.0003) (Hill, Hunter et al. 2007). However a more 
recent study reported that although increased synovitis increased the 
risk of more frequent knee pain  the reverse was not observed i.e. 
improved synovitis did not convey a decrease in the risk of frequent 
pain (Zhang, Nevitt et al. 2011). 
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Effusions on MRI are common and have been observed in over two 
thirds of people with normal knees (Hill, Gale et al. 2001). Moderate 
and large effusions are less common but are more common in those 
with SOA (54.6%) compared to ROA (15.6%).  Hill (2007) reported that 
changes in effusion over time were not associated with changes in pain 
and Zhang (2011) reported that there was no association between 
change in effusion and change in frequency of knee pain in the either 
direction. 
Other MRI features associated with knee pain include bone marrow 
lesions (BMLs) which are present in 35% of those with SOA compared 
to just 2% of those without. (Felson, Chaisson et al. 2001). Unique to 
this feature, in comparison to effusions and synovitis, is that a change 
in  BML scores over time is associated with a concomitant change in 
knee pain presence and severity, in either direction (Zhang, Nevitt et al. 
2011). 
Other peri-articular pathologies such as popliteal cysts and pes 
anserine bursitis are also more commonly observed in patients with 
SOA compared to ROA though the overall prevalence is low (less than 
15%) and they have not been found to be associated with pain severity. 
(Hill, Gale et al. 2003). 
1.6 Ultrasound assessment of inflammation in knee OA 
Over the past decade ultrasound (US) imaging has gained popularity as 
an imaging tool for the musculoskeletal system, particularly in the 
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assessment of joint disease. In OA the advantage of US over traditional 
radiographs is that it allows the evaluation of joint effusion and synovitis 
as well as peri-articular lesions such as bursitis. 
Grey-scale or B-mode US is the most common mode used in 
musculoskeletal imaging and produces a two-dimensional scan where 
reflected waves are represented by white images. The acoustic 
impedance of bone is such that US waves are all reflected and appear 
as white, whereas articular cartilage and liquids like synovial fluid do not 
reflect any sound waves at all and will appear as black. Reflection from 
muscle and fat vary depending on their density and water content and 
appear as different shades of grey (Schmidt and Backhaus 2008), 
Figure 1-12.  
Figure 1-12 Grey-scale US image showing appearance of different tissues  
 
 
1.6.1 Grey scale features: Effusion 
Effusions in the knee are observed in the supra-patellar recesses and 
appear as abnormal anechoic areas that are displaceable and 
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compressible but do not exhibit Doppler signal (Wakefield, Balint et al. 
2005) (Figure 1-13).  They are usually recorded as present or absent or 
measured on a continuous scale at their maximal depth in millimetres.  
Figure 1-13 Grey-scale US image of an effusion in the supra-patellar pouch 
(taken from study participant). 
 
The use of US to detect knee effusions is more sensitive than clinical 
examination (Hauzeur, Mathy et al. 1999; Kane, Balint et al. 2003) and 
can detect small volumes of fluid in as many as 77% of normal healthy 
knees (Schmidt, Schmidt et al. 2004). The validity of US effusion has 
been established by comparison with MRI in a number of studies 
across a range of knee pathologies (Ostergaard, Courtpayen et al. 
1995; Scheel, Schmidt et al. 2005).  In OA knees, MRI has been found 
to be more sensitive than US in detecting effusion (effusion was 
detected in 85% of 58 symptomatic OA knees on MRI compared to 
70% on US) but a good correlation between the two was found (r=0.63, 
p<0.001) (Tarhan and Unlu 2003).  
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Cadaver studies have shown that MRI can detect volumes as small as 
4ml (Schweitzer, Falk et al. 1992) within the knee joint whereas the 
smallest volume detected by US was 7.4 ml (Delaunoy, Feipel et al. 
2003). However this is unlikely to have any clinical significance and 
agreement between MRI and US in the detection of knee effusion is 
excellent (Scheel, Schmidt et al. 2005). 
Reliability for the US detection of effusion has been evaluated for both 
intra and inter-observer agreement across a range of knee conditions. 
A study of 23 European experts in musculoskeletal sonography 
demonstrated an overall agreement of 91% for presence of knee 
effusion and synovitis (Naredo, Moller et al. 2006). A more recent study 
of inter-observer reliability specifically in knee OA, was undertaken by 
two sonographers who evaluated 18 participants (34 knees) within a six 
week period (Abraham, Goff et al. 2011). High inter-observer reliability 
was found for both the presence of effusion (kappa= 0.65, 0.77 for right 
and left knees respectively) and for direct measures of effusion size 
(ICC = 0.70, 0.85 for right and left knees respectively). Wu et al 
reported similar reliability for the intra-observer reliability of repeat  
scans of 12 OA knee participants acquired on the same day kappa = 
0.78 (Wu, Shao et al. 2012). 
The prevalence of US detected effusion in knee OA varies in the 
literature though this can be attributed in part to variations in defining 
criteria and scanning protocols. In the most extensive US study of knee 
OA to date, a large cross-sectional European study by EULAR, 
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clinically assessed effusion was present in 44% of 600 patients with 
SOA (D'Agostino, Conaghan et al. 2005). US detected effusion (defined 
as pUHVHQW LI PD[LPDO GHSWK  PP ZDV present in 43.5% of 
participants (mean of 7.5mm, SD 5). Multivariate analysis showed that 
the probability of US detected effusion was increased for more severe 
OA, K&L grade >3 (OR=1.91, 95%CI 1.32-2.77), sudden aggravation in 
knee pain in the previous two weeks (OR=2.7, 95%CI 1.76-4.16) and a 
moderate knee effusion on clinical examination (OR=1.77) which the 
DXWKRUV SURSRVH LV VXJJHVWLYH RI DQ ³LQIODPPDWRU\ IODUH´ &linical 
features including morning stiffness and pain severity were not found to 
be good predictors of effusion. 
Similar observations on the frequency of effusions in participants with 
SOA were reported by Naredo et al (2005) (47% of 50 participants), 
Iaggnocco (2010) (43% of 82 participants) and Wu et al (2012) (33% of 
112 knees) who used the same cut-off value of 4mm for defining the 
presence of effusion. Higher frequencies were reported by some 
studies which used smaller (>2mm) or no cut-off values, specifically  
72% (Mermerci, Garip et al. 2011), 79% (de Miguel Mendieta, Cobo 
Ibáñez et al. 2006) and 86% (Kristoffersen, Torp-Pedersen et al. 2006). 
Effusions were less frequently seen in patients with ROA without knee 
pain (35%) (de Miguel Mendieta, Cobo Ibáñez et al. 2006) and those 
with normal knees (0-16%)(Tarhan and Unlu 2003; Naredo, Cabero et 
al. 2005) though numbers for these groups were small. 
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1.6.2 Grey scale: Synovitis 
In the knee joint, synovitis tends to occur in the supra-patellar pouch, 
but can also be visualised in the medial and lateral recesses of the 
pouch and the medial and lateral aspects of the knee joint. Synovium 
cannot be seen on US unless it is hypertrophic when it appears as 
³DEQRUPDOK\SR-echoic (relative to sub-dermal fat, but sometimes may 
be iso-echoic or hyper-echoic) intra-articular tissue that is non-
displaceable and poorly compressible and which may exhibit Doppler 
VLJQDO´ (Wakefield, Balint et al. 2005). Its appearance can vary from 
flattened, thickened synovium to frond like protrusions into the synovial 
fluid (Figure 1-14). Pathology of the synovium can be assessed using 
grey-scale US and graded according to thickness or measured directly 
in millimetres.    
Figure 1-14 US images of synovial hypertrophy  
 
 
 
 
 
(A) showing thickened flattened synovium (B) showing frond like protrusions 
into the synovial fluid    
 
A          B 
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Most US studies of synovitis are concerned with establishing the validity 
of US findings by comparison with macroscopic and microscopic 
evaluation of the joint and findings on MRI. This has been convincingly 
demonstrated in a number of studies.  
In a study of 60 patients with a variety of knee pathologies the 
sensitivity and positive predictive value for US was 98% compared to 
macroscopic evaluation on arthroscopy (Karim, Wakefield et al. 2004). 
The specificity and negative predictive value were both 88%, with an 
overall accuracy of 97%.  This was considerably higher than the 
comparison for clinical examination and arthroscopy which resulted in a 
sensitivity of 85% and specificity of 25% and an overall accuracy of 
77%. Intra- and inter-observer reproducibility for the presence or 
absence of US detected synovitis read from stored scans was 0.85 and 
0.71 (p<0.05) respectively.  
A comparison of US detected synovial thickening with MRI findings 
demonstrated a moderate but highly significant correlation between US 
and MRI measurements of thickened synovium in symptomatic OA 
knees (r= 0.66, p<0.0001) (Tarhan and Unlu 2003).  
There have also been studies which have sought correlations between 
sonographic severity and biomarkers of synovium, cartilage and bone 
(Jung, Do et al. 2006; Kumm, Tamm et al. 2009). While HA is 
commonly associated with synovitis, COMP is more associated with 
cartilage breakdown but has been correlated with clinical signs of 
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synovitis (joint tenderness, non-bony swelling and warmth) in knee OA 
(9LOÕғP9\WiãHNHWDO). 
 Jung et al (2006), set out to examine whether abnormal features 
detected by US correlated with serum levels of HA and COMP. Fifty 
one patients with primary knee OA were examined using US by a single 
sonographer and fasting blood samples which were analysed for serum 
COMP and HA.  Pain was also measured RQD9$6DQG/HVTXHQH¶V
functional index. A range US features were examined though the 
scanning protocol and measurements were peculiar to the study and 
therefore the results cannot easily be compared or generalised. 
Synovial hypertrophy was measured in the supra-patellar recess where 
thickness >3.1mm was considered abnormal. Frequency data for 
synovial hypertrophy were not reported but serum HA was significantly 
higher in those with synovial proliferation than those without (p=0.03) 
and in those with larger effusion (p=0.02). Serum HA was positively 
correlated with capsular distension (r=0.468, p=0.001) and the length of 
medial and lateral osteophytes (r=0.484, p< 0.001; r= 0.315, p<0.05).  
Serum COMP showed a positive but not statistically significant 
correlation with US parameters. The results reflect what has been 
reported in other studies, specifically that there is a relationship 
between serum biomarkers and radiographic severity of knee OA and 
that biomarkers are elevated in people with US detected inflammation.  
Kumm et al (2009) investigated the association between US findings 
and several bone and cartilage (COMP) biomarkers in 106 participants 
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with early knee OA. Ultrasound assessment followed EULAR guidelines 
and features were recorded as present or absent. Effusion and synovial 
hypertrophy were observed in 25% and 31% respectively. Several 
significant associations between US findings and biomarkers (including 
effusion and COMP) were reported but the strength of these 
associations was not included and therefore the validity of the findings 
remains uncertain. Furthermore, most associations were between US 
measures of bone and cartilage and markers of bone and cartilage 
turnover as opposed to inflammation. 
Prevalence of synovial hypertrophy in knee OA is infrequently reported 
in the literature. Studies by Naredo et al (2005) and de Miguel (2006) 
surprisingly did not address synovitis in their studies of US features and 
pain. Synovitis  was reported in the EULAR study where it was defined 
as hypo-echoic synovial hypertrophy (4mm thickness) and diffuse or 
nodular appearance (D'Agostino, Conaghan et al. 2005). Hypertrophy 
was observed in 16.7% of participants though a further 37% showed 
nodular or diffuse hypertrophy <4mm. The mean depth of hypertrophy 
in those with hypertrophy was 5.8mm (SD 3) compared to 1.3mm (SD 
1.5) in those without.  A strong association was found between synovial 
hypertrophy and joint effusion (p<.001) that remained strong even when 
continuous measures of depth (mm) were used (r=0.51, p<0.001) 
(D'Agostino, Conaghan et al. 2005).  
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Multivariate analysis showed that subjects with more severe OA (K&L 
VFRUH  JUDGH 3) and a moderate clinical effusion had an increased 
likelihood of synovitis on US (OR 2.2, 95%CI 1.33-3.64). 
Other studies that have reported frequency data for synovitis in OA 
show wide variation. Tarhan et al (2003) reported hypertrophy in 34% of 
symptomatic knees using US, whereas Mermerci et al (2011), reported 
a much higher occurrence of 72% though this was a measure which 
incorporated effusion and hypertrophy and was considered an 
³LQIODPHG VXSUD-SDWHOODU SRXFK´  Iagnocco (2010) used the same 
definition and cut-RIIYDOXHVUHSRUWHGE\'¶$JRVWLQRand found synovitis 
to be present in 22% of participants with SOA.  
More recently, Wu et al (2012) reported on a study of 56 patients with 
bilateral knee OA of the same grade in each knee. Synovial 
hypertrophy was examined using US in the median longitudinal plane, 
and medial and lateral recesses of the suprapatellar pouch and was 
found in 93% of symptomatic knees and 63% of asymptomatic knees. 
Intra and inter-observer reliability was established as substantial (kappa 
was 0.80 and 0.79 respectively). A linear regression model with 
generalised estimating equation (GEE) was used to examine the 
association between synovitis and pain VAS scores. Synovitis in the 
medial compartment had a positive linear relationship with VAS pain 
scores on motion; pain VAS at rest and pain WOMAC scores after 
adjusting for age, sex, BMI and K&L grade. Of other US features only 
effusion was associated with pain on motion (Wu, Shao et al. 2012).  
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1.6.3 Power Doppler assessment of synovitis 
The application of Doppler mode to greyscale US has added another 
dimension to the assessment of inflammation in OA. The Doppler 
principle refers to the fact that sound waves alter in frequency when 
they are reflected by moving objects. This principle is largely employed 
in the study of blood flow where sound waves are reflected off moving 
erythrocytes. Within rheumatology this has been applied in the 
detection and evaluation of hyperaemia (increased blood flow) in the 
synovium, which is considered to represent inflammation (Schmidt and 
Backhaus 2008).  
Colour Doppler (CD) combines information on the velocity of the blood 
flow with grey-scale imaging to produce a colour signal where the 
direction of blood flow is indicated by red signals for flow directed 
towards and blue signals for flow directed away the transducer. Power 
Doppler (PD) measures the shift in energy caused by the Doppler 
effect, rather than velocity or direction of blood flow, and is therefore 
very sensitive to slower flow rates within small vessels (Torp-Pedersen 
and Terslev 2008), (Figure 1-15).  For this reason, PD is more 
commonly utilised in musculoskeletal imaging.  
Figure 1-15 US image showing colour (A) and power (B) Doppler activity at the 
medial knee joint line 
 
 
 
A      B 
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Grading of Doppler signal is usually recorded dichotomously as present 
or absent or is scored on a four-point semi-quantitative scale (0-3) 
representing normal, mild moderate or marked Doppler signal.  More 
recently this subjective scale has been improved by addition of 
descriptive bands for each grade (Table 1-4) (Iagnocco, Meenagh et al. 
2010). Establishing reliability of Doppler in evaluating synovial perfusion 
is difficult due the subjectivity of the grading used (absolute values are 
generally not assigned) and is further complicated by the type of US 
equipment used, its settings and the experience of the operator.  
Table 1-4 Semi-quantitative grading system for synovitis  
Grade  Definition 
Grade 0 Normal ± no Doppler signal within the synovium (grey scale 
area) 
Grade 1 Mild ± up to 3 single spots or up to 2 confluent spots or one 
confluent and 2 single spots  
Grade 2 Moderate ± more than Grade 2 but <50% of the grey scale 
area 
Grade 3 Marked ± Doppler signal in >50% of the grey scale area 
 
Most studies utilising US Doppler are concerned with inflammatory 
conditions and usually report on participants with a range of pathologies 
some of which include OA as a comparison. One such early study of 
Doppler was carried out in a small group of patients undergoing total 
knee replacement (TKR) for either OA (10) or RA (10) (Schmidt, Volker 
et al. 2000) where US assessments from two sonographers were 
compared to surgical and histological evaluation.  The presence of 
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effusion and synovial hypertrophy were evaluated using conventional 
grey-scale US and measured in mm. Colour and or power doppler 
signal were graded on a scale of 0-3, where 0= normal and 1-3 
represented subjectively increasing perfusion.  
There was good agreement between sonographers and surgeons for 
grey-scale US features. Twelve out of thirteen surgically confirmed 
effusions were also detected by US. Synovial hypertrophy was 
observed in 4 OA patients by sonographers. Rates of agreement 
between the two sonographers was 80% and between sonographers 
and surgeons were between 80-85% and. No correlations were found 
between greyscale measures of effusion, synovial thickening, and the 
surgical or histological findings of pannus, therefore highlighting that 
grey scale US cannot differentiate pannus from non-destructive 
synovial hypertrophy. 
Synovial perfusion detected by both CD and PD provided a higher 
correlation between pathological findings and the detection of pannus 
by histology. Mild or moderate perfusion was more common in patients 
without pannus, more marked or intense perfusion was more common 
in those with pannus. Pannus was present histologically in 8/10 patients 
with RA and 1/10 with OA. There was no correlation between the 
number of vessels seen on histology and the extent of synovial 
hypertrophy or intensity of perfusion in colour Doppler.  
These findings were confirmed in a further study of OA and RA knees 
(n=23) undergoing TKR (Walther, Harms et al. 2001). US effusion, 
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synovial hypertrophy and PD signal were graded and samples of the 
synovium were graded for vascularity. Digital imaging analysis was also 
applied to both the histological samples and the US PD images. RA 
patients showed a significantly higher degree of synovial hypertrophy 
(p<0.01) than patients with knee OA but no significant difference in 
effusion. There was a very good correlation between semi-quantitative 
evaluation of PD signal and the pathologist¶s grading of vascularity 
(r=0.89 p<0.01) and between visual and digital analysis of PD signal 
(r=0.89 p<0.01). The findings also demonstrated that while moderate 
correlations existed between thickness of the synovial membrane, 
vascularity on histology and PD signal, having a thickened synovium or 
joint effusion does not mean that inflammation is present.  
In contrast, a study of joints with known inflammatory disease found no 
significant correlation between US  and histological evaluations (Koski, 
Saarakkala et al. 2006). Grey scale and PD findings were reported and 
graded on a semi-quantitative scale of 0-3 and compared to histological 
grading of synovial biopsy samples in a range of joints. Grey scale 
effusion, synovial hypertrophy and PD signal were found in 80%, 89% 
and 83% of patients with histological inflammation but no significant 
correlation was found between US and histological grading, though the 
authors state that a negative doppler signal does not preclude the 
possibility of synovitis. The authors also questioned the use of semi-
quantitative grading for Doppler signal as this bears no correlation to 
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histopathological findings and instead suggested a dichotomous scale 
which demonstrated better sensitivity.  
A larger study of Doppler activity focused on patients with knee OA 
(n=71) and 10 healthy volunteers (Kristoffersen, Torp-Pedersen et al. 
2006). Patients studied had been referred to secondary care and 
fulfilled ACR criteria for knee OA and had radiographic osteophytes. 
Effusion, synovial hypertrophy and colour Doppler signal within the 
synovium was recorded as present or absent. Synovial hypertrophy 
was demonstrated in all patients and effusion in 86% (though no criteria 
or cut-off values were stated).  Colour Doppler activity was recorded in 
73% of patients, of whom more than half had a diastolic blood flow 
profile which the authors stated was indicative of inflammatory blood 
flow. By contrast, a trace effusion was observed in 1 control knee and a 
small isolated spot of colour Doppler signal in 2 control knees but no 
synovial thickening was found.  
The authors reported no associations between US features and 
radiographic appearance, knee pain severity (VAS), function 
(WOMAC/Lequesne score) or CRP values, though they called for larger 
studies with longitudinal follow-ups to address this. There were a 
number of methodological issues in this study particularly regarding the 
number of US examiners, reliability of US findings, definitions and cut-
off points for effusion and synovial hypertrophy, and lack of detail 
regarding radiographic assessment and healthy volunteers. The results 
should therefore be considered with caution. 
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Song et al reported a prevalence of PD signal in 63% of 41 participants 
with symptomatic knee OA and reported even greater sensitivity being 
found using  contrast-enhanced US which detected synovitis in 95% of 
patients (Song, Burmester et al. 2008). Other studies to have reported 
Doppler activity in knee OA have shown show a very low prevalence. 
Iagnocco et al (2010) reported PD in only 3% of SOA participants while 
Mermerci et al (2011) reported no PD activity in any of the 143 SOA 
patients they assessed. It is not clear from the methodologies of these 
studies why there should be such a wide variation in the prevalence of 
PD signal.  
1.6.4 Bursitis    
3RSOLWHDO RU ³%DNHU¶V´ F\VWV DUH IUHTXHQWO\ UHSRUWHG LQ 86 VWXGLHV RI
knee joints. A popliteal cyst is a composite of 2 bursae: the sub 
gastrocnemius bursa between the medial gastrocnemius tendon and 
medial femoral condyle and a second bursa between the medial 
gastrocnemius and semimembranosus tendon (Figure 1-16). The sub 
gastrocnemius bursa is the point of communication with the posterior 
joint capsule and the posterior extension represents the second bursa.  
The validity of US in detecting popliteal cysts is well established and the 
reported sensitivity is very high when compared to MRI (84-100%) 
(Ward, Jacobson et al. 2001; Tarhan and Unlu 2003). Inter-observer 
agreement among sonographers in the detection of popliteal cysts is 
also high (k=0.82, Naredo et al 2006; and  k=1, (Scheel, Schmidt et al. 
2005). 
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Figure 1-16 Anatomy of popliteal fossa and location of popliteal cyst 
 
The reported prevalence of popliteal cysts in those with symptomatic 
knee OA  ranges from 6.6% (Iagnocco, Meenagh et al. 2010) to 42.6% 
(Mermerci, Garip et al. 2011) and is low (2%)  in age matched controls 
(Chatzopoulos, Moralidis et al. 2008).  As with other US features, 
variations in definition, scanning protocols and the use of a minimal cut-
off measure may explain the differences in prevalence.  
De Miguel (2006) and Naredo (2005) both used the same criteria for 
defining Baker¶s but reported different rates of occurrence.  De Miguel 
reported a prevalence of 37% patients with SOA and a rate of 15% in 
those with ROA whereas Naredo (2005) reported a lower occurrence of 
22.2% for SOA and 0% in control participants with normal knees. The 
presence of a BDNHU¶VF\VWLQFUHDVHGWKHULVNRISUHVHQFHRISDLQE\DQ
OR of 5.5 (95% CI 1-31.05) but did not associate with pain severity.  
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Frequency of popliteal cysts was considerably higher in those studies 
which did not define minimum cut-off points for the cyst size. 
Chatzopoulos et al (2008) reported popliteal cysts in 37% of patients 
with chronic knee OA. The mean size of cyst was 4.0cm (SD 1.1) cm 
(range 1.4±6.2) taken from its maximum diameter. The prevalence of 
cysts was not influenced by age, gender, symptom duration or limited 
range of movement. Knee effusions within the supra-patellar recess 
were almost invariably present and even when classified as large were 
not significantly different LQSUHYDOHQFHLQWKRVHZLWKDQGZLWKRXW%DNHU¶V
cysts.  Early phase bone scans were able to discriminate between OA 
and non-OA knees and abnormally elevated synovial perfusion was 
REVHUYHGPRUH IUHTXHQWO\ LQ WKRVHZLWK%DNHU¶V F\VWV VXJJHVWLQJ WKDW
WKHSUHVHQFHRI%DNHU¶VF\VWVLVDVVRFLDWHGZLWKV\QRYLDO LQIODPPDWLRQ
and its grade, and may play a role in its patho-aetiology. 
0HUPHUFLHWDOUHSRUWHG%DNHU¶VF\VWs to be present in 42.6% of 
94 patients with SOA and 6.1% with ROA. Pain severity scores were 
significantly higKHULQWKRVHZLWK%DNHU¶VF\VWVWKDQWKRVHZLWKRXW. 
Frequency of bursitis at other sites around the knee joint  in SOA have 
been reported for infra-patellar superficial and deep bursae (8.6%) and 
the pes anserine bursa (6.2%) (de Miguel Mendieta, Cobo Ibáñez et al. 
2006). 
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1.6.5 Responsiveness of Ultrasound  
Surprisingly the responsiveness of US in knee OA has only been 
looked at in a small number of studies. Responsiveness can be 
considered in terms of internal and external dimensions. Internal 
responsiveness is the ability to demonstrate temporal changes or 
changes in response to an intervention whereas external 
responsiveness is the extent to which those changes correlate with the 
changes of other established measurements (Keen, Mease et al. 2011). 
The effect of an intra-articular corticosteroid (IACS) injection on 
popliteal cyst size and synovial hypertrophy was measured in 30 
patients with a diagnosis of knee OA and US confirmed popliteal cyst 
(Acebes, Sánchez-Pernaute et al. 2006).  The cross-sectional area of 
the cyst, cyst wall thickness (hypertrophy), knee pain, range of 
movement (ROM) and circumferential swelling were measured at 
baseline and after 4 weeks. Internal responsiveness of US measures 
was demonstrated by the significant improvements in thickness of 
synovial hypertrophy (p<0.01) and popliteal cyst size (p<0.05) following 
the intervention. The decrease in cyst area was correlated with 
increased ROM (r=0.38, p<0.05) thus showing a degree of external 
responsiveness. Significant improvements in knee pain and swelling 
(p<0.01) were also reported but these did not correlate with US 
measures. The initial size of the cyst was not found to predict clinical or 
sonographic improvement.  
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Yoon et al (2005) investigated the effects of local corticosteroid 
injection in pes anserine tendino-bursitis (PATB) syndrome in patients 
with knee OA. Twenty six patients were clinically diagnosed with PATB 
based on history of knee pain in the previous two weeks, pain on 
activity and tenderness on palpation of the anserine bursa. US 
assessment included thickness of anserine bursa (mean of 3 
measures), presence of tendonitis, and presence of bursitis (2mm). 
Pain VAS scores, global patient and physician assessments of 
improvement and WOMAC scores were also measured. Only 2 (8%) 
patients were found to have evidence of a bursitis on US examination. 
Other US findings included supra-patellar effusion (85%), osteophytes 
(62%), popliteal cysts (15%) and infra-patellar bursitis (4%). 
Local steroid injection was administered to 17 patients though it is not 
clear how or why these participants were chosen. Significant 
improvements in knee pain, WOMAC pain and function scores were 
reported following injection (but the paper does not state a time point 
for re-assessment). Global patient response showed that no patients 
were worse following injection, 2 had complete symptom relief, 6 were 
good, 1 was fair and 8 remained unchanged. No significant changes 
were found in US measures. 
Another study investigated the effects  of shortwave diathermy (SWD) 
in 36 patients with knee OA on synovial hypertrophy in the supra-
patellar pouch (Jan, Chai et al. 2006).  SWD is purported to reduce 
inflammation and pain in OA via changes in the microcirculation and 
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resultant changes in tissue temperature so US would seem an ideal 
outcome measure to demonstrate these effects. US was used to 
measures synovial sac thickness (this incorporated both the synovium 
and synovial fluid) at the midline, the medial and lateral para-patellar 
recess and the sum of the thicknesses calculated and knee pain was 
assessed using a 10 cm VAS. 
Participants in the study self-selected one of 3 treatment arms - SWD 
alone, SWD with NSAIDs as needed and a control group (no 
intervention). The intervention groups received their treatments over 30 
sessions with follow-up US assessments at the end of the 10th, 20th and 
30th sessions and the control was re-assessed every 2-3 weeks. There 
were no significant difference between groups at baseline in terms of 
demographic or US measures though pain VAS was lower in the control 
group. Change in synovial sac thickness was reported as a percentage 
change in thickness from baseline. Changes in pain were reported as 
difference in pain from baseline. 
The results showed that for both treatment groups there was a 
decrease in synovial sac thickness of up to 72% which was not 
observed in the control group, thus demonstrating some internal 
responsiveness of the measure.  US measures of thickness continued 
to decrease with increasing treatment sessions (p<0.0001). Knee pain 
also showed a significant decrease in both treatment groups compared 
to the control group (p<0.005) but with no significant difference between 
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the groups. Correlation between synovial thickness and knee pain was 
weak (spearman r=0.17, p=0.05).  
There are some obvious caveats to this study. The self-selection of 
treatment arms by participants may have influenced expectancy and 
thus may bias towards greater reported improvements. A standardised 
protocol was used for scanning and patient positioning but US 
measurement was peculiar to the study. It is not clear why the authors 
used a composite measure of synovial sac thickness rather than 
separate measures of effusion and synovial thickening. Furthermore 
reliability of US was not evaluated in this study and it is not explicitly 
stated whether the US assessments were carried out by one or more 
observers. In terms of the statistical analysis the data were not treated 
consistently with some data expressed as a percentage change (US 
measures) and others as actual difference (pain VAS).   
A trial by Pendleton et al set out to evaluate whether US detected 
synovitis could be a useful clinical predictor of response to intra-
articular cortico-steroid (IACS) injection (Pendleton, Millar et al. 2008). 
A baseline US assessment was carried out in 86 patients with 
confirmed symptomatic knee OA. Grey-scale features and PD signal  
were examined  by a single sonographer according to published 
guidelines at the time (Backhaus, Burmester et al. 2001). The presence 
or absence of clinical effusion, US detected effusion, synovial 
hypertrophy, pes-anserine bursitis and popliteal cyst were recorded. 
Pain and function were assessed using the WOMAC questionnaire. 
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Follow-up evaluation took place at 1 and 6 weeks but only included 
pain and function in the re-assessment. There was no placebo arm to 
the trial, the authors¶ justification being that there is sufficient evidence 
of a positive effect of IACS in knee OA.  
At baseline effusion were detected in 79% of patients using US 
(compared to 46% clinically), synovial hypertrophy was detected in 
62%, popliteal cysts in 36% and  PD signal was observed in 6% of 
patients. Pes anserine bursitis was found in 12% and patellar 
tendinopathy in less than 5%.  Higher WOMAC scores at baseline were 
associated with significant improvements in pain and function at week 1 
and 6 (p<0.01) but the presence of US effusion or synovial hypertrophy 
did not predict response to IACS injection. It is unfortunate that this 
study did not repeat the US assessment at the follow-up time points 
since this may have demonstrated responsiveness of US measures.  
The ability of US features to predict response to IACS injection was 
also considered in a randomised placebo study of 79 military veterans 
with symptomatic knee OA (Chao, Wu et al. 2010). Baseline evaluation 
included the WOMAC questionnaire and grey-scale US evaluation of 
the supra-patellar pouch. Inflammation was defined as the presence of 
synovial hypertrophy with or without effusion. Pathological effusion was 
defined as >5mm. Assessments were carried out at baseline, 4 and 12 
weeks. A small sub-sample (n=13) also provided blood samples for 
biomarker analysis at baseline (which included  inflammatory cytokines 
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and chemokines, serum metalloprotease 1 and 3, and C-reactive 
protein levels. 
Participants were randomised to the treatment (IACS injection) or 
placebo group (saline injection). WOMAC pain scores were comparable 
at baseline though total WOMAC scores were slightly higher (denoting 
worse function) in the treatment group. Significant improvements were 
observed in the treatment group between baseline and 4 weeks for 
WOMAC pain scores (p=0.001) and VAS pain scores (p=0.03) 
compared to placebo but this was not maintained at 12 weeks.   
In the treatment group 47% of patients had evidence of synovitis on US 
at baseline; WKHVH ZHUH FDOOHG ³LQIODPPDWRU\´ SDWLHQWV There was no 
difference in the presence or absence of synovitis at 4 and 12 weeks 
for these participants. At 4 weeks there was no significant difference in 
improvement of WOMAC scores between those with and without 
synovitis but there was a significant improvement in pain subscale 
among ³QRQ-LQIODPPDWRU\´ patients at 12 weeks. The presence of 
effusion at baseline did not have an effect on response. Biomarker 
analysis found no differences between ³LQIODPPDWRU\´ DQG ³QRQ-
LQIODPPDWRU\´SDWLHQWV 
The authors concluded that the results suggest that ³QRQ-LQIODPPDWRU\´
patients, that is those without synovial hypertrophy may benefit more 
from IACS than those with. However the generalisability of this study is 
questionable as the population comprised mainly male military veterans 
(97%) and the prevalence of secondary OA due to trauma was not 
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reported. Furthermore, WKH GHILQLWLRQ RI ³LQIODPPDWRU\´ ZDV OLPLWHG E\
the scope of the assessment which was restricted to grey-scale US of 
the supra-patellar pouch in the midline. Further exploration of the joint 
as well as the use of Doppler US may have resulted in a different 
number of patients being FDWHJRULVHGDV³LQIODPPDWRU\´ 
 
1.7 Management of OA 
Universally guidelines on the management of OA promote an 
individualised patient-centred approach utilising both non-
pharmacological and pharmacological modalities (American College of 
Rheumatology Subcommittee on Osteoarthritis (2000; Jordan, Arden et 
al. 2003; Zhang, Moskowitz et al. 2008; Hochberg, Altman et al. 2012). 
In 2008, the National Institute of Health and Clinical Excellence (NICE) 
recommendations published recommendations which included core 
treatments applicable to all persons with OA, specifically education and 
advice, exercise and weight loss in those who are overweight or obese 
(shown in inner circle, Figure 1-17) (NICE 2008).  Relatively safe 
pharmacological treatments which include paracetamol and topical 
NSAIDs (middle circle) should be considered before the use of other 
adjunctive treatments (shown in the outer circle, Figure 1-17). These 
include pharmaceutical options, self-management techniques, surgery 
and other non-pharmaceutical treatments. Despite this, wide variation in 
management practice within Europe is reported (Denoeud, Mazieres et 
al. 2005; Mazieres, Scmidely et al. 2005). The efficacy of these 
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therapeutic intervention have most recently been reviewed by the 
OARSI Treatment Guideline Committee (Zhang, Nuki et al. 2010) and a 
summary of effect sizes for pain relief in shown in Table 1-5. 
Figure 1-17 NICE summary of recommended treatments in the management of  
                  OA (NICE 2008)
 
 
Table 1-5 Effect sizes with 95% CI for relief of pain for pharmacological and non-
pharmacological treatments for OA. (Zhang, Nuki et al. 2010) 
Modality Joint  Effect size (95% CI) 
Education Hip & Knee 0.06 (0.03, 0.10) 
Aerobic Exercise Knee 0.52 (0.34, 0.70) 
Strengthening Knee 0.32 (0.23, 0.42) 
Weight loss  Knee 0.20 (0.00, 0.39) 
Acetaminophen (paracetamol) Hip & Knee 0.14 (0.05, 0.23) 
Oral Non-steroidal anti-inflammatory drugs Hip & Knee 0.29 (0.22, 0.35) 
Topical non-steroidal anti-inflammatory drugs  Knee 0.44 (0.27, 0.62) 
Intra-articular corticosteroid injection  Knee 0.58 (0.34, 0.75) 
Surgical Lavage/debridement Knee 0.21 (-0.12, 0.54) 
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Intra-articular corticosteroid injections are recommended as an adjunct 
for the relief of moderate to severe pain. The effects size for the 
treatment of pain is relatively large and is strongest for the first week   
following the injection (0.72, 95% CO 0.42, 1.01), diminishing   over 
subsequent weeks with a pooled ES of 0.58 (0.34, 0.75). Guidelines by 
the American College of Rheumatology (2000; Hochberg, Altman et al. 
2012) suggest that intra-articular injection of corticosteroid may be of 
particular benefit to patients with signs of local inflammation but 
whether inflammatory features can predict treatment response has yet 
to be substantiated.  
Further to this, the effect size of placebo should not be under-rated 
since it is often higher than the additional benefit conferred by the 
specific effect of an individual treatment.  A systematic review of 198 
randomised controlled trials reported an overall effect size of 0.51 (95% 
CI 0.46, 0.55) for placebo compared to 0.03 ( -0.13, 0.18) for untreated 
controls (Zhang, Robertson et al. 2008). The magnitude of the placebo 
response varies between treatments but is higher with increased effect 
size of the active treatment, increased baseline symptom severity and 
invasive route of delivery. 
To date, no disease-modifying OA drugs have been found to reverse or 
halt the progression of OA, though several drugs have demonstrated 
some effects. They can be divided in to those targeting cartilage, 
inflammatory pathways and subchondral bone. Identification of sub-
groups of patients who may benefit from such drugs and improved 
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outcome measures are important areas for development in the future 
(Davies, Graham et al. 2013). 
 
1.8 Study Rationale 
Ultrasound evaluation of symptomatic OA knees has shown that grey-
scale features of joint effusion and synovial hypertrophy are not 
uncommon (43-79%), and that Doppler activity may be present in a 
subset of patients. Most studies have been carried out in hospital-
referred patients who are likely to represent patients with more severe 
structural changes and pain. The prevalence of these features has not 
yet been fully explored in community participants. 
The relationship between US features, ROA and knee pain suggest that 
US features are more common as radiographic severity increases and 
in the presence of knee pain but the extent to which they reflect joint 
inflammation is as yet unconvincing. Furthermore their responsiveness 
to change has not yet been determined and therefore their potential 
role for monitoring disease progression or outcome following 
intervention is unclear. 
 
1.9 Thesis Aims  
The aims of the thesis are to determine the frequency of US detected 
inflammatory features in the knees of community-derived adults and the 
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relationship of these features to knee pain, structural damage on x-ray, 
and symptoms and signs that support inflammation (pain, clinical 
effusion, self-reported stiffness and biomechanically assessed 
stiffness). 
1.9.1 Primary Objectives  
To determine in a community sample:  
1.  The frequency of US features of joint inflammation (effusion, 
synovial hypertrophy and PD signal) in normal knees, painful knees, 
radiographic OA knees and symptomatic OA knees.  
2. To determine if US features of inflammation are associated with 
structural change on x-ray, knee pain or clinical symptoms and signs of 
inflammation (night pain, clinical effusion, self-reported stiffness and 
biomechanically assessed stiffness) and function.  
1.9.2 Secondary Objectives  
1.   To determine if US features of inflammation change over time (over 
3 months) in tandem with fluctuations in knee pain in SOA knees and 
healthy control knees. 
2. To determine if US features of inflammation change following an 
accepted intervention for knee OA pain (IACS injection) or a placebo 
injection in SOA knees. 
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1.9.3 Hypotheses 
Hypothesis 1. US features of inflammation will be more common in 
knees with radiographic changes, irrespective of pain status, and will be 
more pronounced in people with knee pain. 
Hypothesis 2. US features of inflammation will be independently 
associated with an increased risk for knee pain  
Hypothesis 3. Changes in US features of inflammation in SOA knees 
will correlate with changes in reported knee pain over time and also 
following an intervention for knee pain. 
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2 Methods 
This chapter starts by describing the training undertaken in 
musculoskeletal ultrasonography prior to the onset of the study. 
Following a statement of ethical approval for the study, recruitment for 
the study is described.  Study designs are then described for: 
x establishing the intra and inter-observer reliability of  US 
measures and biomechanical assessment of joint stiffness and 
damping co-efficients 
x an evaluation of diurnal variation of US measures 
x a cross-sectional multiple group comparison study and follow-up 
analysis 
x an intervention study looking at pain and US response following 
intra-articular injection of a cortico-steroid and placebo using a 
randomised cross-over design 
Detailed protocols for the clinical, US and radiographic assessments 
undertaken are presented. The methods used for checking data 
accuracy and the treatment of missing data are described. Finally, 
study sample size and power are stated and the statistical analysis is 
described. 
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2.1 Ultrasonographic Training 
Prior to the start of the study, US training was undertaken over a four 
month period under the supervision of Dr Philip Courtney, Consultant 
Rheumatologist and Dr Khalid Latief, Consultant Radiologist at 
Nottingham University Hospital NHS Trust. Training included: 
x One to one teaching sessions with demonstrations on a variety 
of patients and joints whilst attending a rheumatology clinic. 
x Self - directed learning using recommended  texts (Bradley and 
O'Donnell 2002; Martino, Silvestri et al. 20006), DVDs (Arthritis 
Research UK DVD ± Musculoskeletal Ultrasound: a beginner's 
guide to normal peripheral joint anatomy)  and  on-line 
educational resource available on the website of the EULAR 
Working Group for Musculoskeletal Ultrasound in Rheumatology 
http://www.sameint.it/eular/ultrasound) 
x One to one teachings on the principles of musculoskeletal 
ultrasound and practical skills for scanning at the knee joint 
including  patient positioning, transducer alignment, multiplanar 
scanning, optimising images, detection of effusion, synovial 
hypertrophy, bursitis, osteophytes and cartilage damage, use of 
power and colour Doppler, and  recognising and minimising 
artefacts and saving images and cine-clips. 
 
Over 40 hours training was accrued including scanning of normal 
knees, knee joints with osteoarthritis and knees joints with inflammatory 
pathology referred to the rheumatology clinic at Nottingham University 
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Hospital NHS Trust. Competency was not formally assessed at the end 
of the training period although both trainers were satisfied with the 
quality and interpretation of the US images produced by the author at 
end of the training period. At present there is no standardised model of 
training in musculoskeletal US but similar approaches that undertaken 
here have been shown to achieve competency (Filippucci, Unlu et al. 
2003; Atchia, Birrell et al. 2007). Intra and inter-observer reliability was 
formally assessed for key US measures. 
 
2.2 Ethics 
Ethical approval for the study was granted by the Derbyshire Research 
Ethics Committee in December 2009 (Ref 09/H0401/83). Research & 
Development Approval was granted by the Nottingham University 
Hospitals NHS Trust in January 2010 (CSP Ref: 28550). All participants 
gave their informed written informed consent. Supporting 
documentation, participant information sheets and consent forms are 
included in Appendix 1. 
 
2.3 Recruitment 
Participants were recruited from databases held by the Division of 
Academic Rheumatology, of community dwelling men and women over 
the age of 50.  All persons had previously participated in community 
studies of knee pain or knee OA (as either cases or controls) and had 
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consented to being approached for future research (Limer, Tosh et al. 
2009; Doherty, Hawkey et al. 2011; Ingham, Zhang et al. 2011).  
Participants were purposefully recruited with the aim of attaining fifty 
participants in each of the four comparison groups (control knees, knee 
pain, radiographic OA, symptomatic OA) for the main cross-sectional 
study.  A phased approach was used, recruiting as many participants 
as possible from a single study source before recruiting from the next. 
Potential participants were invited to take part in this study.  A reminder 
letter was sent to non-responders after 6 weeks. 
 Exclusion criteria for the study included:  
x Diagnosis of inflammatory arthritis  
x Clinical Hip OA 
x Steroid injection to either knee within the previous 3 months 
x Knee arthroplasty 
x 6LJQLILFDQW QHXURORJLFDO GLVHDVH HJ 3DUNLQVRQ¶V GLVHDVH
multiple sclerosis, stroke) 
x Chronic widespread pain / diagnosis of Fibromyalgia 
x Steinbrocker Grade IV 
 
Participants were allocated to one of four comparison groups based on 
their current knee pain and radiographic data (which may have 
changed since their original involvement in the previous studies). While 
participants were not matched on an individual basis, there was an 
attempt to match (where available) gender and age within a 5 year age 
band across the four groups. Group numbers were monitored 
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throughout the study and recruitment continued until the comparison 
group was full or no further participants could be recruited for that 
group.   
The primary source of study participants was a cohort study of incident 
knee pain in the community (Ingham, Zhang et al. 2011). This study 
followed-up participants from two earlier studies, a survey of knee pain 
in the community and an exercise intervention study for knee pain, both 
of which were recruited direct from the community using a 
questionnaire (O'Reilly, Muir et al. 1996; Thomas, Muir et al. 2002). 
During 2007- 2008, 5,479 participants were followed-up of which 3,109 
responded and 424 were x-rayed. After removing those who had not 
given additional consent to be approached (322) and those who had 
undergone TKR (76), 328 potential participants with knee pain data and 
radiographs were identified.  
The second source of recruitment was a randomised controlled trial of 
non-prescription analgesics for people with chronic knee pain (Doherty, 
Hawkey et al. 2011).  Original study participants (n=892) were recruited 
direct from the community between 2007-2008, were over 40 years of 
age and had moderate knee pain for most of the previous 3 months but 
were not under direct medical supervision for their pain. Radiographic 
OA was present in 63% (n=559) of participants. Exclusions criteria 
included concomitant rheumatic disease, joint misalignment, recent joint 
disease-modifying drugs and gastrointestinal, renal or hepatic 
conditions.   
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Thirdly, participants were recruited from a population based case-
control study (Genetics of OA and Lifestyle (GOAL) study). Between 
2002 -2006 Caucasian men and women aged between 45 and 86, were 
recruited as cases (hip or knee OA) (n=2049) or controls (n=1123) for 
genetic association and gene-environmental interaction studies of knee 
and hip OA (Limer, Tosh et al. 2009; Valdes, McWilliams et al. 2010; 
Valdes, De Wilde et al. 2011). All cases and controls were excluded if 
they had rheumatoid arthritiVDQN\ORVLQJVSRQG\OLWLV3DJHW¶VGLVHDVHRI
the bone adjacent to the hip or knee joints, trauma directly to the index 
joint, Perthe's disease, childhood hip dysplasia, polio or congenital 
lower limb deformities. 
 
2.4 Study designs 
2.4.1 Intra and Inter-observer reliability of US measures  
Intra-observer reliability in the acquisition of the inflammatory US 
measures was tested for the study assessor (MH) by scanning the 
knees of 14 participants (28 knees) on two separate days within a 
seven day period.  
Inter-observer reliability was tested against a consultant radiologist with 
clinical expertise in musculoskeletal ultrasound (Dr Khalid Latief (KL), 
Consultant Musculoskeletal Radiologist at Nottingham University 
Hospitals NHS Trust). The knees of 5 participants (10 knees) were 
scanned independently by MH and KL on the same day.  
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Participants were scanned at the same time of day for the key US 
features listed in Table 2-1.  Both investigators were blinded to previous 
PHDVXUHV DQG HDFK RWKHU¶V PHDVXUHPHQWV 5HSHDW :20$& DQG
ICOAP questionnaires and a pain VAS were also completed at each 
visit.  
Intra and inter-reliability of structural features (the presence of 
osteophytes, and measurement of FAC both in transverse and 
longitudinal planes) were assessed in a subset of 10 knees.  
Table 2-1 US Measures included in Reliability study 
Inflammatory 
US Features 
Dichotomous 
 
Continuous data Ordinal data 
Effusion absent/present  Max diameter (mm)  
Synovial hypertrophy absent/present  Max thickness (mm)  
Popliteal cyst absent/present  Max depth (mm)  
PD Signal 
 
absent/present  -  Grade 0-3 
Structural US features 
   
Osteophytes absent/present Depth (mm)  
FAC Transverse view 
 Thickness (mm)  
FAV longitudinal view 
 Thickness (mm)  
 
   
PD signal was recorded for each of 3 sites (suprapatellar pouch, medial joint 
line and lateral joint line). 
Osteophytes were recorded in any compartment. 
 
2.4.2 Reliability of biomechanical assessed stiffness measures 
Intra-observer reliability of the pendulum test used to calculate 
biomechanical stiffness and damping co-efficient was carried out on ten 
participants (20 knees with and without knee OA). Both knees were 
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tested on two separate days within one week. Testing was carried out 
under the same conditions, at the same time of day by the same 
assessor (MH). 
2.4.3 Diurnal variation of US measures 
Ten knees from 5 participants with bilateral SOA underwent US 
examination of both knees at two time points, morning (between 9 and 
10am) and afternoon (3 and 4 pm) during the same day. The same 
participants were re-examined on two further days, morning and 
afternoon, one week apart. Knees were examined by one sonographer 
(MH) for the features listed in Table 2-1.   WOMAC and ICOAP 
questionnaires and a pain VAS were completed in the morning session 
of each assessment day. 
 
2.4.4 Cross-sectional comparative study 
The main study had a cross-sectional multiple group comparison design 
and was implemented to achieve the primary objectives (Figure 2-1). 
Participants underwent clinical, ultrasound and radiographic 
assessment of both knees. The study population comprised of four 
comparison groups based on the presence or absence radiographic OA 
and the presence or absence of knee pain (Table 2-2). 
Radiographic OA was determined from knee x-rays taken in a 
standardised posterior-anterior, semi-flexed weight bearing and skyline 
views of both knees. Radiographic scoring was undertaken blind to the 
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clinical and pain status of the participants.  For the purpose of allocating 
participants to groups for analysis ROA was classified according to the 
overall Kellgren & Lawrence grade. Grades0/1 were classified as 
none/minimal radiographic change and grade 2/3/4 were classified as 
positive. 
Knee pain was classified according to responses on the WOMAC 
Index. Reporting of at least moderate pain during the previous week in 
one or more of the pain items of the index was considered pain 
positive. Those reporting no pain or mild pain in this section were 
classified as pain negative.  
 
Table 2-2 Study groups for cross-sectional comparative study. 
 ROA absent ROA present 
 
Knee Pain  
absent 
 
Controls 
 
ROA 
(Radiographic OA  
without knee pain) 
 
Knee Pain 
present 
 
KP 
(Knee pain only) 
 
SOA 
(Symptomatic OA) 
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Figure 2-1 Flow chart of cross-sectional multiple group comparison study,  follow-
up evaluation and entry into intervention study  
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up at 
 
 
 
Recruitment of community participants 
 with and without  
radiographic OA and knee pain. 
 
Responders screened for exclusion criteria 
x Inflammatory arthritis  
x Hip OA 
x Steroid injection within 3 months 
x Knee arthroplasty 
x Significant neurological disease  
x Chronic widespread pain 
x Steinbrocker Grade IV 
 
 
Allocated to 1 of 4 groups based on  
Knee pain and ROA  
 
 
Controls 
n=50 
ROA only 
n=50 
Knee pain only 
n=50 
Symptomatic 
OA 
n=50 
 
Consent taken 
 
Baseline Assessment  
Bilat X-rays, Clinical Examination, Ultrasound Evaluation 
Follow-up if pain 
changes or at 3 
months 
Follow-up if 
pain changes or 
at 3 months 
Invited to take 
part in 
Observational 
Injection Study 
Follow-up if pain 
changes 
(self-reported) 
Follow-up if pain 
changes 
(self-reported) 
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2.4.5 Follow-up evaluation 
A follow up evaluation (at 3 months) of participants in the control and 
SOA groups examined temporal changes in pain and US findings. In 
addition, participants who self-report a significant change in pain (in 
either direction) during the 3 months following initial assessment were 
re-assessed. A significant change in symptom pain was defined as an 
increase or decrease in the worst item score reported in the WOMAC 
Pain subscale. 
 
2.4.6 Intervention study 
After completing the multiple group comparison study and follow-up 
evaluation, participants with symptomatic OA were invited to take part 
in an intervention study (Figure 2-2). Participants were randomly 
allocated to a two treatment sequence (balanced randomisation using 2 
blocks): intra-articular saline followed by corticosteroid injection or intra-
articular corticosteroid followed by saline injection. A cross-over design 
was used to ensure each participant received both treatments. The 
purpose of this intervention was not examine the efficacy of the 
treatments but to change the pain status and to observe the 
relationship between the changes of pain status and US features of 
inflammation. There is little systematic evidence to guide the choice and 
dose of corticosteroid  but Methylprednisolone is commonly used within 
clinical practice in England and the manufacturers recommended dose 
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of 40mg has been shown to be effective for pain relief  (Jones and 
Doherty 1996; Pyne, Ioannou et al. 2004). A recent review concluded 
that there is no evidence to support the use of corticosteroid doses 
beyond those recommended by the manufactures (Douglas 2012). 
All participants consenting to the intervention study had a baseline 
assessment of both knees which included assessment of clinical 
effusion, WOMAC and ICOAP questionnaires, visual analogue scales 
(VAS) for knee pain and a US examination of both knees (for effusion, 
synovial hypertrophy, PD signal and popliteal bursitis).  
Participants were then randomised to receive the first intra-articular 
injection of either 40mg (1ml) methylprednisolone or placebo 1ml 
(0.9%) saline, to their most painful knee.  Where both knees were 
equally painful, one knee was chosen randomly (computer generated). 
Injections were delivered by an experienced rheumatology consultant 
(MD) and both participants and assessors were blinded to the order of 
the injections.  
A second assessment was performed one week following the 1st 
injection and a third when the partcipants reported their pain to have 
returned to their pre-injection level which was monitored by a weekly 
phone call.  At the third assessment, the 2nd injection was also 
administered. A fourth assessment was performed one week following 
the 2nd  injection and a final fifth assessment when the participant 
reported their pain severity had returned to their pre-injection level 
again.  
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Figure 2-2 Flow chart of intervention study 
 
 
 
 
Assessments            Intervention 
 
 
 
 
 
 
 
 
 
 
 
  
SOA participants invited to take part in 
intervention study. 
Consent taken 
Randomised to 1 of 2 groups 
  
Group A 
1st IA Injection 
1ml 0.9% Saline 
 
Group B 
1st IA Injection  
40 mg (1ml) Methyl-
prednisolone 
 
2nd IA Injection 
 1ml 0.9% Saline 
 
2nd IA Injection 
40 mg (1ml)  
Methyl-prednisolone 
 
1st - Baseline 
 
3rd - when pain 
severity returns to 
baseline level 
 
4th ± 1 week after 2nd 
injection 
 
5th - when pain 
severity returns to 
baseline level 
2nd -1 week after 
injection 
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2.5 Clinical assessments 
Participants attended the Clinical Sciences Building at Nottingham City 
Hospital for their assessments (Table 2-3). All assessments for the 
cross-sectional group comparison study and follow-up evaluations were 
carried out by the author (MH) who was blind to SDUWLFLSDQWV¶ 
radiographic status but aware of their pain status at the baseline 
assessment. All assessments for the injection study were carried out a 
research nurse (SD) with experience in sonography who was aware of 
WKHSDUWLFLSDQW¶VSDLQDQGUDGLRJUDSKLFVWDWXVDOOKDGV\PSWRPDWLFNQHH
OA). 
All participants were asked where appropriate to discontinue taking 
non-steroidal anti-inflammatory drugs (NSAIDs) 48 hours before 
attending. This would ensure an adequate washout period of five times 
the half-life period  for most short-acting NSAIDs (including in ibuprofen, 
and diclofenac) (Brater 1988). Paracetamol could be taken for rescue 
pain-relief up to the evening before their appointment. 
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Table 2-3 Summary of Clinical Assessments 
Anthropometric 
measures 
 
Body mass index (BMI) (kg/m2) 
 
Pain WOMAC Knee Index (Pain subscale) 
ICOAP Questionnaire (Knee version) 
Current knee pain - VAS (mm) 
Current medication  
Current pattern of analgesic use 
 
Knee joint 
examination 
 
Knee pain map pain & tenderness 
Joint deformity  
Effusion  
Warmth  
Range of movement  
 
Function WOMAC Knee Index (Function subscale) 
Muscle strength ±Quadriceps and Hamstring muscles 
Get Up and Go (GUG) test 3m (seconds) 
Get Up and Go (GUG) test 50ft (seconds) 
 
Stiffness WOMAC Knee Index (Stiffness subscale) 
Duration of morning stiffness (sec) 
Biomechanical assessed stiffness co-efficient (Nm/rad)  
and damping  co-efficient(Nm/rad/sec) 
  
Ultrasound 
Evaluation 
Joint effusion                (present/absent)  (mm)  
Grey scale synovitis     (present/absent)  (mm) 
Power Doppler signal   (present/absent) (grade 0-3) 
Bursitis                          (present/absent) (mm) 
Osteophytes                 (present/absent) (mm) 
Femoral Articular Cartilage                      (mm) 
 
Radiographic 
Evaluation 
Standardised bilateral weight bearing tibio-femoral and 
skyline patello-femoral x-rays 
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2.5.1 Body Mass Index (BMI) 
BMI (kg/m2) was calculated from height measured using a standard 
stadiometer to the nearest 0.5cm and weight using a set of standard 
aviary scales (to the nearest 0.1kg).  
BMI was classified as normal (BMI <25 kg/m2), overweight (BMI 25 - 
30kg/m2) and obese (BMI >30 kg/m2).  
2.5.2 Knee pain 
A variety of pain measures were used in the clinical assessment. The 
presence of unilateral or bilateral knee pain and the most symptomatic 
knee (Index knee) if any, was recorded. Two questionnaires relating to 
knee pain and disability experienced over the past week were 
administered (Appendix 2).  
2.5.2.1 Western Ontario MacMaster (WOMAC) OA Index  
The WOMAC index for the knee joint (Bellamy, Buchanan et al. 1988) is 
a  24 item questionnaire relating to pain, stiffness and function. Items 
are rated on a five point Likert scale and subscales calculated for pain 
(0-20), stiffness (0-8) and function (0-68).  Knee pain was classified 
according to responses on the WOMAC Index as previously described 
by Baker et al (2010). Reporting of at least moderate pain during the 
previous week in one or more of the five pain items of the index was 
considered pain positive. Those reporting no pain or mild pain in this 
section were classified as pain negative.  
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2.5.2.2 Intermittent and Constant Osteoarthritis Pain (ICOAP) 
Knee Questionnaire 
The ICOAP questionnaire (Hawker, Davis et al. 2008) is an 11-item tool 
designed to assess knee pain taking both constant and intermittent pain 
into account. Items are scored on a 5 point Likert scale with 5 items 
considering constant pain (subscore 0-20) and 6 items considering 
intermittent pain (subscore 0-24). Intermittent KP was scored 
dichotomously using the ICOAP intermittent subscale. Those who 
reported at least moderate intensity intermittent knee pain were 
considered positive. Those reporting none or mild intermittent pain 
intensity were considered negative. Constant KP was scored 
dichotomously using the ICOAP constant subscale. Those who 
reported at least moderate intensity constant pain were considered 
positive. Those reporting none or mild constant pain intensity were 
considered negative. 
2.5.2.3 Night pain 
The presence of night pain was scored dichotomously as present or 
absent using question 3 from the WOMAC index. Those reporting at 
least moderate pain at night were considered night pain positive. Those 
reporting no pain or mild pain at night were considered night pain 
negative. 
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2.5.2.4 Pain severity 
A current knee pain score was taken from a 100mm visual analogue 
scale (VAS) where 0 represented NO PAIN and 100mm represented 
EXTREME PAIN.   
Change in knee pain for follow-up evaluations was defined as an 
increase or decrease in pain VAS of 15mm or an increase or decrease 
of the worst item score reported in the WOMAC Pain subscale. 
2.5.3 Drugs history and current medication 
Current medication related to knee pain was documented. Participants 
were asked to describe their pattern of analgesic use from the following 
options (Blamey, Jolly et al. 2009): 
x Always, every day 
x When pain gets too bad 
x Depends on how bad pain is 
x Every day when having a bad patch, otherwise only as needed 
x Usually before bed 
x Usually before exercise 
 
2.5.4 Knee pain location 
Knee pain was recorded on a knee pain map and the pattern of the 
knee pain characterised as localised, regional or diffuse  (Thompson, 
Boudreau et al. 2009) (Figure 2-3). The use of this interviewer-
administered assessment of knee pain location has been shown to be a 
reliable method for the identification of localised and regional pain 
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SDWWHUQV LQ SDWLHQWV ZLWK NQHH SDLQ ɤ   -0.9 and 0.7-0.8 
respectively).  
Figure 2-3 Knee pain map  
 
 
Localised pain was defined by the use of 1 or 2 fingers to point to a 
specific area of pain, whereas regional pain was defined by the use of 
all of the fingers or the whole hand to cover larger region. Participants 
who were not able to identify areas of localized or regional pain and/or 
ZKRVDLGWKDWWKHSDLQZDV³DOORYHU´WKHNQHHZHUHFODVVLILHGDVKDYLQJ
diffuse pain.  
Participants were allowed to identify multiple areas of localized and/or 
regional pain but were classified as diffuse if: >3 areas of localized pain 
or >2 areas of regional pain or 1 area of localised and 1 non-
overlapping regional area of pain. 
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2.5.5 Joint tenderness 
Site(s) of maximal tenderness on palpation were recorded on a 
separate knee pain map.  
2.5.6 Joint deformity 
Valgus or varus alignment was documented according to validated line 
drawings (Ingham, Moody et al. 2010). 
2.5.7 Effusion 
-RLQWHIIXVLRQZDVDVVHVVHGDQGJUDGHGXVLQJWKH³6WURNHWHVW´(Sturgill, 
Snyder-Mackler et al. 2009). The stroke test was performed with the 
participant in sitting on a plinth with their knees extended. An upward 
stoke was applied from the medio-femoral joint line towards the 
suprapatellar pouch 2-3 times followed by a single downwards stroke 
on the lateral distal thigh just superior to the suprapatellar pouch.  An 
observed wave of fluid at the medial side of the knee was indicative of 
an effusion. The effusion was graded according to a scale where 
0=no/trace wave produced, 1= large bulge produced, 2= spontaneous 
wave without down stroke, 3= unable to move effusion from medial 
aspect of the knee. The inter-UDWHU UHOLDELOLW\ RI WKLVPHWKRG ɤ   
95%CI 0.54 -0.81) has been shown to be higher than other methods of 
assessing clinical effusion (fluctuation tHVWɤ SDWHOODUWDSWHVWɤ
= 0.21 (Fritz, Delitto et al. 1998)). For analysis, clinical effusion was 
GLFKRWRPLVHGDVSUHVHQWJUDGHRUDEVent (grade 0/trace).  
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2.5.8 Joint Warmth 
The knee joint was palpated anteriorly and along the medial and lateral 
MRLQW OLQHVZLWK WKHGRUVDODVSHFWRI WKHH[DPLQHU¶VKDQGIRU LQFUHDVHG
temperature relative to the surrounding tissue and contra-lateral knee 
joint. 
2.5.9 Range of Movement (ROM) 
Knee ROM was measured using a standard clinical goniometer in 
degrees using a standardised protocol (Clarkson 2005). 
The axis of the goniometer was placed over the lateral condyle of the 
femur, and the arms of the goniometer in line with the lateral malleolus 
of the ankle and the greater trochanter of the femur.  
Maximal active knee joint flexion was measured with the participant in 
supine in reclined long sitting.  Maximal knee joint extension was 
PHDVXUHGZLWKWKHSDUWLFLSDQW¶VIRRWHOHYDWHGRQDVPDOOEROVWHUWRDOORZ
for hyperextension if present.  Overall ROM was calculated as the angle 
(in degrees) between full available extension and flexion. 
For analysis overall ROM was divided by tertiles using SPSS to create 
third groups. Tertile 1 represented greatest ROM whilst tertile 3 
represented those with the most restricted ROM. 
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2.5.10 Joint instability 
Medial and lateral collateral and cruciate ligaments were tested for 
instability (Doherty and Doherty 1992). 
2.5.11 Muscle strength 
Maximal isometric strength of the quadriceps and hamstring muscles 
was tested using a manual muscle tester (MMT) (Nicholas Manual 
Muscle Tester; Lafayette Instruments). The MMT displayed the maximal 
force generated in kilograms (Figure 2-4).  
Figure 2-4 Manual muscle manometer 
 
Quadriceps testing was performed with the participant in upright sitting 
on the edge of an examination plinth with the knee joints in 90° flexion 
(Figure 2-5 A).  The MMT was placed on the distal tibia above the ankle 
joint. Participants were asked to push their leg against the pad of the 
manometer as strongly as possible for a period of 5 seconds. The 
examiner was positioned in a lunge position using their body weight to 
87 
 
prevent any movement of the lower leg and knee joint, maintaining a 
static contraction. 
Hamstring strength was measured with participants in prone lying with 
the knee joint flexed to 90° (Figure 2-5 B). The MMT was placed at the 
distal calf above the insertion of the Achilles tendon. Participants were 
asked to push their calf against the pad as strongly as possible for 5 
seconds. The examiner stood facing caudally to resist the movement.  
Figure 2-5 Strength testing using the MMT: (A) Quadriceps (B) Hamstrings 
A       B 
 
Three attempts were recorded on each limb for quadriceps and 
hamstring muscles and the average force calculated. For analysis 
average strength scores were divided by tertiles to create third groups 
for comparison. Tertile 1 represented those with strongest muscles 
whilst tertile represented those with the weakest muscles. 
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2.5.12 Function - WOMAC  Function subscale 
A summated score (0-68) for function was calculated for WOMAC 
function from the 17 questions in the index. 
2.5.13 Function: Get Up and Go (GUG) tests 
Two simple tests of lower limb performance were assessed. The Get 
Up and Go (50ft) test which measured the time in seconds it took to rise 
from a chair and walk 50ft as fast as possible along a level and 
unobstructed walk way (Hurley, Scott et al. 1997). A second  Get Up 
and Go (3m) test measured the time it took to rise from a chair, walk 
3m, turn around, walk back and sit down (Mathias, Nayak et al. 1986). 
Participants were allowed to use a walking aid where required.  
Scores for the 3m test were dichotomised into those who could 
complete the test in 10 seconds or under (normal mobility) and those 
who took longer than 10 seconds to complete the test (impaired 
mobility) (Podsiadlo and Richardson 1991). 
2.5.14 Morning stiffness 
Maximal duration of early morning stiffness in or around the knee was 
recorded in minutes. A dichotomous variable was created for morning 
stiffness lasting longer than 30 minutes. 
2.5.15 WOMAC ± Stiffness subscale 
A summated score (0-8) was calculated for WOMAC stiffness from the 
2 questions in the index. 
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A dichotomous score was also calculated. Those reporting at least 
moderate stiffness during the previous week in one or more of the 
stiffness items of the index was considered positive. Those reporting 
none or mild stiffness in this section were classified as negative. 
2.5.16 Biomechanical measures of joint stiffness  
Two objective measures of knee joint stiffness (stiffness and damping 
co-efficients) were obtained by tracking the angular displacement of the 
knee during D³SDVVLYHSHQGXOXPWHVW´XVLQJWKH&RGDPRWLRQDQDO\VLV
system (Figure 2-6). 
Figure 2-6 Coda Motion analysis system camera 
 
 
Infra-red LED (light emitting diode) markers were attached to both limbs 
at the greater trochanter, lateral knee joint line on the femoral condyle, 
and lateral malleolus of each limb using double sided adhesive tape 
(Figure 2-7). Participants sat on the edge of plinth with the test knee 
positioned in a loosely packed position (around 75° knee flexion) and 
their contra-lateral limb supported on a stool. The test limb was 
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extended passively by the investigator just short of full extension before 
releasing the lower leg and allowing it to oscillate freely until it came to 
a stop (Figure 2-8).  
Figure 2-7 LED markers used for capturing notion data 
 
Figure 2-8 Participant with LED markers in situ at onset of pendulum test 
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Motion data was collected at a frequency of 60Hz for a period of 10 
seconds during the test. Average stiffness and damping co-efficient 
were calculated using the following previously published equations: 
ț ǿ[Ȧ2 
ZKHUH ț   WKH VWLIIQHVV FR-efficient expressed as Newton meters per 
radian (Nm/rad), I is the moment of inertia of the leg-foot segment with 
UHVSHFW WR WKH NQHH MRLQW DQG Ȧ LV WKH QDWXUDO IUHTXHQF\ RI WKH
oscillation. The moment of inertia is calculated through the 
measurements of the total body weight and lower leg length. 
F [ȗ[Ȧ[O 
where c is the damping co-efficients expressed as Newton meters per 
UDGLDQ SHU VHFRQG 1PUDGVHF DQG ȗ LV WKH YLVFRXV GDPSLQJ IDFWRU
calculated using the angular displacement of the knee over time (Oatis 
1993). 
Three valid tests for each participant were required to calculate average 
stiffness and damping co-efficients. A valid test was defined by the 
pattern of the displacement graph of the knee joint during the pendulum 
test which displays a smooth sinusoidal decaying oscillation over time 
(Figure 2-9). Aberrations in the pattern of the graph can be due to poor 
visualisation of the markers by the Coda cameras, or by muscle activity 
around the knee joint (Figure 2-10). Where this was identified the test 
was repeated. Where 3 valid tests could not be completed the data was 
not included in the analysis.  
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The average scores from 3 trials of the passive pendulum test were 
used to calculate stiffness and damping co-efficients. These scores 
were divided by tertiles to create three 3 groups. Tertile 1 represented 
those with the least stiff knees and tertile 3 represented those with the 
stiffest.  
Figure 2-9 Oscillation data of valid trial showing sinusoidal decaying of 
amplitude 
  
 
Figure 2-10 Oscillation data from an un-relaxed limb and therefore unsuccessful 
trial 
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2.6 Radiographic assessment 
Radiographs of both knees were obtained for each participant. 
Standardised, semi-flexed weight-bearing tibio-femoral x-rays (using an 
adapted Rosen template) and skyline patella-femoral x-rays were taken 
with knees flexed (with a jig) in lying. Radiographs were taken at the 
Radiology Department at the Nottingham City Hospital.   
Radiographs were scored by a blinded single trained reader (SAD) with 
established reliability. X-rays were scored using the Nottingham 
logically derived Line Drawing Atlas (Wilkinson, Carr et al. 2005) 
(scoring sheet is located in Appendix 3). Individual features were 
scored for in all three compartments; osteophytes (0-5) and joint space 
narrowing (0-5), and summated scores were calculated for osteophytes 
(0-40) and joint space narrowing (0- 20), and for the tibio-femoral (0-30) 
and patello-femoral (0-30) compartments. A global x-ray score for the 
whole knee joint was also calculated (0-60). The total number of 
osteophytes was counted (0-8). The presence or absence of 
chondrocalcinosis in the fibrocartilage and or hyaline cartilage, 
subluxation (lateral/medial) and attrition was scored as present or 
absent.  
An overall Kellgren & Lawrence grade (0-4) was also given for the tibio-
femoral and patello-femoral compartments of each knee (Ball, Jeffrey et 
al. 1963). 
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Table 2-4 Definitions of the severity according to Kellgren & Lawrence. 
Grade 0 Normal 
Grade 1 Doubtful narrowing of joint space, possible osteophyte 
Grade 2 Definite osteophyte, possible narrowing 
Grade 3 Moderate multiple osteophytes, definite narrowing, 
some sclerosis, possible deformity of bone ends 
Grade 4 Large osteophytes, marked narrowing, severe 
sclerosis, definite deformity of bone ends 
 
2.7 Ultrasound assessment 
Ultrasound examinations of both knees was performed using the 
Toshiba Aplio SSA-770A machine by a single assessor (MH) using a 
multi-frequency (7-12 MHz) linear array transducer with standard image 
windows. A standardised research protocol, reflecting current EULAR 
definitions and measurements (D'Agostino, Conaghan et al. 2005) was 
followed. Definitions for pathological features published by the 
OMERACT group (Wakefield, Balint et al. 2005) were used throughout 
and though these were published with inflammatory arthritis in mind 
they also reflect the pathology seen to a lesser severity in osteoarthritis.  
Power doppler settings were standardised with a pulse repetition 
frequency (PRF) of 1000-1300 Hz with a wall filter of 5. For optimum 
sensitivity, PD gain was set manually with the transducer focused on 
the area interest. Gain was increased manually until the colour box was 
uniformly filled with colour, then reduced until the background signal 
was removed.  
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Motion artefacts during PD assessment were minimised by ensuring 
participants were comfortable during the examination and that the 
positioning of the examiner was also comfortable. Random noise on the 
power Doppler setting was minimised by setting the gain levels just 
below the level where noise was generated.  
Participant positioning was standardised so that a supine position was 
adopted for ventral and lateral scans and a prone position for dorsal 
scans. The knee joint was maintained in 30° flexion for ventral scans 
and lateral scans (using a bolster behind the knee) and was 
standardised to 90° flexion for imaging of the intercondylar sulcus. A 
combination of both longitudinal and transverse transducer planes were 
used throughout the examination. Generous amounts of scanning gel 
were used to ensure a minimal pressure between the transducer and 
SDUWLFLSDQW¶VVNLQZKLFKFDQDIIHFWPHDVXUHVRIMRLQWHIIXVLRQDVZHOO3'
signal. Focus points for both grey-scale and doppler examination were 
adjusted throughout for the features examined.   
The following features were examined: 
2.7.1 Effusion 
Effusion is defined as an abnormal hypoechoic or anechoic (relative to 
sub dermal fat, but sometimes maybe isoechoic or hyperechoic) intra-
articular material that is displaceable and compressible but does not 
exhibit Doppler signal (Wakefield, Balint et al. 2005) (Figure 2-11).  
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Maximal depth of effusion (mm) was measured using a longitudinal 
VFDQQLQJSODQHDQGUHFRUGHGDVDEVHQWLIPPDQGSUHVHQWLIPP
(D'Agostino, Conaghan et al. 2005). 
Figure 2-11 US scan image of suprapatellar pouch showing joint effusion 
 
 
2.7.2 Synovial hypertrophy 
Synovial hypertrophy is defined as abnormal hypoechoic (relative to 
sub dermal fat, but sometimes maybe isoechoic or hyperechoic) intra-
articular tissue that is non-displaceable and poorly compressible and 
which may exhibit Doppler signal (Wakefield, Balint et al. 2005) (Figure 
2-12).  
Supra-patellar recesses, medial and lateral joint lines were scanned for 
synovial thickening with the knee joint in 30° flexion. Maximal synovial 
thickness (mm) was measured on the longitudinal scan and 
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GLFKRWRPLVHG DV DEVHQW LI PP RU SUHVHQW  LI  PP (D'Agostino, 
Conaghan et al. 2005). 
Figure 2-12 US scan image of synovial hypertrophy 
 
 
2.7.3 Power Doppler Signal 
PD was used to detected abnormal blood flow within the hypertrophic 
synovium.  Standard transverse and longitudinal scans of the medial 
and lateral recesses of the supra-patellar pouch and medial and lateral 
joint lines were used focusing on areas of synovial hypertrophy. Signal 
within the synovium was recorded as absent or present and graded 0-3  
(Iagnocco, Meenagh et al. 2010) (Table 2-5) (Figure 2-13). 
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Table 2-5 Semi-quantitative grading for PD signal 
Grade  Definition 
Grade 0 Normal ± no Doppler signal within the synovium (grey scale 
area) 
Grade 1 Mild ± up to 3 single spots or up to 2 confluent spots or one 
confluent and 2 single spots  
Grade 2 Moderate ± more than Grade 2 but <50% of the grey scale 
area 
Grade 3 Marked ± Doppler signal in >50% of the grey scale area 
 
 
 
 
 
Figure 2-13 US scan images of medial knee joint line showing grades of PDS 
within the synovium. A: Normal, B: Grade 1, C: Grade 2, D: Grade 3 
 
 
  
 
 
2.7.4 Bursitis 
Bursae can have a hypoechoic, anechoic or mixed echolucency 
appearance when present. Three sites were examined for the presence 
of bursitis.  
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The popliteal fossa was examined with the participant in prone lying 
and the knee joint in extension. When present  the popliteal bursa lies 
between the semimembranosus and medial gastrocnemius tendons 
(Chatzopoulos, Moralidis et al. 2008) . Maximum depth was measured 
(mm) in the longitudinal planes (Schmidt, Schmidt et al. 2004) and 
recorded as absent if <4mm and present if > 4mm (de Miguel Mendieta, 
Cobo Ibáñez et al. 2006) (Figure 2-14). 
Figure 2-14 US scan image of popliteal cyst  
 
 
The insertion of the patella tendon was examined with the knee joint in 
30° flexion. The patellar bursa appears hypoechoic with a slit like 
hypoechoic appearance centrally. Patellar bursitis was recorded as 
present or absent if> 4mm, and maximal depth in mm was recorded 
(Figure 2-15). 
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Figure 2-15 US scan image of patellar tendon bursae (B) taken in transverse 
plane 
 
The insertion of the pes-anserine tendon, inferior and anterior on the 
tibia to the insertion of the medial collateral ligament was also examined 
in 30° flexion.  Bursitis was recorded as present or absent if > 2mm, 
and maximal depth in mm was measured where present (de Miguel 
Mendieta, Cobo Ibáñez et al. 2006).  
Figure 2-16 US scan image of Pes anserine bursae (B)  
 
101 
 
2.7.5 Additional US features 
The following additional features were noted during the US assessment 
2.7.5.1 Osteophytes 
Osteophytes are defined as cortical protrusions located at the edges of 
the joint surfaces seen in 2 planes (Keen, Wakefield et al. 2008). The 
presence was recorded as present or absent and the location noted. A 
measure representing the size of the osteophyte was taken from the 
apex of the osteophyte to a line connecting the medial or lateral edges 
of the femur and tibia (Jung, Do et al. 2006) (Figure 2-17). 
2.7.5.2 Femoral articular cartilage 
Normal cartilage has a homogenous hypoechoic appearance with a 
smooth contour parallel to the bone (O'Connor and Grainger 2002). The 
sharpness of the synovial space-cartilage interface and the clarity of the 
cartilaginous layer  is reduced in OA joints, the articular cartilage is 
narrowed and an increased intensity of the bone-cartilage interface can 
be observed (Grassi, Lamanna et al. 1999). Thickness of the femoral 
articular cartilage was measured in two planes 1) in the transverse 
plane at 10mm to the medial and lateral midpoint of the intra-condylar 
groove (Ostergaard, Courtpayen et al. 1995) (Figure 2-18) and 2) in the 
longitudinal plane taken at the mid-area of the medial and lateral 
femoral condyles at the centre-point of the concavity (Yoon, Kim et al. 
2008). 
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2.7.5.3 Chondrocalcinosis 
Calcification within the hyaline cartilage can be detected using US 
where it appears as fine linear echogenic foci within the normally 
hypoechoic  articular cartilage (Sofka, Adler et al. 2002). The 
appearance of chondrocalcinosis was noted during the examination of 
the femoral articular cartilage and recorded as present or absent 
(Figure 2-19). 
 Figure 2-17 US image of osteophytes on medial joint line 
 
Figure 2-18 US image of femoral articular cartilage (FAC) (transverse image) 
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Figure 2-19 US image of chondrocalcinosis (CCĺ) within FAC  
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2.8 Statistical analysis 
2.8.1 Sample size 
There was limited previous work on which to base a sample size for the 
cross-sectional comparison study. Three published studies which have 
investigated US changes in symptomatic OA of which only one had an 
independent control sample of non-symptomatic OA (D'Agostino, 
Conaghan et al. 2005; Naredo, Cabero et al. 2005; de Miguel Mendieta, 
Cobo Ibáñez et al. 2006). Furthermore, all three studies reported on 
different US features and had different definitions and defined cut-off 
values. The single common feature reported was joint effusion in the 
supra-patellar pouch. The reported occurrence ranged from 43% 
(D'Agostino, Conaghan et al. 2005) to 79% (de Miguel Mendieta, Cobo 
Ibáñez et al. 2006) in subjects with symptomatic OA.  
The power analysis was based on a 2 x 2 fixed effects analysis of 
variance. Fifty participants were required for each cell (200 in total) for 4 
groups to achieve a balanced design and detect the minimum 
difference between groups with 90 % power and less than 5% type I 
errors.  
Main effects: Knee pain included 2 levels, with 100 cases per level. 
The effect size (f) was 0.35, which yielded power of 1.00. Radiographic 
OA included 2 levels, with 100 cases per level. The effect size (f) was 
0.25, which yielded power of 0.94.  
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Interactions: It was not the purpose of the study to look at the 
interaction between pain and x-ray changes but to look at the 
spectrum and difference of prevalence between groups. 
For the follow-up evaluation, the power analysis was based on the null 
hypothesis that there was no correlation between changes in US 
synovitis and knee pain. The criterion for significance was set at 0.05 
and the test was two tailed. The proposed sample size for the SOA 
group to be followed up was 50, which yielded a power of 97.9%. The 
calculation was based on an assumed correlation of 0.5 within the 
population, the observed value being test against the theoretical value 
of 0.00. 
No formal power calculations were carried out for the injection study as 
this was a small observational study. The data from this study may be 
used in a power calculation to determine the sample size needed for a 
larger study. 
 
2.8.2 Analysis: Intra-observer and Inter-observer reliability  
Intra-observer reliability was examined whereby measures from day 1 
(MH) were compared to the measures from day 2 (MH).  
Inter-observer reliability was examined whereby measures from day 2 
(MH) were compared to measures from day 2 (KL). 
106 
 
&RKHQ¶V NDSSD WHVW ZDV XVHG WR H[DPLQH DJUHHPHQW RI GLFKRWRPRXV
data and a weighted kappa for ordinal data. The strength of agreement 
was classified according to criteria in Table 2-6 (Landis and Koch 
1977). 
Table 2-6 Strength of agreement for the values of kappa 
Value of kappa Strength of agreement 
0     - 0.2 Slight 
0.2  - 0.4 Fair 
0.41 - 0.6 Moderate 
0.61 - 0.8 Substantial 
0.81 - 1.0 Almost perfect 
 
For continuous variables, intra-class correlation co-efficients (ICC) and 
95% confidence intervals were reported. Criteria for describing the 
strength of ICC reliability indices have been proposed where  less than 
0.5 indicates poor reliability, between 0.5  -  0.75 moderate reliability, 
between   0.75 - 0.90 good reliability and > to 0.90 excellent (Portney 
and Watkins 2003). 
Bland & Altman plots were also used to explore the intra and inter-
observer agreement in continuous US measurements.  The plots show 
the difference between the two measures as a function of the average 
of the two measurements with 95% limits of agreement (Bland and 
Altman 2010). 
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2.8.3 Analysis: Diurnal variation of US measure 
A repeated-measures ANOVA and post-hoc tests with Bonferonni 
corrections or non-SDUDPHWULF HTXLYDOHQW )ULHGPDQ¶V $129$ and 
Wilcoxon signed-rank test with Bonferonni adjustment) were performed 
to determine whether within participant measures differed significantly 
over the 3 weeks or between morning and afternoon measures.  
 
2.8.4 Analysis: Cross-sectional comparison study  
Data for this study are described for index (most symptomatic or a 
randomly chosen knee) and contralateral (non-index knee) knees are 
presented.  As data relating to pain severity was collected only for the 
index knee and not each individual knee, analyses were carried out 
using data from the index knee joint using standard analysis 
techniques. These analyses are therefore both knee- and subject-
specific. 
More sophisticated statistical methods can be use which can take into 
account the correlation between data from two joints coming from the 
same person such as random effects modelling, marginal modelling 
and generalised estimating equations (GEE) (Sutton, Muir et al. 1997) 
but as that data was not collected these methods are not suitable for 
this study.  
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2.8.4.1 Primary analysis ± difference between groups 
Primary analysis was the analysis based on the study design and 
compared the differences between groups.  Chi-square test was used 
for nominal or frequency data. Where the expected frequencies were 
OHVV WKDQ  )LVKHU¶V H[DFW WHVW ZHUH UHSRUWHG 3RVW-hoc comparisons 
were made using the z-test with adjusted p values (Bonferroni method). 
Continuous variables that were normally distributed were compared 
using the one-way ANOVA and post-hoc Bonferroni tests performed. 
:HOFK¶V ) VWDWLVWLF DQG SRVW-hoc Games-Howell test were reported 
where variance between groups were unequal. 
Non-normally distributed data were analysed using the Kruskal-Wallis 
test and selected post-hoc Mann Whitney tests with a Bonferroni 
correction performed. 
2.8.4.2 Secondary analysis 
2.8.4.2.1 Pain and US features. 
Associations between knee pain and the presence of US features were 
investigated using logistic regression. All odds ratios (OR) were 
adjusted for age, sex and BMI and ROA .	/  *UDGH . Similar 
analysis adjusting for these features have been previously used in the 
analysis of cross-sectional studies examining associations between 
MRI features and knee pain (Hernández-Molina, Guermazi et al. 2008; 
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Hernández-Molina, Neogi et al. 2008).Crude OR and adjusted OR for 
each adjustment are presented. 
The same adjusted models were used to evaluate the associations 
between US features and night pain, intermittent and constant knee 
pain. 
The relationships between pain severity and continuous US measures 
were examined using correlation co-efficients. Pearson correlation co-
efficient is reported for parametric data and 6SHDUPDQ¶VFRUUHODWLRQFR-
efficient for non-parametric or ordinal data.   
2.8.4.2.2 ROA and US features 
$VVRFLDWLRQVEHWZHHQUDGLRJUDSKLF2$DVGHILQHGE\.	/JUDGH
and the presence of US features were also examined using logistical 
regression. All OR were adjusted for age, sex, BMI and knee pain. 
Chondrocalcinosis on radiographs was also examined as an individual 
feature, as clinically it is associated with inflammation. 
Relationships between radiographic severity (as determined by 
radiographic scoring from the Nottingham LDA) and continuous US 
measures were examined using non-parametric correlation co-
efficients. 
2.8.4.2.3 Clinical signs and symptoms and US features 
Associations between clinical signs and symptoms which support 
inflammation (clinical effusion, self-reported morning stiffness and 
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biomechanically assessed stiffness and damping co-efficients) and US 
features were also explored. OR were adjusted for age, sex BMI, the 
presence of knee pain and ROA.  
2.8.4.2.4 Knee joint stiffness 
Joint stiffness was explored as a clinical symptom that is commonly 
associated with joint inflammation. Univariate analysis identified 
variables associated with biomechanically measured stiffness and 
damping co-efficients and multiple linear regressions was used to 
explore their contribution in the overall variance of stiffness. 
2.8.5 Analysis: Follow-up evaluation 
Change in knee pain was defined as an increase or decrease in 
maximal pain rating on the WOMAC pain subscale.  Change in reported 
symptoms was examined in control and SOA groups separately. 
Associations between change in knee pain at follow-up and change in 
presence or absence US features were examined using Chi-square 
analysis for both groups. 
Further exploration of possible relationships between change in pain 
VAS scores and change in continuous measures of US effusion, 
synovial hypertrophy and popliteal cyst were examined using a 
correlation matrix.  
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Correlations between change in pain VAS, US features and 
biomechanical assessed stiffness and damping co-efficients were also 
explored. 
2.8.6 Analysis: Intervention study 
The primary outcome measure was change in knee pain VAS from the 
time of the injection to 1 week after the injection.  
Whilst it was not the intention of this study to examine the efficacy of 
the steroid against the placebo injection, standardised statistical 
methods for analysis of a cross-over trial were carried out.  An order 
effect was excluded by comparing the response to the steroid and 
placebo injection in each intervention period using unpaired t ±tests or 
Mann-Whitney U test. 
Response following the steroid and placebo injection and the 
differences between them were then examined using paired t-tests or 
the non-parametric equivalent and Chi-square test for dichotomous 
data. 
Responders to the steroid and placebo injections were defined as those 
whose pain VAS scores decreased by 15mm or greater, one week after 
injection.  Associations between response to injection and presence of 
baseline US features were examined using simple logistical regression. 
Correlations between change in pain VAS scores and change in 
FRQWLQXRXV86PHDVXUHVZHUHH[SORUHGXVLQJ6SHDUPDQ¶VFRUUHODWLRQ
rho. Individual responses in VAS pain scores and US variables 
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following both steroid and placebo injections were then examined for 
trends. 
2.9 Data management  
2.9.1 Data accuracy 
Completeness and accuracy of the data was checked in a sample of 30 
participants. Hard copy records were compared against the study 
database by two persons independently (15 data records each). Each 
data input was examined for errors and omission and these were 
recorded in a separate document. The errors for each section of the 
assessment were totalled and a percentage error calculated. Errors in 
each section are shown in Table 2-7 below. An error below 2% was 
considered acceptable. There was no difference in the overall number 
of errors detected by each person. 
 Table 2-7 Percentage errors detected  
Assessment section % Errors detected 
Clinical history/physical examination <0.5 
Knee pain map <0.5 
Knee tenderness map 
  1.42 
WOMAC questionnaire <0.5 
ICOAP questionnaire 0 
Ultrasound assessment <1.0 
Biomechanical assessment of joint stiffness  
 1.6 
X-ray scores 0 
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2.9.2 Missing data 
Missing data was entered as a discrete value (99) in the database and 
was included in the analysis.  Missing data in the US assessment was 
usually due to difficulty in positioning the participant, for example some 
participants were unable to prone lie for examination of the popliteal 
fossa. 
Some participants failed to complete all questions in the WOMAC 
Index. Missing values were dealt with as recommended by the authors. 
Where one pain, one stiffness or up to 3 physical function items were 
missing, the average value for that subscale was substituted. This 
method is similar to that employed by other indices such as the SF36 
and AIMS2 (Bellamy 1995). 
 
114 
 
3 Results 
The results for this thesis are reported in sections as follows: 
Section 3.1 Recruitment 
Section 3.2 Reliability of outcome measures: 
x intra and inter-observer reliability of ultrasound 
assessment 
x inter-observer reliability of ultrasound assessment 
x intra-observer reliability of biomechanical 
assessed stiffness and damping co-efficient 
Section 3.3 Diurnal variation in US measures 
Section 3.4 Cross-section multiple group comparison study  
x primary analysis: difference between groups 
 x secondary analysis: associations between knee 
pain, structural change and US features 
Section 3.5 Follow-up evaluation 
x correlations and associations between changing 
knee pain and change in US features 
Section 3.6 Intervention with corticosteroid or placebo injection 
x response following interventions 
x correlations and associations between response 
following intervention and change in US features 
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3.1 Recruitment 
Of 1090 potential participants approached to take part in the study, 241 
were enrolled in the study. An overview of the recruitment is presented 
in Figure 3-1 and a detailed breakdown of recruitment in Table 3-1. Two 
additional participants were recruited from other sources. One was a 
spouse of a study participant with knee pain and without ROA, and the 
other was a patient with knee pain who was referred to the OA out-
patient clinic at Nottingham University Hospital with knee pain but 
without radiographic changes.  
The characteristics of participants invited for the current study, those 
who did not reply, those who declined those who were unsuitable and 
those who were enrolled are shown in Table 3-2 along with the baseline 
characteristics of their original studies. At the point of invitation, 
potential participants from the community knee pain trial were younger 
(mean age, 58 SD(7) years) than other participants, and the potential 
participants from the incident KP cohort had a higher proportion of 
females (m: f = 29:71%) 
Response rates varied across the 3 sources of recruitment  with the 
highest proportion of positive responders coming from the incident knee 
pain study (67.5%) followed by the community KP trial (57.8%) and 
then the GOAL database (33.4%). The ratio of males to females 
recruited was similar across the three sources (1:2.2), and mean age 
reflected the differences observed at the point of invitation.  
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Conversely, non-responders were highest from the GOAL database, 
followed by the community knee pain trial and incident knee pain cohort 
(52%, 26% and 12% respectively), age and gender were representative 
of those who were approached. The proportion of those who replied but 
declined to take part was similar across the three recruitment sources 
(14-17%) and also closely reflected the age and gender of those initially 
invited to participate.   
The proportion of participants who were unsuitable due to exclusion 
criteria were more common in the incident KP cohort compared to the 
community KP trial and GOAL database (12.6%, 6.3% and 1.6% 
respectively). Mean age reflected those invited to participate, though 
the proportion of females was higher from the incident knee pain cohort 
and GOAL database. More men were excluded from the community 
knee pain trial than women.  
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Figure 3-1 Overview of Recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Participants approached 
n=1090 
No response=438 (40%) 
No=160 (15%) 
Deceased= 10 (1%) 
Unable to contact = 4 (0.4%) 
 
Yes=478 (44%) 
 
Recruited from 
other source  (2)  
SOA 
(Symptomatic OA)  
62 
 
ROA 
(Radiographic OA)  
32 
 
KP 
(Knee Pain only) 
59 
 
 
 (Controls) 
90 
 
 
 
Baseline assessment 
243 
Unsuitable on screening = 46 
(4.2%) 
 
Unsuitable due to group 
allocation  =183 (16.8%) 
 
Unable to contact/ changed 
mind = 8 (0.7%)  
 
Yes=241 (22%) 
 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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Table 3-1 Breakdown of recruitment 
 
 
 
Total invites sent out n=1090 
 
Incident KP cohort 
N = 265 
n (%) 
Community 
 KP trial N = 95 
n (%) 
GOAL database 
N = 730 
n (%) 
 
No response 
 
32 (12.1%) 
 
 
25 (26.3%) 
 
381 (52.1%) 
5HSO\µ1R¶ 46 (17.4%) 
 
14 (14.7%) 100 (13.7%) 
Deceased 4 (1.5%) 
 
1 (1%) 5 (0.7%) 
Unable to 
contact 
4 (1.5%) 0 0 
5HSO\µ\HV¶ 
 
179 (67.5%) 55 (57.8%) 244 (33.4%) 
Unable to 
contact 
 
8 (3%) 0 0 
Excluded 28 (10.6%) 
- TKR   (14) 
- Hip OA (8) 
- Neurological   
(2) 
- Fibromyalgia 
(3) 
- Cancer (1) 
 
6 (6.3%) 
- Hip OA (3) 
- Neurological (1) 
- Fibromyalgia (1) 
- Inflammatory 
Arthritis (1) 
12 (1.6%) 
- Hip OA (1) 
- TKR (1) 
- Fibromyalgia (3) 
- Inflammatory 
Arthritis (1) 
- Care Home (1) 
- Acute knee 
injury(3) 
- Chronic other 
pain (2) 
 
Unsuitable 
for Group 
0 18 (18.9%) 165 (22.6%) 
Recruited 
and included 
 
143 (54%) 
 
31 (33%) 
 
67 (9.2%) 
 
Control 50 6 35 
KP 16 25 16 
ROA 20 0 12 
SOA 57 0 5 
    
(TKR = Total knee replacement; KP= knee pain; ROA= radiographic OA; SOA= 
symptomatic OA) 
119 
 
Table 3-2 Characteristics of individuals selected for recruitment  
Recruitment source Incident KP cohort 
 
Community 
 KP trial  
GOAL database 
 
Baseline data collected 1996-2001 2007-2008 2002-2006 
Population (n) 
 3109 892 3171 
Age at baseline 
Mean (SD) years 
 
57 (9) 
 
60.6  
range (40-84) 
 
66.5 (7.9) 
Gender      male: female % 44.5: 55.5% 49: 51% 52: 48% 
Invited for current study (n) 265 95 730 
*Mean age (SD) years  72.5 (8.1) 58 (6.9) 70 (8.0) 
male:female % 29:71% 42 % 58% 47: 53% 
No reply  
*Mean age (SD) years 
 
72.4 (9.1) 
 
59.9 (7.0) 
 
70 (9.0) 
male:female % 28: 72% 44:56% 48:52% 
Reply No   
*Mean age (SD) years 
 
73.9 (7.9) 
 
57.7 (3.6) 
 
72 (8.0) 
male:female % 24:73% 36:64 45:56% 
Excluded  
*Mean age (SD) years 
 
73.4 (7.2) 
 
59.6 (8.0) 
 
69 (9.0) 
male:female % 18.5 :81.5% 55:45% 25:75 
Reply Yes  
*Mean age (SD) years 
 
72 (8.0) 
 
56.1 (7.0) 
 
71 (8.0) 
male:female % 31:69% 32:68% 31:68% 
* age at onset of recruitment for current study 01/03/2010  
(KP= knee pain) 
 
 
  
120 
 
3.2 Reliability of outcome measures 
3.2.1 Intra and inter-observer reliability of US assessment 
3.2.1.1 Participants 
Fourteen participants (28 knees) mean age 67.5 years (range 56-71), 
12 female and 2 males had their knees scanned twice by the same 
examiner (MH) within a 7 day period. 13 knees were identified as 
normal, 3 knees had knee pain only, 2 had ROA only and 10 had SOA. 
Five participants (ten knees), mean age 71.4 years (range 66-77), 4 
women and 1 man took part had their knees scanned independently by 
two examiners (MH and KL) on the same day. 5 knees were identified 
as normal, 3 had knee pain and 2 had SOA. 
3.2.1.2 Results 
Kappa co-efficients for intra- and inter-observer agreement for the 
dichotomous presence or presence of US features and weighted kappa 
values for PD signal are shown in Table 3-3. 
Table 3-3 Intra- and Inter-observer agreement for the presence of US features 
 Kappa 
Inflammatory US Features Intra-observer Inter-observer 
Effusion 0.76 p<0.001 0.78  p=0.001 
Synovial hypertrophy 0.79 p<0.01 0.78  p<0.01 
Popliteal cyst  0.70 p<0.001 0.62  p=0.04 
PD Signal        (unweighted) 1.0   p<0.001 0.76  p<0.001 
Grade PD Signal  (weighted) 1.0   p<0.001 0.78  p<0.001 
Structural US Features 
  
Osteophytes 0.80 p<0.001 0.55 <0.01 
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The level of agreement for effusion and synovial hypertrophy was 
substantial, and for popliteal cysts was moderate for inter-observer 
reliability and substantial for intra-observer reliability. Intra-observer 
agreement was better for PD signal than inter-observer agreement. 
There was moderate agreement between different observers for 
presence of osteophytes, and good agreement within the same 
observer.  
Intra-class correlation co-efficients for the continuous measures of 
effusion, synovial hypertrophy and bursitis are shown in Table 3-4. The 
ICC values demonstrate that the reliability for both intra and inter-
observer measures were good to excellent for all US features of 
inflammation. ICCs for the measurement of structural features was 
good for osteophytes. Measurement of femoral articular cartilage depth 
had higher ICCs when measured in the transverse plane compared to 
the longitudinal plane, and was higher for intra compared to inter-
observers. 
Table 3-4 Intra-class correlation co-efficients (ICC) and 95% confidence interval 
(CI) for reliability of continuous US features 
 ICC  (95% CI) 
Inflammatory US Features Intra-observer Inter-observer 
Effusion (mm) 0.91 (0.81-0.96) 0.88 (0.60-0.97) 
Synovial hypertrophy (mm) 0.95 (0.9-0.98) 0.84 (0.50-0.96) 
Popliteal cyst (mm) 0.82 (0.66-0.91) 0.80 (0.60-0.90) 
Structural US Features 
  
Osteophytes (mm) 0.86 (0.76-0.92) 0.79 (0..5-0.89) 
Femoral articular cartilage (mm)   
Transverse view 0.71 (0.41-0.87) 0.52 (0.12-0.78) 
Longitudinal view 0.66 (0.33-0.84) 0.14 (-0.41-0.44) 
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Bland & Altman plots were also used to explore the intra and inter-
observer agreement for inflammatory US features (Figure 3-2, Figure 
3-3).  
The plots show the difference between the two measures as a function 
of the average of the two measurements. The solid line indicates the 
mean difference of the paired measures; the distance from zero 
provides an estimate of the bias from the two methods (Bland and 
Altman 2010). Values close to zero indicate lesser bias.  The dashed 
lines indicate the 95% limits of agreement. A summary of the mean 
differences and 95% limits of agreement for intra and inter-observer 
measures are presented in Table 3-5. 
Table 3-5 Summary of mean differences and 95% limits of agreement for intra 
and inter-observer measures of continuous US measures 
 Intra-observer agreement 
(MH, day1- day2) 
Inter-observer agreement 
(MH-KL) 
 
US measures 
(mm) 
mean 
difference 
(SD) 
95% limits of 
agreement 
mean  
difference 
(SD) 
95% limits of 
agreement  
 
Effusion  
 
-0.1 
 
(2) 
 
(-4.0, 4.0) 
 
1.4 
 
(2.1) 
 
(-2.7, 5.5) 
Synovial hypertrophy 0.5 (1.4) (-3.2, 2.1) 1.3 (2.6) (-3.8, 6.3) 
Bursitis  0.2 (1.5) (-2.8, 3.2) 0.5 (1.0) (-1.4, 2.3) 
 
For intra-observer agreement the mean discrepancy between 
observations on day 1 and day 2 was less than 1mm for all measures. 
For inter-observer agreement between MH and KL, the mean difference 
was less than 1.4mm for all measures.  There was a visible trend on all 
three plots where measures taken by MH were higher than that of KL 
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indicating a degree of systematic bias. However the magnitude of the 
difference is unlikely to be clinically significant.  
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 Figure 3-2 Bland_Altman plots for intra-observer agreement of US measure of 
effusion, synovial hypertrophy and popliteal cysts. 
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Figure 3-3 Bland-Altman plots for inter-observer agreement of US measures of 
effusion, synovial hypertrophy and bursitis. 
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3.2.2 Reliability of biomechanically assessed stiffness 
3.2.2.1 Participants 
10 subjects participated in this test-retest study, 4 women and 6 men, 
aged 61-77 (mean age 69.3). Twenty knees were tested of which 14 
had radiographic changes and 13 were painful. Four participants were 
unable to complete valid test trials on both days and were excluded 
from the analysis.  
3.2.2.2 Results 
Intra-class correlation co-efficients and 95% confidence intervals for the 
stiffness and damping between days are presented in Table 3-6. 
Reliability for damping co-efficinets was very good and excellent for 
stiffness co-efficient. 
Table 3-6 Intra-class correlation co-efficients (ICC) and 95% confidence 
intervals (CI) for intra-observer reliability for stiffness and damping co-efficients 
 ICC (95% CI) 
Damping  0.85 (0.52 - 0.96) 
Stiffness  0.96 (0.85 - 0.99) 
 
For the damping co-efficient, the mean difference between measures 
on day 1 and day 2 was 0.02 Nm /rad/sec (SD 0.06) with 95% limits of 
agreement from -0.09 to 0.14 (Figure 3-4).  For the stiffness co-efficient, 
the mean difference was 0.35 Nm/rad (SD 1.05) with 95% limits of 
agreement from -1.70 to 2.40 (Figure 3-5).  
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Figure 3-4 Bland & Altman plot of damping co-efficient (Nm/rad/sec) taken on 2 
days by the same observer 
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Figure 3-5 Bland & Altman plot of stiffness co-efficient (Nm/rad) taken on 2 days 
by the same observer 
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3.3 Diurnal variation of US measures  
3.3.1 Participants 
Five participants, mean age 70.4 (range 61-76), 4 women and 1 man 
took part in this study, all with bilateral symptomatic knee OA. US 
assessments took place in the morning and were repeated in the 
afternoon, on 3 separate occasions, one week apart. Effusions and 
synovial hypertrophy were observed in all knees, popliteal cysts were 
found in 3 knees. PD signal was not detected in any of the knees 
assessed and so this was not subjected to statistical analysis. 
3.3.2 Results 
Descriptive data for pain and US variables are presented in Table 3-7. 
WOMAC, ICOAP and VAS pain scores were found to be normally 
distributed (Shapiro Wilks test p>0.05). Repeated-measures ANOVA 
showed no significant differences in participant reported WOMAC 
scores, ICOAP scores or VAS scores between weeks 1, 2 and 3. 
US measures of synovial hypertrophy were normally distributed 
(p>0.05) but effusion and popliteal cysts were not and were analysed 
XVLQJ)ULHGPDQ¶V$129$.  
)ULHGPDQ¶VANOVA found no statistical difference between measures 
IRU HIIXVLRQ ȋ2  S  RU IRU SRSOLWHDO F\VWV ȋ2(5)=6.06, 
p=0.33. Repeated measures ANOVA for synovial hypertrophy showed 
no significant difference between measures F=1.13, p=0.36.
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Table 3-7 Descriptive data for pain and US variables in diurnal variation study 
        Week 1 Week 2 Week 3 
Pain variables Mean (SD) Mean (SD) Mean (SD) 
Pain VAS (mm)  41.00 (27.82) 56.00 (19.11) 51.40 (21.31) 
WOMAC Pain scores 
 7.60 (2.70)  8.00 (4.30)  8.80 (5.07) 
ICOAP Intermittent score 11.80 (4.66) 11.90 (5.07) 12.40 (6.66) 
            Constant score 
 
7.80 (3.70) 9.60 (4.16) 9.20 (3.56) 
US measures am pm am pm am pm 
Synovial hypertrophy (mm)      
Mean(SD) 6.25 (3.29) 7.09 (2.68) 7.29 (3.61) 7.04 (2.99) 5.89 (3.22) 6.77 (3.28) 
Effusion (mm) 
     
Mean(SD) 8.13 (6.19) 8.08 (5.19) 8.47 (4.80) 8.31 (4.76) 7.90 (4.29) 7.95 (6.05) 
Median (range) 5.15 (4.00,21.80) 6.60 (3.10,17.00) 6.45 (3.10,17.20) 6.80 (4.40,16.30) 7.70 (3.80,16.00) 5.75 (2.70,18.20) 
Popliteal cyst (mm) 
     
Mean(SD) 2.35 (3.41) 2.18 (3.03) 2.27 (3.15) 2.73 (3.92) 2.68 (3.79) 2.32 (3.21) 
Median (range) 0.00 (0-8.40) 0.00 (0-6.60) 0.00 (0-6.90) 0.00 (0-9.20) 0.00 (0-8.90) 0.00 (0-10.32) 
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3.4 Results: Cross-sectional comparison study  
This section describes the results of the cross-sectional multiple group 
comparison study which set out to achieve the primary objectives of this 
body of work. Participant recruitment, baseline demographics, clinical 
signs and symptoms, radiographic scores and US findings are 
presented. Primary analysis of differences between controls (those 
without knee pain or radiographic changes) and participants with painful 
knees, ROA and SOA are reported. Secondary analysis exploring the 
associations between knee-pain, US features and structural damage 
are reported.   
3.4.1 Participant demographics 
A total of 243 participants were included in the analysis of the study, 
157 (64.6%) women and 86 (35.4%) men. Participant characteristics 
are presented for each study group according to the index knee (most 
symptomatic or randomly chosen knee) (Table 3-80).  
There was no significant difference in the number of men and women 
within each group (p=0.29). One way ANOVA showed there was a 
significant difference in age across the groups (p<0.001). Bonferroni 
post-hoc comparisons revealed that the KP group was significantly 
younger compared to all other groups p<0.001 (Figure 3-6). The control 
group had a significantly lower BMI p<0.05, but the other groups were 
not significantly different to each other (Figure 3-7). 
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Table 3-8 Participant demographics ± comparison between groups 
Group Controls KP ROA SOA p 
 
         
N (%) 
 
90 (37%) 59 (24%) 32 (13%) 62 (26%)  
Gender 
         
Men               n (%) 27 (30%) 26 (44.1%) 13 (40.6%) 20 (32.3%)  
 0.29 Women         n (%)  63 (70%) 33 (55.9%) 19 (59.3%) 42 (67.7%) 
Age (years) 
        
mean (SD) 71 (7.9) 63.8 (8.8) 73.1 (7.9) 73.9 (7.78) <0.001 
Median (range) 
 
70 (51-90) 64  (50-81) 71  (61.9) 74 (56-91)  
BMI (kg/m2) 
        
mean (SD) 26.5 (4.4) 28.5 (4.0) 29.60 (5.3) 29.21 (4.1) <0.001 
median (range) 
  25.9 (19.1-39.6) 28.5 (21.7 ± 40) 28.37 (22.5 - 41.4) 28.97 (20 - 40.9)  
KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA 
BMI=Body mass index
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Figure 3-6 Mean Age with 95% confidence intervals (CI) for each comparison 
group.  
 
 
Figure 3-7 Mean body mass index (BMI) with 95% confidence intervals (CI) for 
each comparison group.  
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3.5 Primary Analysis 
3.5.1 Radiographic evaluation ± comparison between groups 
3.5.1.1 Index knee 
Table 3-9 summarises the radiographic scores for the index knee using 
the logically derived Line Drawing Atlas. Mean summated scores are 
presented for individual features of osteophytes and joint space 
narrowing, and for tibio-femoral and patello-femoral compartments. A 
global score for all features in all compartments is also presented.  The 
median (range) is presented for the number of osteophytes observed 
and frequency data for the presence of radiographic chondrocalcinosis 
is given. Descriptive data for Kellgren & Lawrence grading is also 
presented. 
One way-ANOVA showed significant differences between groups for 
global radiographic scores (p<0.001). Post-hoc tests found no 
significant difference between control and KP groups for all summated 
scores. Participants with SOA had significantly worse x-rays compared 
to those with ROA (mean difference = 5.6 for global scores, p=0.005) 
(Figure 3-8). 
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Table 3-9 Summated radiographic scores for index knee ± comparison between groups 
Summated radiographic scores 
 
Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
           P 
         
 
Global Score (0-60) 
         
 Mean (SD) 1.1 (1.5) 0.5 (1.1) 11.9 (7.14) 17.5 (8.0) <0.001 
Median (range) 0.5 (0-7) 0 (0-5) 11 (3-30) 16 (4-38)  
Osteophytes (0-40) 
         
Mean (SD) 0.6 (.1.0) 0.2 (.8) 7.9 (5.9) 12.4 (7.0) =0.001 
Median (range) 0 (0-6) 0 (0-5) 7 (1-25) 11 (2-30)  
Joint Space Narrowing  (0-20) 
         
Mean (SD) 0.6 (1.0) 0.3 (0.6) 4.0 (2.1) 5.2 (2.1) <0.001 
Median (range) 0 (0-5) 0 (0-3) 4 (0-9) 5 (1-11)  
Tibio-femoralJoint (0-30) 
         
Mean (SD) 0.8 (1.2) 0.3 (0.7) 4.6 (3.9) 8.6 (5.5) <0.001 
Median (range) 0 (0-6) 0 (0-3) 4 (0-18) 8 (0-22)  
Patellofemoral joint (0-30) 
         
Mean (SD 0.4 (0.8) 0.2 (0.8) 7.3 (5.7) 9.0 (4.9) <0.001 
Median (range) 0 (0-4) 0 (0-5) 6.5 (0-19) 9 (0-19)  
Number of Osteophytes 
         
Median (range) 
 
0 (0-5) 0 (0-3) 4 (1-8) 6 (1-8) =0.001 
Chondrocalcinosis                                N (%) 5 (5.6%) 3 (5.8%) 1 (3.1%) 8 (12.9%) =0.27 
 
         
Kellgren & Lawrence Grade           N (%) G0 71 (79.0%) 54 (91.5%) 0  0   
G1 19 (21.0%) 5 (8.5%) 0  0   
G2 0  0  9 (28.1%) 5   (8.1%)  
G3 0  0  15 (46.9%) 23 (37.1%)  
G4 0  0  8 (25.1%) 34 (54.8%)  
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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Figure 3-8 Index knee: mean global x-ray scores for each comparison group 
 
Comparison of individual features found the number of osteophytes 
was significantly higher in the SOA group (p=0.001), as was the 
summated score for osteophytes (mean difference = 4.5, p<0.001) 
(Figure 3-9). There was no significant difference for joint space 
narrowing (p=0.09) (Figure 3-10). 
For comparison by joint compartment, tibio-femoral joint scores were 
also significantly worse in the SOA group (mean difference = 4.0, 
p<0.001) (Figure 3-11) but not patello-femoral joint score (p=0.5) 
(Figure 3-12). No difference was found in the frequency of 
chondrocalcinosis between any groups (p=0.27).  
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Figure 3-9 Index knee: mean summated scores for osteophytes for each 
comparison group 
 
Figure 3-10 Index knee: mean summated score for joint space narrowing (JSN) 
for each comparison group 
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Figure 3-11 Index knee: mean summated scores for tibio-femoral joint (TFJ) for 
each comparison group 
  
Figure 3-12 Index knee: mean summated scores for patello-femoral joint (PFJ) 
for each comparison group 
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3.5.1.2 Contra-lateral knee 
Table 3-10 summarises the radiographic scores of the contra-lateral 
(non-index) knees.  
A Kruskal-Wallis test showed significant difference in the summated 
knee scores between groups (p<0.001) (Figure 3-13). Post-hoc Mann-
whitney U tests revealed the SOA group had higher global scores and 
summated scores for osteophytes (Figure 3-14), joint space narrowing 
(Figure 3-15) and the tibio-femoral joint (Figure 3-16) in the contra-
lateral knee compared to those in the ROA group (p<0.05). There was 
no significant difference for patello-femoral joint scores between SOA 
and ROA groups (Figure 3-17). 
Kellgren & Lawrence scores for the contra-lateral (non-index) knee 
showed no significant differences between control and knee pain 
groups. The SOA group had a higher proportion of participants with G3 
and G4 KL scores than all other groups (p<0.05) but was not 
significantly different to ROA group for grade G2. There was no 
significant difference between all groups for G0 and G1. 
No significant differences were observed in the proportion of 
participants with radiographic chondrocalcinosis in the contra-lateral 
knee (p=0.52).  
  
139 
 
Table 3-10 Summated radiographic scores for contra-lateral knee ± comparison between groups 
Summated radiographic scores 
 
Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
p 
Global Score (0-60) 
         
 Mean (SD) 1.07 (2.0) 0.5 (1.1) 8.67 (6.9) 12.2 (8.3)  
Median (range) 0 (0-12) 0 (0-5) 8 (0-23) 12.5 (0-36) <0.001 
Osteophytes (0-40) 
         
Mean (SD) 0.6 (1.3) 0.3 (0.6) 5.8 (5.4) 8.3 (6.6)  
Median (range) 0 (0-9) 0 (0-2) 5.5 (0-19) 7 (0-28) <0.001 
Joint Space Narrowing  (0-20) 
         
Mean (SD) 0.5 (1.0) 0.2 (0.7) 2.9 (2.5) 4.0 (2.6)  
Median (range) 0 (0-5) 0 (0-4) 3 (0-11) 4 (0-10) <0.001 
Tibio-femoralJoint (0-30) 
         
Mean (SD) 0.6 (1.2) 0.2 (0.6) 3.1 (3.5) 5.3 (4.9)  
Median (range) 0 (0.7) 0 (0-3) 2 (0.13) 4 (0.19) <0.001 
Patellofemoral joint (0-30) 
         
Mean (SD 0.5 (1.26) 0.3 (0.8) 5.6 (4.9) 7.0 (5.3)  
Median (range) 0 (0-6) 0 (0-4) 6 (0-20) 6 (0-18) <0.001 
Number of Osteophytes 
         
Median (range) 0 (0-5) 0 (0-2) 3.5 (0-8) 5 (0-8) 
 
 
Chondrocalcinosis                                                   N (%) 5 (5.6%) 3 (5.1%) 0 (0%) 9 (14.5%)  
 
         
Kellgren & Lawrence Grade                                   N (%) G0 69 (76.7%) 53 (89.8%) 9 (28.1%) 7 (11.3%)  
G1 13 (14.4%) 5 ( 8.5%) 2 (6.3%) 5 (  8.1%)  
G2 4 ( 4.4%) 1 ( 1.7%) 3 (9.4%) 13 (21.0%)  
G3 3 ( 3.3%) 0 (0%) 16 (50%) 13 (21.0%)  
G4 1 ( 1.1%) 0 (0%) 2 (6.3%) 24 (38.7%)  
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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Figure 3-13 Contra-lateral knee: mean global x-ray scores for each comparison 
group  
 
Figure 3-14 Contra-lateral knee: mean summated scores for osteophytes for 
each comparison group 
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Figure 3-15 Contra-lateral knee: mean summated score for joint space 
narrowing (JSN) for each comparison group 
 
Figure 3-16 Contra-lateral knee: mean summated scores for tibio-femoral  joint 
(TFJ) for each comparison group 
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Figure 3-17 Contra-lateral knee: mean summated scores for patella-femoral joint 
(PFJ) for each comparison group 
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3.5.2 Pain evaluation ± comparison between groups 
Half of all participants (n=122) reported having at least moderate pain in 
the previous week, of which 79 (65%) had pain bilaterally. Participants 
with pain were asked to consider which knee was most symptomatic ± 
left, right or neither, 49% reported their right knee, 36.5% reported their 
left knee and 14.5% reported neither knee as more symptomatic.   
Contra-lateral knee pain was present in 36 (61%) of participants with 
KP and 43 (69%) of those with SOA. Pain severity in the contra-lateral 
knee was recorded. 
Measures of pain included a 100mm VAS, the pain section of the 
WOMAC index and the ICOAP questionnaire which has subscales for 
intermittent and constant knee pain. Descriptive data are presented in 
Table 3-11. All pain measures demonstrated significant differences 
between those with and without knee pain (p<0.001). No significant 
differences were observed between those with KP and SOA for 
measures of knee pain, (Figure 3-18 - Figure 3-21) patterns of knee 
pain, and type of current pain medication used (p<0.05). Pain VAS 
measures for the contra-lateral knee were not recorded.  
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Table 3-11 Descriptive Pain data for Index knee ± comparison between groups 
Group 
n 
Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
p 
VAS (mm)     
Mean (SD) 6.6 (11.0) 48.9 (22.0) 7.2 (14.4) 48.2 (24.6)   <0.001 
WOMAC (0-20) 
       
Mean (SD) 1.0 (1.5) 8.0 (3.3) 0.9 (1.3) 8.0 (3.2)  
Median (range) 0 (0-8) 8 (2-15) 0 (0-5) 8 (2-15)    <0.001 
ICOAP Subscales  
Constant (0-20) 
      
Mean (SD) 0.5 (1.2) 5.9 (4.8) 0.2 (0.6) 6.9 (5.2)  
Median (range) 0 (0-5) 6 (0-17) 0 (0-2) 6 (0-18)    <0.001 
Intermittent (0-24) 
      
Mean (SD) 1.6 (2.5) 10.2 (4.1) 2.0 (3.1) 10.6 (5.5)  
Median (range) 0 (0-11) 10 (0-21) 0 (0-14) 10.5 (0-24)    <0.001 
Knee pain pattern   n %   n % 
 
Localised   19 (32.2%)   16 (25.8%) <0.05 
Regional   31 (52.5%)   27 (43.5%) <0.05 
Diffuse   9 (15.3%)   19 (30.6%) <0.05 
         
 
Current pain medication n (%) n (%) n (%) n (%) 
 
None 84 (93.3%) 19  (32.2%) 26 (81.3%) 17 (27.4%) <0.05 
Paracetamol only 2 (2.2%) 12 (20.3%) 1 (3.1%) 14 (22.6%) <0.05 
Oral NSAID only 1 (1.1%) 8  (13.6%) 1  (3.1%) 6 (9.7%) <0.05 
Other only eg co-codamol/ 
tramadol  
 
3 
 
(3.3%) 
 
5 
 
(8.5%) 
 
1 
 
(3.1%) 
 
6 
 
(9.7%) 
 
<0.05 
Combination paracetamol/ 
NSAID oral/topical /Other 
 
0 
 
(0%) 
 
15 
 
(23.7%) 
 
2 
 
(6.2%) 
 
19 
 
(27.4%) 
 
<0.05 
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Figure 3-18 Mean pain visual analogue scale (VAS) scores for each comparison 
group. 
 
 
Figure 3-19 Mean WOMAC Pain subscale scores for each comparison group. 
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Figure 3-20 Mean ICOAP Constant subscale score for each comparison group  
 
 
 
Figure 3-21 Mean ICOAP Intermittent subscale score for each comparison group  
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3.5.3 US evaluation ± comparison between groups 
3.5.3.1 Index knee 
Frequency data for US features in the index knee are presented in 
Table 3-12 and are presented graphically in Figure 3-22. Descriptive 
data for continuous measures of depth of effusion, thickness of synovial 
hypertrophy and depth of popliteal cysts are presented in Table 3-13. 
Table 3-13. There was no statistical difference in the observed 
frequency of US features or measures between control participants and 
those with KP for all features. 
Table 3-12  Index knee: frequency data for US features ± comparison between 
groups 
Group 
n 
Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
 
p 
 n (%) n (%) n (%) n (%)  
Effusion 26 (28.9) 19 (32.2) 26 (81.3) 57 (91.9) <0.001 
Synovial hypertrophy 7 (7.8) 7 (11.9) 13 (40.6) 51 (82.3) <0.001 
Popliteal cysts 11 (12.4) 5 (8.6) 7 (21.9) 23 (39.2) <0.001 
Infra-pat bursitis 3 (3.3) 4 (6.8) 0 (0) 5 (8.1) =0.28 
Pes- Anserine Bursitis 0 (0) 0 (0) 0 (0) 4 (6.5)  
PD signal 2 (2.2) 2 (3.4) 2 (6.3) 10 (16.2) =0.005 
Grade 1 2 (2.2) 1 (1.7) 2 (6.3) 5 (8.1)  
Grade 2 0 (0) 0 (0 ) 0 (0) 5 (8.1)  
Grade 3 0 (0) 1 (1.7) 0 (0) 0 (0)  
Chondrocalcinosis                   2 (2.2) 1  (1.7) 0 (0) 7 (11.3) =0.01 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA; PD = 
power Doppler; CC= chondrocalcinosis) 
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Figure 3-22 Index knee: frequency of US features ± comparison between groups 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
 
 
Table 3-13 Index knee: descriptive data of continuous US measures for each 
comparison group 
 Controls 
90 
KP  
59 
ROA 
32 
SOA 
62 
p 
Effusion           
         
Mean (SD) 2.6  (2.7) 3.4  (3.2) 6.0  (2.6) 8.1  (4.0) <0.001 
Median 
(range) 
2.6 (0-9) 3.1  (0-13.6) 5.6 (1.6-13.7) 8.0  (0-21.8)  
Synovial Hypertrophy   
      
Mean (SD) 0.7  (1.5) 1.0  (1.9) 3.9  (3.9) 6.7  (3.3) <0.001 
Median (range) 0  (0-6.7) 0  (0-8.1) 3.10  (0-12.9) 6.90  (0-12.9)  
Popliteal cysts         
       
Mean (SD) 1.0  (2.6) 0.8  (2.2) 1.8  (3.6) 3.5  (4.7) =0.001 
Median (range 0 (0-12.5) 0 (0-11.7) 0 (0-12.4) 0 (0-14.3)  
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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3.5.3.1.1 Effusion 
Effusions on ultrasound were observed in 28.9% of control participants 
and 32.2% of those with knee pain. The frequency was significantly 
higher in those with ROA (81.3%; p<0.05) and was higher again in 
those with SOA (91.9%) but not significantly so. 
The mean depth of effusion showed a trend increasing in size in those 
with KP, ROA and SOA compared to controls (Figure 3-23). Post-hoc 
comparisons revealed no difference between the control group and the 
KP group but significant differences between all other groups (p<0.05).  
Figure 3-23 Index knee: mean US measures of effusion (mm) (95% CI) for each 
comparison group 
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3.5.3.1.2 Synovial Hypertrophy 
The frequency of synovial hypertrophy was significantly different 
between groups (p<0.001). The frequency was less than 8% in controls 
and 12% in those with KP but was significantly higher in those with 
ROA (40.6%) (p<0.05) and higher again in SOA (82.3%) (p<0.05). 
The depth of synovial hypertrophy also differed significantly between 
groups (Figure 3-24). Post hoc analysis revealed no significant 
difference between the control and KP groups. The ROA and SOA 
groups differed significantly from the control group and from each other 
(both p<0.05).  
Figure 3-24 Index knee: mean US measures of synovial hypertrophy (mm) 
(95%CI) for each comparison group 
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3.5.3.1.3 Popliteal cyst 
Popliteal cysts were observed in 12.4% of controls which was not 
significantly different from the KP group where they were observed less 
frequently (8.6%). A higher occurrence was found in the ROA (21.9%, 
p<0.05) and SOA (39%, p<0.05) groups which was significantly 
different from the control and KP groups but were not significantly 
different to each other.  
The size of popliteal cyst also differed significantly between groups 
(p=0.001). Post-hoc tests showed that popliteal cysts were significantly 
larger in the SOA group compared to both the control and KP groups 
(p<0.05) but not significantly different to the ROA group (p=0.11).  
Figure 3-25 Index knee: mean US measures of popliteal cyst (mm) (95% CI) for 
each comparison group 
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3.5.3.1.4 Power Doppler Signal 
The frequency of PD signal in the SOA group (16.2%) was significantly 
higher than in the control (2.2%, p<0.05) and KP groups (3.4%, p<0.05) 
but not significantly different to the ROA group (6.3%). The grade of PD 
signal was not subject to analysis due to the low frequency observed. 
3.5.3.1.5 Chondrocalcinosis 
US-detected chondrocalcinosis was significantly higher in the SOA 
compared to all other groups (p=0.01).  
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3.5.3.2 Contra-lateral knee 
US features in the contra-lateral knee are presented in Table 3-14 and 
are presented graphically in Figure 3-26. Descriptive data for 
continuous US measures are presented in Table 3-15.  No significant 
differences were observed in the contra-lateral knees of controls and 
knee pain participants for any US measure. 
In the SOA group, contra-lateral knees had a significantly higher 
frequency of US effusion, hypertrophy and popliteal cysts compared to 
the contra-lateral knees of all other groups (p<0.05). Size of effusion 
and synovial hypertrophy were also significantly higher (p<0.05) when 
compared to all other groups (Figure 3-27, Figure 3-28). Popliteal cyst 
size was only significantly greater compared to controls and knee pain 
only participants (p<0.05) (Figure 3-29).  
Frequency of Power Doppler activity was only significantly different 
between controls and SOA participants (p<0.05), There was no 
significant difference between groups for US detected 
chondrocalcinosis in the contra-lateral knee (p=0.07) 
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Table 3-14 Contra-lateral knee: frequency data for US features in each 
comparison group 
Group 
n 
Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
 
p 
 n (%) n (%) n (%) n (%)  
Effusion 17 (18.9) 21 (35.6) 14 (43.8) 46 (74.2) <0.001 
Synovial hypertrophy 6 (3.7) 6 (10.2) 10 (31.3) 35  (36.5) <0.001 
Popliteal cysts 8 (9) 4 (6.9) 2 (6.3) 20 (33.9) <0.001 
Infra-pat bursitis 0 (0) 2 (3.4) 1 (3.1) 2 (3.2) =0.39 
Pes- Anserine Bursitis 0 (0) 0 (0) 0 (0) 2 (3.2) =0.12 
PD signal 0 (0) 4 (6.8) 2 (6.3%) 8 (12.9) =0.01 
Grade 1 0 (0) 4 (6.8) 2 (6.3%) 5 (8.1)  
Grade 2 0 (0) 0 (0) 0 (0) 3 (4.8)  
Grade 3 0 (0) 0 (0) 0 (0) 0 (0)  
Chondrocalcinosis                   2 (2.2) 2 (3.4) 0 (0) 4 (6.5) =0.07 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA; PD = 
power Doppler; CC= chondrocalcinosis) 
 
Figure 3-26 Contra-lateral knee: frequency of US features in each comparison 
group 
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Table 3-15 Contra-lateral knee: descriptive data of continuous US measures in 
each comparison group 
 Controls 
90 
KP  
59 
ROA 
32 
SOA 
62 
p 
Effusion           
         
Mean (SD) 2.2 (2.4) 2.8 (2.6) 3.8 (2.9) 6.4 (4.1)  
Median (range) 1.7  (0-9.3) 3.1 (0-10.4) 3.4 (0-9.4) 5.3 (0-14.6) <0.001 
Synovial Hypertrophy   
      
Mean (SD) 0.6 (1.6) 1.1 (2.5) 2.5 (3.1) 5.0 (4.2)  
Median (range) 0 (0-8.7) 0 (0-13.1) 0.8 (0-9.4) 4.1 (0-13.8) <0.001 
Popliteal cysts         
       
Mean (SD) 0.8 (2.3) 0.6 (1.8) 0.7 (1.5) 2.9 (4.7)  
Median (range) 0 (0-13.5) 0 (0-9.0) 0 (0-4.7) 0 (0-20.2) <0.001 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
 
Figure 3-27 Contra-lateral knee: mean US measures of effusion (mm) (95% CI) in 
each comparison group 
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Figure 3-28 Contra-lateral knee: mean US measures of synovial hypertrophy 
(mm) (95% CI) for each comparison group 
 
Figure 3-29 Contra-lateral knee: mean US measures of popliteal cyst size (mm) 
95% CI) for each comparison group 
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3.5.3.3 Relationships between US features 
US measures of effusion and synovial hypertrophy were strongly 
associated with each index  and non-index knee joints (Table 3-16). 
Popliteal cysts measures showed only a weak correlation with both 
effusion and synovial hypertrophy. 
Table 3-16 Relationship between continuous US measures for Index and Non-
index knees 
Knee 
 Effusion 
(mm) 
Synovial  
Hypertrophy 
(mm) 
 Popliteal 
cyst (mm) 
Index Effusion (mm) r 1.00   
 Hypertrophy( mm) r  0.79** 1.00  
 Popliteal cyst (mm) 
 
r  0.22**  0.35** 1.00 
Non- Effusion (mm) r 1.00   
Index Hypertrophy (mm) r  0.61** 1.00  
 Popliteal cyst (mm) r  0.26**  0.38** 1.00 
* Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level  
mm = millimetres 
 
When correlations were examined within the SOA group (data not 
shown), the strength of the relationship between effusion and 
hypertrophy was reduced but remained significant  for both index and 
non-index knees (r=0.55, p<0.01 and r= 0.53, p<0.01 respectively) ) 
and remained similar for synovial hypertrophy and popliteal cyst 
(r=0.30, p<0.05, and r= 0.37 p<0.01 respectively). 
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3.5.4 Clinical evaluation (Index knee) and function± comparison 
between groups  
Clinical evaluation and functional assessment included clinically 
detected knee effusion, range of movement, quadriceps and hamstring 
muscle strength, timed get up and go tests and a biomechanical 
assessment of stiffness and damping co-efficients. The WOMAC 
questionnaire was also used to evaluate self-reported stiffness and 
function. Table 3-17 shows the descriptive data for clinical and 
functional measures. 
3.5.4.1 Clinical Effusion 
For the index knee, clinical effusions were detected in just 2.2% of 
control knees and 3.4% of knee pain only knees. A significantly higher 
number of effusions were observed in ROA knees (15.6%) and higher 
again (50%) in SOA knees (p<0.001). 
3.5.4.2 Stiffness 
Measures of knee joint stiffness included self-reported morning stiffness 
of greater than 30 minutes duration, the stiffness subscale from the 
WOMAC index, and the damping and stiffness co-efficient calculated 
from the passive pendulum knee test.  
Self-reported stiffness that was at least moderate in intensity was 
reported more frequently in participants with knee pain (69.5%) and 
SOA (82.3%) compared to those with ROA (6.3%) and control 
participants (12.2%). 
159 
 
Table 3-17 Clinical and functional measures ± comparison between groups 
 Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
 
p 
 Mean SD Mean SD Mean SD Mean SD  
ROM (degrees) 141 (8.2) 136 (13.2) 135 (8.4) 121 (20.5) <0.001 
Quadriceps St (kg) 16.7 (4.2) 16.6 (5.0) 16.6 (4.4) 12.8 (4.1) <0.001 
Hamstring St (kg) 7.4 (1.6) 8.0 (2.1) 7.9 (2.0) 6.9 (1.8) =0.038 
Timed GUG  3m (s) 7.7 (1.8) 8.9 (2.3) 8.5 (1.9) 11.9 (5.3) <0.001 
Timed GUG  50ft (s) 10.7 (2.1) 12.0 (2.6) 11.8 (2.4) 15.8 (6.9) <0.001 
WOMAC sub-scale: 
         
Stiffness (0-8) .8 (1.1) 3.4 (1.6) 0.9 (0.9) 4.0 (1.8) <0.001 
Function (0-68) 4.2 (6.5) 25.8 (12.3) 5.5 (6.6) 29.6 (11.8) <0.001 
 
         
Damping co-eff (N/m/rad/sec) 0.46 (0.15) 0.49 (0.19) 0.47 (0.11) 0.50 (0.18) =0.70 
Stiffness co-eff (N/m/rad) 15.25 (4.41) 17.21 (4.99) 18.17 (3.37) 18.16 (5.52) =0.009 
 
         
Clinical Effusion                       n (%) 2 (2.2%) 2 (3.4%) 5 (15.6%) 31  (50%) <0.001 
Valid Stiffness test                   n (%) 63 (70%) 34 (57.6%) 21 (65.5%) 36 (58.1%) =0.34 
Moderate Stiffness (WOMAC)  n (%) 11 (12.2%) 41  (69.5%) 2 (6.3%) 51 (82.3%) <0.001 
AM Stiffness >30mins               n (%) 0 (0%) 20 (37.7%) 0 (0%) 15 (27.3%) <0.001 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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Morning stiffness lasting 30 minutes or longer was reported only by 
participants with knee pain regardless of radiographic OA, which was 
highly significant (p<0.001).  
WOMAC scores for stiffness reflected the same pattern and showed 
differences between groups that were significant for KP and SOA 
compared to controls and ROA (p<0.001) (Figure 3-30).There was no 
significant difference between the KP group and SOA group for self-
reported stiffness. 
The calculation of stiffness and damping co-efficients were dependent 
on the performance of a valid pendulum test. Not all participants were 
able to complete the passive pendulum test. Successful tests were 
performed by 154 participants (63%). A higher proportion of control 
participants (70%) were able to complete the pendulum test compared 
to other groups but this was not statistically significant (p=0.34).  
Mean stiffness co-efficients were significantly higher in the SOA group 
(mean difference = 2.91 Nm/rad (95% CI 0.07-5.75),p=0.04) compared 
to controls (Figure 3-31). There were no other significant differences 
between groups. Mean damping co-efficients did not show any 
differences between groups (p=0.70) (Figure 3-32). 
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Figure 3-30 Mean WOMAC Stiffness subscale (95% CI) for each comparison 
group  
 
Figure 3-31 Index knee: mean stiffness co-efficient (95% CI) for each 
comparison groups.  
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Figure 3-32 Index knee: mean damping co-efficient (95% CI) for each 
comparison groups  
 
3.5.4.3 Range of movement 
Significant differences between groups were observed for ROM, 
p<0.001 (Figure 3-33). Those with SOA had significantly less ROM 
compared to all other groups (p<0.001).  Those with KP or ROA also 
has significantly less ROM compared to controls (p<0.01) but were not 
significantly different to each other. 
3.5.4.4 Muscle strength 
Quadriceps strength was significant lower in the SOA group compared 
to other groups (p<0.001). Other groups did not differ from each other 
(Figure 3-34). No significant differences were found for hamstring 
strength (p=0.07) (Figure 3-35). 
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Figure 3-33 Index knee: mean range of movement (ROM) (95% CI) for each 
comparison group  
 
Figure 3-34 Index knee: mean Quadriceps strength (kg) (95% CI) for each 
comparison group  
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Figure 3-35 Index knee: mean Hamstring strength (kg) (95%CI) for each 
comparison group  
 
3.5.4.5 Get Up and Go tests 
Those in the SOA group were significantly slower than all other groups 
(p<0.001) (Figure 3-36).Those with KP were slower compared to 
controls (p=0.007) but not significantly different to those with ROA. The 
same observations were also significant in the GUG (50 feet) test 
(p<0.001).  
3.5.4.6 WOMAC Function subscale 
Differences between groups were observed for WOMAC function 
subscale (p<0.001) (Figure 3-37). Those in the KP and SOA groups 
has significantly higher WOMAC scores (denoting worse function) 
compared to controls and ROA (p<0.001). There was no difference in 
self-reported function between ROA and controls.  
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Figure 3-36 Mean time GUG 3m (seconds) (95% CI) for each comparison group  
 
Figure 3-37 Mean WOMAC Function scores (95%CI) for each comparison group   
 
 
 
166 
 
3.5.4.7 Clinical evaluation in the Contra-lateral knee 
Joint specific clinical evaluations included the presence of clinically 
detected effusion, range of movement, muscle strength of quadriceps 
and hamstrings, and stiffness and damping co-efficients Table 3-18.  
Table 3-18 Contra-lateral knee: Clinical and functional measures in each 
comparison group 
 Controls 
90 
KP 
59 
ROA 
32 
SOA 
62 
 
p 
 n  (%) n  (%) n  (%) n  (%)  
Clinical Effusion      0 (0%) 1 (1.7%) 2 (6.3%) 16 (25.8%) <0.001 
 
         
 
Mean SD Mean SD Mean SD Mean SD  
ROM       (degree) 142.2 (8.3) 136.6 (12.4) 134.4  (8.1) 126.9 (19.7) <0.001 
Quadriceps St (kg) 16.9 (4.1) 17.2 (4.9) 17.1 (4.7) 14.9 (4.6) <0.001 
Hamstring St   (kg) 7.4 (1.7) 8.2 (2.0) 7.8 (1.6) 7.2 (2.5) =0.076 
Damping co-eff: 
         
        (N/m/rad/sec) 0.44 (0.17) 0.47 (0.18) 0.51 (0.17) 0.49 (0.18) =0.26 
Stiffness co-eff: 
         
               (N/m/rad) 15.28 (4.42) 17.30 (4.90) 18.43 (3.66) 18.03 (5.07) =0.003 
 
Effusions in the contra-lateral knee were only significantly higher in the 
SOA group (p<0.05). Kruskal-Wallis tests identified differences between 
groups for contra-lateral ROM, quadriceps strength and stiffness co-
efficients. Post hoc Mann-Whitney U tests identified that ROM was 
significantly reduced in SOA participants compared to controls 
(p<0.05)(Figure 3-38), that contra-lateral quadriceps strength was 
significantly lower in SOA participants compared to all other groups 
(p<0.05)(Figure 3-39), and that stiffness co-efficients were significantly 
higher in SOA and ROA participants compared to controls 
(p<0.05)(Figure 3-40). 
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Figure 3-38 Contra-lateral knee: mean range of movement (ROM) (degrees) (95% 
CI) 
 
Figure 3-39 Contra-lateral knee:mean quadriceps strength (kg) (95% CI) 
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Figure 3-40 Contra-lateral knee: mean stiffness co-efficient (Nm/rad) (95% CI) 
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3.6 Secondary analysis 
3.6.1 Associations between knee pain and US features 
Knee pain was determined from the pain subscale of the WOMAC 
questionnaire. Of 243 participants, 121 (49.8%) were classified as knee 
pain positive and 122 (50.2%) as pain negative. Knee pain was 
examined in relation to the presence US features (Table 3-19). After 
adjusting for age, sex, BMI and ROA, only synovial hypertrophy was 
independently associated with knee pain (aOR=6.56, 95%CI 2.85, 
15.11). 
Table 3-19 Association between US features and knee pain  
US features  
 
Knee pain 
 
Odds ratio (95% confidence interval) 
no yes Crude OR Adjusted1 Adjusted2 
Effusion   
     
no 70 45 1 1 1 
yes 
  
52 76 2.27 (1.36, 3.80) 2.61 (1.48, 4.57) 1.54 (0.80, 2.95) 
Hypertrophy 
     
no 102 63 1 1 1 
yes  
 
20 58 4.70 (2.58, 8.53) 8.87(4.22,18.64) 6.56 (2.85,15.11) 
Popliteal cyst 
     
no 103 89 1 1 1 
yes 
  
18 28 1.80 (0.93, 3.47) 2.40 (1.18, 4.86) 1.82 (0.87, 3.84) 
PD signal 
     
no 118 109 1 1 1 
yes  4 12 3.25(1.02,10.37) 4.31(1.25,14.82) 3.43 (0.96, 12.30) 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
Knee pain is defined as the reporting of at least moderate knee pain in the previous 
week on WOMAC index. 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and ROA 
 
Significant associations are highlighted in bold 
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3.6.1.1 Night Pain 
Night pain of at least moderate intensity was reported by 61 (25.1%) 
participants. Synovial hypertrophy was associated with night pain and 
remained so after adjusting for co-variates, (aOR=4.93, 95%CI 2.28, 
10.63). The presence of US detected effusion, popliteal cysts and PD 
signal were not associated with night pain (Table 3-20). 
 
Table 3-20 Association between US features and night pain  
US features  
 
Night pain 
 
Odds ratio (95% confidence interval) 
no yes Crude OR Adjusted1 Adjusted2 
Effusion   
     
no 92 23 1 1 1 
yes  
 
90 38 1.69 (0.93, 3.06) 1.80 (0.96, 3.41) 1.80 (0.94, 3.57) 
Hypertrophy 
     
no 135 30 1 1 1 
yes  
 
47 31 2.97 (1.63, 5.42) 4.47 (2.17, 9.21) 4.93(2.28, 10.63) 
Popliteal cyst 
     
no 147 45 1 1 1 
yes  
 
32 14 1.43 (0.70, 2.91) 1.74 (0.81, 3.75) 1.69 (0.78, 3.70) 
PD signal 
     
no 170 57 1 1 1 
yes  12 4 0.99 (0.31, 3.21) 1.17 (0.34, 4.01) 1.13 (0.33, 3.92) 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
Night pain is defined as the reporting of at least moderate night pain in the 
previous week on WOMAC index. 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and ROA 
 
Significant associations are highlighted in bold 
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3.6.1.2 Intermittent and Constant knee pain 
Intermittent knee pain of at least moderate intensity was reported in 102 
(42%) and constant knee pain in 58 (23.9%) of all participants. 
Associations between US features and intermittent and constant knee 
pain are presented in Table 3-21 and  Table 3-22. 
The presence of moderate intermittent knee pain was associated with 
US detected effusion and synovial hypertrophy. This remained 
significant after adjusting for age, sex, BMI and ROA (aOR=2.67, 95% 
CI 1.46, 4.92 and aOR =6.30, 95% CI 3.03, 13.08 respectively). 
Constant knee pain was not associated with the presence of effusion. 
The presence of synovial hypertrophy had an increased risk of constant 
knee pain which remained significant after adjusting for age, sex, BMI 
and ROA (aOR =8.34, 95%CI 3.56, 19.52).  
The presence of a popliteal cyst was also associated with constant KP 
after adjusting for co-variates (aOR=2.88, 95% CI 1.28, 6.45). 
PD signal was neither associated with intermittent or constant knee 
pain as derived from the ICOAP. 
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Table 3-21 Association between US features and intermittent knee pain 
US features  
 
Intermittent 
knee pain 
Odds ratio (95% confidence interval) 
no yes Crude OR Adjusted1 Adjusted2 
Effusion   
     
no 77 38 1 1 1 
yes  64 64 2.03 (1.20,3.41) 2.36 (1.34,4.18) 2.67 (1.46, 4.92) 
Hypertrophy 
  
   
no 110 55 1 1 1 
yes  31 47 3.03 (1.74,5.29) 5.12(2.59,10.15) 6.30(3.03,13.08) 
Popliteal  
     
cyst        no 115 77 1 1 1 
yes  24 22 1.37 (.71, 2.61) 1.83 (.91, 3.68) 1.90 (.93, 3.87) 
PD signal 
     
no 134 93 1 1 1 
yes  7 9 1.85 (.67, 5.15) 2.46 (.82, 7.42) 2.57 (.85,7.80) 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
Intermittent knee pain is defined as the reporting of at least moderate intensity 
intermittent pain in the previous week as reported in the ICOAP questionnaire. 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and ROA 
 
Significant associations are highlighted in bold 
 
 
Table 3-22 Association between US features and Constant knee pain  
US features  
 
Constant 
knee pain 
Odds ratio (95% confidence interval) 
no yes Crude OR Adjusted1 Adjusted2 
Effusion   
     
no 93 22 1 1 1 
yes  92 36 1.65 (.95, 3.03) 1.84 (.96, 3.53) 1.89 (.86, 3.75) 
Hypertrophy 
     
no 139 26 1 1 1 
yes  46 32 3.72 (2.01, 6.83) 6.92(3.18,15.06) 8.34 (3.56,19.52) 
Popliteal 
cyst 
     
no 153 39 1 1 1 
yes  31 15 1.89 (0.93, 3.86) 2.88 (1.31, 6.34) 2.88 (1.28, 6.45) 
PD signal 
     
no 175 52 1 1 1 
yes  10 6 2.01 (0.70, 5.82) 2.52 (0.81, 7.90) 2.51 (0.79, 2.06) 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
Constant knee pain is defined as the reporting of at least moderate intensity 
constant pain in the previous week as reported in the ICOAP questionnaire. 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and ROA 
 
Significant associations are highlighted in bold 
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3.6.2 Correlations between pain and US features 
Correlations between pain measures and continuous measures of US 
detected effusion, synovial hypertrophy and popliteal cyst were 
explored and are presented in Table 3-23.  
Table 3-23 Correlation matrix between pain measures and US features (mm)  
  
Pain VAS 
(mm) 
WOMAC 
Pain 
score 
Pain at 
night in bed 
(WOMAC) 
Intermittent 
pain 
score 
Constant 
pain 
score 
Pain VAS (mm) r 1.00     
WOMAC Pain 
score 
r 0.90** 1.00    
At night in bed 
(WOMAC) 
r 0.72** 0.85** 1.00   
Intermittent pain 
score 
r 0.90** 0.89** 0.75** 1.00  
Constant pain 
score 
r 0.79** 0.81** 0.71** 0.81** 1.00 
Effusion (mm) r 0.29** 0.29** 0.20** 0.30** 0.31** 
Synovial 
hypertrophy (mm) 
r 0.31** 0.32** 0.20** 0.33** 0.31** 
Popliteal cyst 
(mm) 
r 0.09 0.10 0.04 0.11 0.08 
** Correlation is significant at the 0.01 level  
 
All pain measures were strongly correlated with each other. The 
correlation between pain measures and US features were weak but 
significant for effusion (r=0.29, p=0.001 for pain VAS; Figure 3-41) and 
synovial hypertrophy (r=0.3, p<0.001 for pain VAS; Figure 3-42). No 
correlation was found between popliteal cyst size and pain severity.  
These relationships were also explored within the SOA group (data not 
shown). The correlation between pain severity and effusion remained 
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significant (r=0.28, p=0.01) but was non-significant for synovial 
hypertrophy (r=0.20, p=0.06). 
Figure 3-41 Scatterplot of relationship between effusion (mm) and pain visual 
analogue scale (VAS) score (mm). 
 
Figure 3-42 Scatterplot of relationship between synovial hypertrophy (mm) and 
pain visual analogue scale (VAS) score (mm).  
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3.6.3 Associations between ROA and US features of inflammation 
Associations between the presence of ROA (K&/ grade 2) and the 
US features of inflammation were examined using logistic regression 
(Table 3-24). The presence of radiographic OA (K&L grade 2 or above) 
was strongly associated with US detected effusion, synovial 
hypertrophy and popliteal cyst after adjusting for age, sex, BMI and the 
presence of at least moderate knee pain. 
PD signal was observed in 12 participants (12.8%) with ROA compared 
to 4 (2.7%) without ROA. This was highly significant (p=.005). However 
the association became insignificant after adjusting for the presence of 
knee pain. 
Table 3-24 Association between Radiographic OA (ROA) and Ultrasound 
features in Index knee 
 
US Features 
ROA 
No        Yes 
Odds ratio (OR) 
(95% confidence interval) 
 Crude OR Adjusted1 Adjusted2 
Effusion               No  104 11 1 1 1 
Yes 45 83 17.44 
 (8.49, 35.81) 
16.09  
(7.41, 34.96) 
13.39 
 (6.14, 29.02) 
Synovial  
hypertrophy         No 
 
135 
 
30 
 
1 
 
1 
 
1 
Yes 14 64 20.57 
 (10.21, 41.45) 
17.80 
 (8.07, 39.27) 
14.39  
(6.28, 32.94) 
Popliteal cyst      No 131 61 1 1 1 
Yes 16 30 4.03  
(2.04, 7.94) 
3.65  
(1.70, 7.84) 
3.19 
 (1.42, 7.17) 
PD signal            No 145 82 1 1 1 
Yes 4 12 5.31 
(1.66, 16.98) 
3.92 
 (1.10, 13.90) 
2.83  
(0.76, 10.43) 
52$DVGHILQHGE\.	/*UDGH 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 LVDGMXVWHGIRUDJHVH[%0,DQGNQHHSDLQPRGHUDWHRQ:20$& 
 
Significant associations are highlighted in bold 
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Chondrocalcinosis (CC) was also examined as an individual 
radiographic feature (Table 3-25). Grey scale features were not 
associated with radiographic CC. However, PD signal was found to be 
independently associated with CC (p=0.007). In index knees, PD signal 
was detected in almost 30% of participants with CC compared to 5% 
without. The aOR of CC in those with PD signal was 6.6 (95% CI 1.67, 
26.05) after adjusting for co-variates. PD signal was also found to be 
independently associated when left and right knees were examined 
(aOR = 4.98, 95% CI 1.17, 21.10 for left knees and aOR = 4.90, 95% 
CI 1.15, 20.79 for right knees). Additional adjustment for the presence 
of ROA .	/*UDGH did not appreciably alter the aOR. 
Table 3-25 Association between the presence of chondrocalcinosis (on x-ray) 
and US features in Index knees 
 
 
US Features 
Chondro-
calcinosis 
No        Yes 
Odds ratio 
 (95% confidence interval) 
Crude OR Adjusted1 Adjusted2 
Effusion                 No 109 6 1 1 1 
Yes 117 11 1.71 
 (0.61, 4.77) 
1.31 
 (0.44, 3.91) 
1.02 
 (0.31, 3.23) 
Synovial  
    
Hypertrophy          No 156 9 1 1 1 
Yes 70 8 1.98  
(0.73, 5.35) 
1.33  
(0.43, 4.10) 
0.91 
(0.26, 3.27) 
Popliteal cyst         No  183 9 1 1 1 
Yes 40 6 3.05 
 (1.03, 9.06) 
2.28 
(0.73, 7.12) 
2.10 
(0.66,6.71) 
PD signal                No 215 12 1 1 1 
Yes 11 5 8.14 
(2.44, 27.12) 
7.57 
 (1.96, 29.24) 
6.57  
(1.66, 25.94 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 LVDGMXVWHGIRUDJHVH[%0,DQGNQHHSDLQPRGHUDWHRQWOMAC) 
 
Significant associations are highlighted in bold 
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Though US detected chondrocalcinosis was not a primary outcome 
measure for this study, agreement between US and radiographic 
chondrocalcinosis was examined (Table 3-26). A poor level of 
agreement (kappa =0.26, p<0.001) was found between the two and 
consequently US detected chondrocalcinosis was not used in any 
further exploratory analysis. Reasons for this are explored in the 
discussion.   
Table 3-26 Cross-tabulation of chondrocalcinosis detected on radiographs and 
by US  
 
 
Radiographic detected 
Chondro-calcinosis 
 
 
No     
 
Yes 
US- detected 
Chondrocalcinosis 
                     
     No 220 (90.5%) 13 (5.3%) 
    Yes 6 (2.5%) 4 (1.7%) 
  
 
3.6.4 Correlations between radiographic scores and US features  
Radiographic OA and US features were further examined using a 
correlation matrix to identify relationships between global x-ray scores, 
individual radiographic features and compartments, and US features 
(Table 3-27).  
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Table 3-27 Correlations between summated radiographic scores and 
continuous US measures.  
 Effusion 
 (mm) 
Synovial 
Hypertrophy (mm) 
Popliteal cyst  
(mm) 
Index knee 
   
Global score (0-60) 0.57** 0.71** 0.33** 
Osteophytes (0-40) 0.58** 0.73** 0.32** 
 Joint space narrowing (0-20) 0.51** 0.65** 0.30** 
Tibio-fem joint (0-30) 0.54** 0.64** 0.32** 
Pat-fem joint (0-30) 0.50** 0.67** 0.30** 
 
   
* Correlation is significant at the 0.05  
** Correlation is significant at the 0.01 level  
mm = millimeters 
 
All radiographic scores were positively correlated with US features, for 
the index knee (p<0.01). Effusion showed a moderate relationship with 
all features. For individual features this was strongest for osteophytes 
(r=0.58, p<0.01) and for compartments this was strongest for the tibio-
femoral joint score (r=0.54, p<0.01). Synovial hypertrophy 
demonstrated the strongest correlation with radiographic scores. For 
individual features this was strongest for osteophyte scores (r=0.73, 
p<0.01) and for compartments this was strongest for the patello-femoral 
joint (r= 0.67, p<0.001). Correlations between popliteal cyst size and 
radiographic features were weaker but remained significant (r=0.33, 
p<0.01 for global x-ray score). 
Scatterplots showing the relationship between global radiographic 
scores and US measures of effusion, synovial hypertrophy and popliteal 
cysts size are shown for the index knees (Figure 3-43- Figure 3-45). 
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Figure 3-43 Scatterplot showing relationship between global x-ray score and US 
measured effusion (millimetres) for Index knee 
 
Figure 3-44 Scatterplot showing relationship between global x-ray score and US 
measured synovial hypertrophy (millimetres) for Index knee 
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Figure 3-45 Scatterplot showing relationship between global x-ray score and US 
measure of popliteal cyst (millimetres) for Index knee 
 
 
3.6.5 Associations between knee pain and clinical features 
Associations between knee pain and clinical features were explored 
using logistic regression. All ORs were adjusted for age, sex, BMI and 
ROA (Table 3-28). 
The presence of a clinical effusion was associated with more than a six- 
fold risk for knee pain, which remained significant after adjusting for co-
variables (aOR = 5.75, 95% CI 2.15, 15.34). 
After adjusting for covariates restricted ROM was significant for those in 
the third tertile (the most restricted range) (aOR 6.56, 95% CI 2.83, 
15.25). The OR for those in the middle tertile was not significant after 
adjusting for ROA. 
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Table 3-28 Associations between knee pain and clinical features  
 Clinical features Knee 
pain  
No    Yes 
Odds ratio  
(95% confidence interval) 
Crude OR Adjusted1 Adjusted2 
 Clinical effusion 
     
absent  115 88 1 1 1 
present 7 33 6.16 
(2.60,14.58) 
8.53 
(3.36,21.64) 
5.75 
(2.15,15.34) 
 Range of Movement 
    
  Tertile 1   
141° 
 
55 24 1 1 1 
Tertile 2 -140° 45 38 1.94 
(1.02, 3.69) 
2.12 
(1.05, 4.28) 
1.86 
(0.90, 3.84) 
  Tertile 3   
2° 
22 59 6.15 
(3.10, 12.20) 
8.81 
(3.89,19.94) 
6.56 
(2.83, 15.25) 
 Quadriceps strength 
    
  Tertile     
strongest 
 
49 30 1 1 1 
              middle 41 39 1.55 
(0.83, 2.92) 
2.22 
(1.10, 4.50) 
1.99 
(0.97, 4.10) 
         weakest 30 49 2.67 
(1.40, 5.07) 
5.56 
(2.47,12.51) 
4.26 
(1.83, 9.88) 
 GUG 3 m 
     
                time 
<10s 
108 70 1 1 1 
time >10s    13 50 5.93 
(3.01,11.72) 
10.46 
(4.67,23.43) 
9.31 
(4.06, 21.37) 
 Moderate stiffness (WOMAC) 
   
absent 109 29 1 1 1 
present 13 92 26.60 
(13.07,54.14) 
27.14  
(12.88,57.18) 
25.88 
(12.04,55.66) 
 AM stiffness > 30 min 
    
absent 121 79 1 1 1 
present 0 35 2.47 p=.99 2.23 p=.99 2.23 p=.99 
      
 Damping co-efficient 
  
    Tertile       
lowest 
23 23 1 1 1 
                  middle 37 18 0.49 
(0.22, 1.09) 
0.28 
(0.11, 0.69) 
0.25 
(0.9, 0.65) 
highest 24 29 1.21 
(0.54, 2.67) 
0.42 
(0.14, 1.28) 
0.40 
(0.12, 1.28) 
 Stiffness co-efficient 
   
     Tertile       
lowest 
31 20 1 1 1 
                 middle 28 23 1.23 
(0.56, 2.69) 
0.63 
(0.24, 1.60) 
0.63 
(0.23, 1.69) 
                 highest 24 27 1.74 
(0.79, 3.83) 
0.32 
(0.08, 1.28) 
0.29 
(0.07, 1.22) 
Knee pain is defined as the reporting of at least moderate knee pain in the 
previous week on WOMAC index. 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and radiographic OA 
Significant associations are highlighted in bold 
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An association between muscle strength and knee pain was only 
significant for those with the weakest quadriceps strength.  These had 
an aOR of 4.26 (95% CI 1.83, 9.88) compared to those with the 
strongest quadriceps.  
Fifty participants with knee pain (41.6%) took over 10 seconds to 
complete the GUG 3m test compared to 10.7% of participants without 
knee pain. This conferred over a nine-fold risk for knee pain after 
adjusting for co-variables (aOR  9.31, 95% CI 4.03, 21.37). 
Moderate self-reported stiffness reported on the WOMAC index strongly 
associated with knee pain (aOR 25.88, 95% CI 12.04, 55.66). Morning 
stiffness lasting more than 30 minutes duration was reported by 35 
participants all of whom had knee pain.  
Biomechanical assessments of joint stiffness found no association 
between stiffness co-efficient and knee pain. Damping co-efficient 
derived from the same test showed a negative association for those in 
the middle tertile where there was a 75% reduction in odds for knee 
pain after adjusting for co-variates (aOR 0.25, 95% CI 0.9, 0.65). The 
OR for those in the stiffest third was not significant. 
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3.6.6 Association between clinical signs and symptoms and US 
features 
3.6.6.1 Clinical Effusion  
All US features were associated with the presence of a clinical effusion 
although the association with PD signal became insignificant after 
adjusting for co-variates Table 3-29. 
Table 3-29 Odds ratios for US features in the presence of clinical effusion. 
Presence of 
US Features 
 
Clinical Effusion 
      
Odds ratio 
 (95% confidence interval) 
No Yes Crude OR Adjusted1 Adjusted2 Adjusted3 
Effusion   
    
      No 114 1 1 1 1 1 
Yes 89 39 49.95 
 (6.73, 370.67) 
35.75  
(4.75, 269.41) 
24.51  
(3.2, 188.03) 
11.81  
(1.44, 97.10) 
Synovial Hypertrophy 
     
         No 162 3 1 1 1 1 
Yes 41 37 48.73  
(14.31, 165.97) 
36.14  
(10.12,129.04) 
24.56  
(6,58, 91.7) 
13.55 
(3.26, 56.46) 
Popliteal cyst   
   
                 No  173 19 1 1 1 1 
Yes 27 19 6.41 
(3.01, 13.62) 
5.81  
(2.50, 13.54) 
4.77 
 (1.93, 11.81) 
3.46 
(1.33, 8.97) 
PD signal   
      
          No 196 31 1 1 1 1 
Yes 7 9 8.13  
(2.82, 23.41) 
5.91 
(1.84, 18.99) 
4.39 
 (1.30, 14.75) 
3.35  
(0.88, 12.75) 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and knee pain 
Adjusted3  is adjusted for age, sex, BMI, knee pain and radiographic OA 
Significant associations are highlighted in bold 
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3.6.6.2 Self-reported stiffness  
US features were not associated with self-reported stiffness after 
adjusting for co-variates (Table 3-30).  
Table 3-30 Associations between the presence of US features and self-reported 
stiffness. 
Presence of 
US Features 
 
Self-reported 
Stiffness 
 (>mod WOMAC)   
Odds ratio 
 (95% confidence interval) 
No Yes Crude OR Adjusted1 Adjusted2 Adjusted3 
Effusion   
    
      No 114 1 1 1 1 1 
Yes 89 39 1.81  
(1.08, 3.02) 
1.88 
(1.06, 3.31) 
0.97 
(0.45, 2.09) 
0.86 
(0.35, 2.07) 
Synovial Hypertrophy 
     
         No 162 3 1 1 1 1 
Yes 41 37 2.58  
(1.49, 4.49) 
3.47  
(1.79, 9.72) 
0.89  
(0.71, 4.88) 
0.75 
 (0.27, 2.09) 
Popliteal cyst   
   
                 No  173 19 1 1 1 1 
Yes 27 19 1.82 
(0.95, 3.48) 
2.50 
 (1.22, 5.14) 
1.86 
 (0.71, 4.88) 
1.83 
 (0.69, 4.92) 
PD signal   
      
          No 196 31 1 1 1 1 
Yes 7 9 2.32  
(0.81, 6.59) 
3.08 
(0.98, 9.69) 
1.44 
 (0.33, 6.28) 
1.41 
 (0.32, 6.20)) 
Adjusted1 is adjusted for age, sex and BMI 
Adjusted2 is adjusted for age, sex, BMI and knee pain 
Adjusted3  is adjusted for age, sex, BMI, knee pain and radiographic OA 
Significant associations are highlighted in bold 
 
 
 
 
185 
 
3.6.6.3 Biomechanical measures of stiffness  
Table 3-31 shows the correlations between biomechanical assessed 
stiffness and damping co-efficients and continuous US measures. 
Modest relationships were observed between stiffness co-efficients and 
US measures of effusion (r=0.33, p<0.01; Figure 3-46) and synovial 
hypertrophy (r=0.32, p<0.01; Figure 3-47). Relationships between 
damping co-efficients  and effusion, and synovial hypertrophy were 
weaker but remained significant (r=0.25, p<.01 and r=0.18, p<0.05 
respectively). Popliteal cyst size was not  correlated with either stiffness 
or damping co-efficients. 
 
Table 3-31 Relationship between biomechanical measures of stiffness and 
measures of US features in index knee  
  Damping 
co-efficient 
Stiffness co-
efficient  
Stiffness co-efficient r    0.74**  
Effusion (mm) r  0.25**  0.33** 
Synovial hypertrophy (mm) r  0.18*  0.33** 
 Popliteal cyst (mm) r -0.09 -0.08 
*  Correlation is significant at the 0.05 
** Correlation is significant at the 0.01 level  
mm = millimetres 
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Figure 3-46 Scatterplot of relationship between effusion and stiffness co-
efficient in index knee  
 
Figure 3-47 Scatterplot of relationship between US measured synovial 
hypertrophy (m) and stiffness co-efficient in index knee 
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3.7 Exploratory analysis of biomechanically assessed stiffness  
Exploratory analysis was undertaken to see if the biomechanical 
assesed stiffness and damping co-efficients were correlated with 
symptoms and other clinical and radiographic features of OA.  
3.7.1 Self-reported morning stiffness and biomechanically 
assessed stiffness 
The relationship between self-reported stiffness on the WOMAC index 
and the biomechanical measures were examined using correlation 
analysis (Table 3-32). Biomechanically assessed stiffness and damping 
were strongly associated with each other (r =0.74, p <0.001) (Figure 
3-48). A weak but significant correlation was found between self-
reported stiffness and the stiffness co-efficient (r=0.29, p<0.001, Table 
3-32). This was stronger when examined in the SOA group (r=0.39, 
p<0.05; data not shown, Figure 3-50). The weak relationship between 
self-reported stiffness and damping co-efficients (r=0.14, p=0.04) was 
not found within the SOA group. 
Table 3-32 Correlation between WOMAC stiffness scores and stiffness and 
damping co-efficients 
 WOMAC 
Stiffness score 
Damping 
co-efficient 
Stiffness 
co-efficient 
WOMAC Stiffness score 1.00   
Damping co-efficient 0.14* 1.00  
Stiffness co-efficient 0.29** 0.74** 1.00 
*  Correlation is significant at the 0.05 level (1-tailed) 
** Correlation is significant at the 0.01 level (1-tailed) 
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Figure 3-48 Scatterplot showing relationship between Stiffness and Damping    
co-efficients for the index knee  
 
 
Figure 3-49 Scatterplot showing relationship between self-reported stiffness 
and stiffness co-efficients for the index knee 
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Figure 3-50 Scatterplot showing relationship between self-reported stiffness 
and stiffness co-efficients for the index knee in the SOA group 
 
3.7.2 Pain and biomechanically assessed stiffness  
Knee pain was not correlated with the damping co-efficient (Table 
3-33). A weak but significant correlation was found between the 
stiffness co-efficient and pain VAS (r=0.28, p=0.001) (Figure 3-51) and 
WOMAC pain score (r=.22, p=0.006).  WOMAC stiffness scores were 
significantly correlated with scores from the WOMAC pain scores 
(r=0.81, p<0.001). 
Table 3-33 Relationships between measures of joint stiffness and pain 
measures 
  WOMAC 
Stiffness 
score 
Damping 
co-efficient 
 
Stiffness 
co-efficient 
Pain VAS (mm) r 0.80** 0.08 0.28** 
     
WOMAC Pain score r 0.81** 0.05 0.22** 
     
** Correlation is significant at the 0.01   
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 Figure 3-51 Scatterplot of relationship between pain VAS score and stiffness 
co-efficient in index knee 
 
 
3.7.3 Correlations between biomechanical stiffness and 
radiographic severity. 
Stiffness co-efficients showed weak but significant correlations with the 
global x-ray score (r=0.19, p=0.02). Individual x-ray features and joint 
compartments also showed weak but significant relationship with all 
features, with no single feature showing a stronger relationship. These 
relationships disappeared when sub-groups were examined (data not 
shown).  The WOMAC stiffness scores also showed a weak correlation 
with radiographic scores, (r=0.23, p<0.001 for global score). No 
relationships were found between damping co-efficients and 
radiographic scores (Table 3-34). 
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Table 3-34 Relationships between radiographic scores and measures of knee 
joint stiffness 
  WOMAC 
Stiffness subscale 
Damping 
co-eff 
Stiffness 
co-eff 
Global x-ray score r 0.23** 0.05 0.19* 
Osteophytes r 0.25** 0.05 0.20* 
Joint space narrowing r 0.22** 0.05 0.19* 
Tib-femoral joint r 0.24** 0.09 0.18 
Pat-fem joint r 0.24** 0.001 0.18* 
*  Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level  
 
 
3.7.4 Correlations between biomechanical stiffness and clinical 
measures 
Other clinical features which may contribute to joint stiffness and 
damping co-efficients were explored (Table 3-35). These were chosen 
on the basis of previously published findings (Oatis 1993; Oatis, Wolff 
et al. 2006; Valle, Casabona et al. 2006). 
Table 3-35 Correlation matrix for measures of joint stiffness and clinical 
features 
  WOMAC 
Stiffness subscale 
Damping 
co-eff 
Stiffness 
co-eff 
Age r -0.10 -0.20** -0.19** 
BMI r   0.32** 0.48** 0.71** 
Range of Movement r  -0.40** -0.21** -0.40** 
Quadriceps strength r   -0.30** 0.31** 0.23** 
Hamstring strength r            -0.09 0.37** 0.37** 
*  Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level  
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Increasing age had a negative relationship with both the damping and 
stiffness co-efficient. The strength of relationship was weak but 
significant for both measures (r= -0.20, p<.01 and r=-0.19, p<0.01 for 
damping and stiffness co-efficients respectively). 
BMI had a strong correlation with stiffness co-efficient (r=0.71, p<0.001) 
and a moderate correlation with damping (r=0.48, p<0.008) (Figure 
3-52). BMI and self-reported stiffness showed a weak relationship 
between the two (r= 0.32, p<0.001). 
Maximum range of movement was inversely correlated with measures 
of stiffness. The relationship was modest for both self-reported stiffness 
(r= -0.40, p<0.001) and for the stiffness co-efficient (r= -0.40, 
p<0.001;Figure 3-53). The relationship with the damping co-efficient 
was weaker but still significant (r= -0.21, p<0.01). 
Quadriceps strength was correlated weakly with the stiffness co-
efficient (r= 0.23, p<0.01) and modestly with the damping co-efficients 
(r=0.31, p<0.001, Figure 3-54). A negative correlation was found with 
quadriceps strength and self-reported stiffness (r= -0.30, p<0.001).  
Hamstring strength was associated with both biomechanical measures 
(r=0.37, p<0.001 for both stiffness and damping co-efficients) but was 
not associated with self-reported stiffness. 
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Figure 3-52 Scatterplot showing the relationship between Body Mass Index and 
stiffness co-efficient in index knee  
 
 
Figure 3-53 Scatterplot showing relationship between range of movement and 
stiffness co-efficient in index knee   
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Figure 3-54 Scatterplot showing relationship between Quadriceps strength and 
damping co-efficient in index knee 
 
3.7.5 Multiple linear regression 
Multiple linear regression was used to explore how clinical, pain, 
radiographic and US variables contributed to the overall variance in 
biomechanically assessed stiffness co-efficients. Age, gender, BMI, 
pain VAS score, global x-ray score and synovial hypertrophy and range 
of movement were examined as these had significant correlations with 
the stiffness co-efficient. 
All of the variables were entered together (Table 3-36). The model had 
an R of 0.85, R2 of 0.72 and adjusted R2 of 0.71; thus this model 
accounted for 71% of the variance. The model as a whole had a 
significant fit to the data (p<0.001). Of the 7 predictor variables, 4 
contributed significantly to the variance in stiffness co-efficient, age 
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(p=0.04), gender (p<0.001), BMI (p<0.001) and synovial hypertrophy 
(p=0.03).  
Table 3-36 Multiple linear regression analyses (forced entry method) for 
stiffness co-efficient and clinical variables  
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
Sig. 95% CI for B 
 B Standard 
Error 
 
Beta   
(Constant) 13.40 4.85  <0.01 ( 3.82, 22.98) 
Age -0.06 0.03 -0.11  0.04 (-0.12, -0.004) 
Gender -4.37 0.45 -0.43 <0.01 (-5.26, -0.49) 
BMI 
 0.71 0.06  0.63 <0.01 ( 0.59, 0.82) 
Pain VAS (mm) -0.01 0.01 -0.03  0.61 (-0.03, 0.02) 
Global x-ray score -0.07 0.04 -0.12  0.08 (-0.16, 0.01) 
Synovial 
hypertrophy (mm) 
 
0.24 
 
0.09 
 
 0.17 
 
 0.01 
 
( 0.06, 0.42) 
ROM (degrees) 
 
-0.03 
 
0.02 
 
-0.09 
 
 0.12 
 
(-0.08, 0.01) 
ROM = range of movement 
 
Significant variables were then re-entered into the equation using a 
hierarchical model to examine the individual contribution of each 
variables (Table 3-37). BMI accounted for almost 50% of the total 
variance in biomechanically assessed stiffness.  Age did not 
significantly change the variance. Gender explained a further 20% to 
the variance whereby females had a lower stiffness co-efficient by 4.52 
(Nm/rad) when other variables were held constant.  Synovial 
hypertrophy exerted a small (1.1% of variance) but significant influence 
on stiffness whereby an increase of 1mm of synovial hypertrophy 
increases stiffness by 0.16 (Nm/rad/) when other variables are held 
constant. Finally pain severity and global x-ray scores were added to 
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the model to see if they contributed but did not demonstrate an 
independent effect on stiffness co-efficients.  
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Table 3-37 Multiple linear regression (hierarchial entry) for biomechanical stiffness co-efficient and clinical variables  
(continued next page) 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
Sig. 95% CI for B Change statistics 
  B Std. Error 
 
Beta   R2 Adjusted R2 Change in R2 Sig for R2 
change 
1 (Constant) -5.32 1.82 
 
< 0.01 (-8.91,-1.72) 0.50 0.49 0.49 <0.01 
BMI 0.80 0.07 0.71 <0.01 (0.67, 0.93)     
2 (Constant) -1.36 3.21 
 
 0.13 (-0.85, 6.33) 0.50 0.50 0.01. 0.14 
BMI 0.78 0.07 0.69 <0.01 (0.65, 0.91)     
Age -0.05 0.03 -0.09  0.14 (-0.12,0.02)     
3 (Constant) 5.62 2.59 
 
 0.03 0.49, 10.74) 0.70 0.70 .20 <0.01 
BMI 0.77 0.05 0.68 <0.01 (0.67, 0.87)     
Age -0.04 0.03 -0.07  0.14 (-0.09, 0.01)     
Gender -4.52 0.45 -0.44 <0.01 (-5.41, -3.62)     
4 (Constant) 7.94 2.73 
 
 <0.01 2.54, 13.33) 0.71 0.71 .01 0.02 
BMI 0.72 0.05 0.64 <0.01 (0.62, 0.83)     
Age -0.06 0.03 -0.11  0.03 (-0.11, -0.01)     
Gender -4.44 0.45 -0.44 <0.01 (-5.32, -3.56)     
Synovial hypertrophy (mm) 0.16 0.07 0.12  0.02 (0.03, 0.29)     
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Table 3-36 continued« Multiple linear regression (hierarchial entry) for biomechanical stiffness co-efficient and clinical variables 
 Model Unstandardized Coefficients Standardized 
Coefficients 
Sig. 95% CI for B Change statistics 
B Std. Error 
 
Beta   R2 Adjusted R2 Change in R2 Sig for R2 change 
5 (Constant) 7.97 2.78 
 
<0010 (2.49, 13.46) 0.71 0.70 0.00 0.93 
BMI 0.72 0.06 0.64 <0.01 (0.61, 0.83)     
Age -0.06 0.03 -0.11 0.03  (0.12, -0.01)     
Gender -4.40 0.45 -0.44 <0.01 (-5.33, 3.55)     
Synovial hypertrophy( mm) 0.16 0.07 0.12  0.02 (0.02, 0.31)     
Pain VAS (mm) 0.00 0.01 0.00  0.93 (-0.02, 0.02     
6 (Constant) 7.20 2.82 
 
0.01 (1.64, 12.77) 0.72 0.71 .01 0.15 
BMI 0.73 0.06 0.65 <0.01 (0.62, 0.84)     
Age -.05 0.03 -0.09 0.07 (-0.11, 0.00)     
Gender -4.40 0.45 -0.43 <0.01 (5.29, -3.52)     
Synovial hypertrophy (mm) 0.25 0.09 0.18 0.01 (0.07,  0.43)     
Pain VAS (mm) 0.00 0.01 0.03 0.98 (-0.02,  0.02)     
 Global x-ray score -0.06 0.04 -0.1 0.15 (-0.14, -0.02)     
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3.8 Results: Follow-up evaluation 
3.8.1 Participants 
A total of 116 participants were followed up after their baseline 
assessments, 3 participants who self-reported changes in symptoms 
and 113 who were followed up by arrangement. Table 3-38 shows the 
descriptive data of follow-up participants and their original group 
allocation (as per index knee). The mean length of time between 
baseline and follow-up assessment was 99 days (SD 24). 
As the preliminary analysis showed no significant differences between 
the control and KP group for US features, these groups were combined 
for the follow-up analysis and referred to as controls to increase the 
power of this analysis. The ROA and SOA groups were also combined 
and are referred to as the OA group. 
 
Table 3-38 Descriptive data for follow-up participants  
Group 
n 
Control 
57 
KP  
8 
ROA 
6 
SOA 
45 
Gender  
        
  male     n(%) 21 (36.8%) 5 (62.5%) 0 (0%) 14 (31.1%) 
female  n(%) 36 (63.2%) 3 (37.5%) 6 (100%) 31 (68.9%) 
Age (yrs) 
        
mean (SD)  70.9 (8.0) 68.3 (8.8) 69.2 (3.4) 73.0 (7.8) 
median (range)   70 (53-90) 68.5 (52-80) 69 (65-75) 73 (56-89) 
(KP= knee pain only; ROA= radiographic OA; SOA= symptomatic OA) 
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3.8.2 Changes in knee pain over time 
Changes in knee pain were defined as an increase or decrease in the 
worst item score reported in the WOMAC Pain subscale and are shown 
in Table 3-39. Eighty one participants (69.8%) did not change their 
maximal rating on the index, 10 participants from each group reported 
lower knee pain scores and 5 controls and 10 with OA reported higher 
knee pain scores. There was no significant difference between the two 
groups for change in pain (in either direction). 
Table 3-39 Change in knee pain at follow-up  
 
Change in WOMAC  
Worst item score  
(pain subscale)  
Control 
65 
OA 
51 
 n (%) n (%) 
No change 50 (76.9%) 31 (57.4%) 
Pain better 10 (15.4%) 10 (19.6%) 
Pain worse 5 (7.7%) 10 (19.6%) 
 
3.8.3 Association between change in knee pain and change in US 
features 
Change in the presence or absence of US effusion, synovial 
hypertrophy, popliteal cyst and power Doppler signal was examined in 
relation to change in pain at follow up. Chi square analysis found no 
association between change in knee pain and change in US features 
for either the control or OA groups (Table 3-40).  
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Table 3-40 Association between change in knee pain and change in presence of 
US features at follow-up  
 
Change in presence of US 
features  
Control group 
Pain changed at 
follow-up          
 
 
 
p 
OA group 
Pain changed at 
follow-up 
 
 
 
p 
 No   Yes  No   Yes 
 
Effusion                          No 41 12 0.86 26 17 0.91 
         Yes 9 3  5 3  
 
Synovial hypertrophy    No 47 12 0.10 25 18 0.37 
             Yes 3 3  6 2  
 
Popliteal cyst                  No 44 16 0.89 25 20 0.13 
            Yes 6 2  3 0  
 
Power Doppler signal    No 50 15  30 19 0.75 
            Yes 0 0  1 1  
(Pain change = Change in worst item score of WOMAC pain subscale) 
 
3.8.4 Correlations between changing pain and US features 
Correlations between the change in pain VAS scores and the change in 
continuous measures of effusion, synovial hypertrophy and popliteal 
cysts were explored for controls and OA groups (Table 3-41).   
Change in VAS pain scores showed no relationship with change in US 
measures. Change in depth of effusion was correlated with change in 
depth of synovial hypertrophy for both groups. The strength of the 
relationship was moderate within the OA group (r=0.66, p<0.01) (Figure 
3-55) and weak within the control group (r=0.34, p<0.01).  
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Table 3-41 Correlation matrix for change in pain and US measures in control 
and OA groups   
 
 
Change 
Pain 
VAS 
(mm) 
Effusion 
(mm) 
Synovial 
hypertrophy 
(mm) 
Popliteal 
cysts 
(mm) 
Control Group 
     
Pain VAS (mm) r 1.0    
 Effusion (mm) r -0.1 1.0   
 Synovial hypertrophy (mm) r -0.1   0.3** 1.00  
Popliteal cysts (mm) r -0.1 -0.02 0.2 1.0 
 
     
OA Group 
     
Pain VAS (mm) r 1.0    
 Effusion (mm) r -0.2 1.00   
Synovial hypertrophy (mm) r -0.01  0 .7** 1.0  
Popliteal cysts (mm) r  0.01 0.2 0.1 1.0 
 
*  Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level  
mm = millimetres 
 
Figure 3-55 Scatterplot showing relationship between change in depth of 
effusion and depth of synovial hypertrophy in OA group 
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3.8.5 Change in biomechanical stiffness and damping co-
efficients with changing pain 
Baseline and follow-up stiffness and damping co-efficients were 
available for 62 (53.4%) of the 116 participants that were followed up 
(35 controls and 27 OA).  
Changes in stiffness and damping co-efficients were explored to see if 
they correlated with changing pain (VAS score) or changing US 
features (Table 3-42). No correlations were observed in the control 
group. Increase in pain severity on the OA group was negatively 
correlated to change in damping co-efficients (r=-4.1, p<0.5) (Figure 
3-56). 
Table 3-42 Correlation matrix for change in pain, US measures and stiffness  
and damping co-efficients 
 Change in 
Damping 
 co-efficient 
Change in  
Stiffness co-
efficient 
Control Group 
   
Change  Pain VAS (mm) r 0.02 -0.01 
Change Effusion (mm) r -0.2 -0.1 
Change Synovial hypertrophy 
(mm) 
r 0.2 -0.3 
Change Popliteal cysts (mm) r 0.1 .06 
 
OA Group 
   
Change Pain VAS (mm) r -0.4* .3 
Change Effusion (mm) r 0.1 -0.03 
Change Synovial hypertrophy 
(mm) 
r 0.2 0.003 
Change Popliteal cysts (mm) r 0.01 -0.02 
 
*  Correlation is significant at the 0.05 (1-tailed) 
** Correlation is significant at the 0.01 level (1-tailed) 
mm = millimetres 
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Figure 3-56 Scatterplot showing relationship between change in pain VAS (mm) 
and change in damping co-efficient in OA group. 
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3.9 Intervention study 
3.9.1 Participants 
Of the 46 participants approached for the intervention study, 25 
participants consented to take part.  Two subjects had undergone a 
total knee replacement since their participation in the cross-sectional 
study but were included as they had SOA in the contra-lateral knee. 
One participant in the study had inconclusive OA (G0) on x-ray but was 
symptomatic and had positive US findings including PD signal. Thirteen 
participants were randomised to receive the placebo injection first and 
twelve to receive the steroid injection first (Figure 3-57). There were no 
withdrawals from the study. 
Figure 3-57 Flow chart of Injection study  
 
 
 
 
 
 
 
 
 
N=46 Invited to participate 
in injection study 
N=25 Consented, screened 
& Randomised 
Placebo 
Injection 1st 
(n=13) 
Steroid Injection 
1st                    
(n=12) 
Completed study 
N=12 
Placebo 
Injection 2nd 
Steroid Injection 
2nd  
Completed study 
N=13 
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3.9.2 Baseline characteristics 
Groups were balanced at baseline with no significant differences in 
age, gender, BMI, radiographic severity, presence of clinical effusion, 
and the number of days between injections (Table 3-43).   
Table 3-43 Participant characteristics according to treatment order 
 Group A 
Placebo first  
n=13 
Group B 
Steroid first  
n=12 
p 
 
   
Age years          mean (SD) 71.2 (10.4) 73 (3.8) 0.57 
BMI (kg/m2)       mean (SD) 30.5 (5.3) 29.9 (3.8) 0.73 
Gender              male n (%) 7 (54%) 3 (24%) 0.23 
Knee injected    right n (%) 8 (61.5%) 6 (50%) 0.70 
 
   
K&L Grade Injected knee 
n (%) 
   
Grade   0     1 (7.7%) 0  
Grade   1     0 0  
Grade   2     0 1 (8%)  
Grade   3     5 (38.5%) 6 (50%)  
Grade   4     7 (53.8%) 5 (42%) 0.75 
 
   
Clinical effusion,        n (%) 
   
absent  2 (15.4%) 3 (25.0%)  
small 3 (23.1%) 4 (33.3%)  
large 8 (61.5%) 5 (41.7%) 0.61 
 
   
Time between 1st and 
 2nd injection, days 
   
  mean (SD) 81 (47) 95 (65) 0.81 
 
   
 
 
 
 
207 
 
3.9.3 Response following injections 
The study was designed to ensure no carryover effect following the first 
LQMHFWLRQE\ZDLWLQJXQWLOSDUWLFLSDQW¶VNQHHSDLQKDGUHWXUQHGWRLWVSUH-
injection severity before administering the second injection.  
Independent t-tests showed no order effect for pain response following 
the steroid injection (mean difference = -1.5, p=0.87) or placebo 
injection (mean difference = - 4.0, p=0.72).  
Baseline measures and differences at 1 week are presented in Table 
3-44 and visually in Figure 3-58  to Figure 3-61. Paired tests showed no 
significant difference in mean pain or US variables at baseline, or for 
change at 1 week, between placebo and steroid injections.  
Significant improvements in pain VAS scores were observed following 
both placebo and steroid injection (mean difference for steroid = -17.4, 
SD 26.8, p=0.003; mean difference for placebo = -13.4, SD 22.4, 
p=0.006) but these were not statistically different from each other.  
Synovial hypertrophy showed a significant difference between baseline 
measures and measures at 1 week following steroid injection (mean 
difference 0.94 (SD 2.18, p=0.04) but was not different from placebo.  
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Table 3-44 Baseline characteristics and change in outcome measures at 1 week following injection. 
 
Baseline 
 Change at 1 week   
 Placebo 
N=25 
Steroid 
N=25 
p  Placebo 
N=25 
Steroid  
N=25 
p 
Frequency of US features n (%) n (%) 
     
Effusion  21 (84%) 21 (84%) 1.0     
Synovial hypertrophy 20 (80%) 18 (72%) 0.51     
Popliteal cyst  8  (32%) 7  (28%) 0.75     
PD signal  7  (28%) 6  (24%) 0.75     
  Change in PDS No change 19 19  
 
  
Change in PDS Increase 4 4  
 
  
Change in PDS Decrease  2 2 0.59 
 
 
 
     
 
Mean (SD) Mean (SD) Paired p  Mean (SD) Mean (SD) Paired p 
Pain VAS (mm) 61.8 (20.5) 61.4 (22.2) 0.95  -13.4 (22. 4) -17.4 (26.8) 0.59 
 
       
US Features    Effusion (mm) 7.3 (3.6) 7.0 (3.9) 0.76  -0.6 (2.5) -0.06 (2.1) 0.40 
Synovial hypertrophy (mm) 7.7 (4.5) 6.9 (3.6) 0.50  -1.0 (3.7) -0.94 (2.2) 0.91 
Popliteal cyst (mm) 2.9 (4.4) 3.12 (4.4) 0.70  0.3 (1.8) -0.72 (2.5) 0.12 
 
       
ICOAP     Intermittent (0- 24) 11.1 (4.2) 11.4 (3.5) 0.74  -0.4 (3.2) -2.48 (5.4) 0.12 
Constant (0-20) 7.5 (4.4) 8.0 (4.3) 0.72  -0.7 (3.2) -1.96 (4.7) 0.28 
 
       
WOMAC                Pain (0-20) 9.2 (3.5) 9.4 (2.7) 0.82  -0.8 (2.4) -1.96 (2.7) 0.13 
Stiffness (0-8) 3.9 (1.7) 3.9 (1.2) 1.00  -0.3 (1.3) -0.60 (1.5) 0.43 
Function (0-58) 33.4 (11.2) 32.3 (10.3) 0.70  -1.0 (6.6) -2.60 (8.4) 0.61 
 
       
Paired p =  significance values for paired test for variables between placebo and steroid injections 
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Figure 3-58 Mean change in VAS pain score (mm) following steroid and placebo 
injection 
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Figure 3-59 Mean change in US effusion (mm) following steroid and placebo 
injection 
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Figure 3-60 Mean change in synovial hypertrophy (mm) following steroid 
andplacebo injection 
 
Sy
n
o
v
ia
l H
yp
e
rt
ro
ph
y 
(m
m
)
M
e
a
n
 
(S
EM
)
baseline 1 week
0
2
4
6
8
10
Placebo
Steroid
 
210 
 
Figure 3-61 Mean change in popliteal cyst (mm) following steroid and placebo 
injection 
 
Po
pl
ite
a
l c
ys
t (m
m
)
 
M
e
a
n
 (S
EM
)
baseline 1 week
0
2
4
6
Placebo
Steroid
 
 
3.9.4 Responders to steroid injection 
The association between response following steroid injection and the 
presence of US features was examined using logistic regression.  No 
statistically significant predictors of response were found Table 3-45 . 
Table 3-45 Crudes odds ratios for predictors for patient response to steroid 
injection 
 
US features  
at Baseline  
 
Responder  
to steroid 
 injection 
Crude Odds ratio 
(95% CI) 
 
 
p 
no yes   
Effusion   
    
no 1 3 1  
yes 
  
9 12 0.44 (0.04, 5.01) 0.51 
Synovial Hypertrophy 
    
no 4 3 1  
yes  
 
6 12 2.67 (0.46, 15.96) 0.28 
Popliteal cyst 
    
no 8 10 1  
yes 
  
2 5 2.00 (0.30, 13.17 0.47 
Power doppler signal 
    
no 8 11 1  
yes  2 4 1.46 (0.21, 9.98) 0.70 
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Individual features were then examined for the 15 participants identified 
DV UHVSRQGHUV GHFUHDVH LQ SDLQ 9$6   PP IROORZLQJ VWHURLG
injection. Continuous US measures for these participants following the 
steroid injection were examined (Table 3-46). 
Correlation analysis found no statistically significant relationships 
between change in pain VAS and change in US measures after steroid 
injection in steroid responders (Table 3-47). Changes in effusion (mm) 
were strongly correlated with changes in synovial hypertrophy (r=0.77, 
p<0.01) (Figure 3-62). 
 
Table 3-46 Pain responders to steroid: Ultrasound responses 1 week following 
steroid injection  
 Responses (change)  
following steroid injection at 1 week 
Participant 
id 
VAS 
(mm) 
Effusion 
(mm) 
Synovial 
Hypertrophy (mm) 
Popliteal 
Cyst (mm) 
 
    
2 -26 -0.4                0  0.6 
3 -20  2.0 -0.4 -0.9 
12 -20 -1.4 -2.0             0 
15 -66 -0.3 -0.1  -9.8 
32 -63  0.1 -0.7           0 
35 -21 -1.0 -0.7 0 
36 -22 -0.3 -0.9 0 
51 -32 -4.7 -4.9 -4.2 
54 -24 -1.4 -2.2 0 
61 -34  5.6  0.4 0.3 
89 -36  5.9  3.9  4.4 
96 -44 -0.9 -2.2 -4.3 
114 -43  2.2 -0.1 -1.6 
136 -36  1.3 -3.9 0 
154 -38  2.0 0.5 0 
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Table 3-47 Correlation matrix for differences in Pain and US measures at 1 week 
in responders to steroid injection    
Differences in 
 
VAS 
(mm) 
Effusion 
(mm) 
Synovial  
Hypertrophy 
(mm) 
Popliteal 
cyst 
(mm) 
VAS  r 1.00    
Effusion r -0.43 1.00   
Synovial hypertrophy r -0.35     0.77**** 1.00  
Popliteal cysts r 0.28 0.27 0.39 1.00 
*  Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level  
mm = millimetres 
 
Figure 3-62 Scatterplot showing relationship between change in effusion (mm) 
and change in synovial hypertrophy in participants responding to steroid 
injection 
 
 
Individual pain and US response were then examined for responders to 
steroid injection (Figure 3-63 to Figure 3-66). Of the 15 participants who 
showed a positive pain response following steroid injection more than 
half (n=9) showed a reduction in effusion depth which increased again 
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when pain returned to pre-injection level (Figure 3-64). Ten participants 
showed a reduction in synovial hypertrophy depth, 8 of which also 
increased when pain returned (Figure 3-65). Popliteal cysts were 
present in 8 of the participants, 5 of whom showed a reduction in size, 
with 2 completely resolving. All showed increased size when pain 
returned apart from the two who had completely resolved (Figure 3-66). 
PD signal was detected in 4 steroid responders at baseline (Table 
3-48). One week after the steroid injection this had resolved in 3 and 
remained unchanged in 1 of the 4. However, new PD signal activity was 
recorded in 2 other participants. At follow-up when pain had returned to 
its pre-injection level, PD signal persisted in 2 participants and 
appeared in 1 new participant.  
Figure 3-63 Pain responders to steroid: Change in pain VAS scores (mm) after 
steroid injection 
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Figure 3-64 Pain responders to steroid: Change in Effusion after steroid 
injection   
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Figure 3-65 Pain responders to steroid: Change in synovial hypertrophy after 
steroid injection  
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Figure 3-66 Pain responders to steroid: Change in popliteal cyst after steroid 
injection  
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Table 3-48 Observed PD signal in pain responders following steroid injection  
 Observed PD signal 
Participant Baseline Week 1 Follow-up 
Id 
 
  (pain returned) 
2 0 1 0 
3 0 0 1 
12 0 0 0 
15 0 0 0 
32 0 1 1 
35 0 0 0 
36 1 0 0 
51 1 0 0 
54 0 0 0 
61 0 0 0 
89 0 0 0 
96 1 0 0 
114 0 0 0 
136 0 0 0 
154 1 1 1 
(1= PD signal observed, 0= PD signal not observed) 
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3.9.5 Pain responders to placebo injection 
Eleven participants were identified as pain responders following 
placebo injection (Table 3-49). US measures were explored in these 
individuals. No association was found between response following 
placebo injection and the presence of US features (data not shown).  
Correlation analysis between change in pain VAS scores and 
continuous US measures found no significant relationships in placebo 
responders (Table 3-50). However as with responders following steroid 
injection changes in effusion were correlated with changes in synovial 
hypertrophy (r= 0.71, p=0.02). 
Table 3-49 Pain responders to placebo: Ultrasound responses 1 week following 
placebo injection 
 Responses (change)  
following placebo injection at 1 week 
Participant 
id 
VAS 
(mm) 
Effusion 
(mm) 
Synovial 
Hypertrophy (mm) 
Popliteal 
Cyst (mm) 
 
    
2 -21 -0.1 1.2 1 
6 -31  2.1  4.5 2 
15 -27  3.5  1.3 0 
24 -61 -1.7  0.2 0 
30 -35  0.6  1.9   4.7 
36 -18 -1.9 -4.2 0 
38 -29 -4.2 -4.9 0 
51 -48  2.5  3.8 0 
61 -45  1.9 -0.7 -0.2 
114 -31  4.1  6.1 -3.1 
164 -38 -1.1  4.0 0 
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Table 3-50 Correlation matrix for differences in Pain and US measures at 1 week 
in responders to placebo injection      
Differences in 
 
VAS 
(mm) 
Effusion 
(mm) 
Synovial  
Hypertrophy 
(mm) 
Popliteal 
cyst 
(mm) 
VAS  r 1.00    
Effusion r 
-0.13 1.00   
Synovial hypertrophy r 
-0.23 0.71* 1.00  
Popliteal cysts r 0.19 -0.20 0.08 1.00 
*  Correlation is significant at the 0.05 level 
mm = millimetres 
 
Individual responses were examined in participants who responded to 
placebo injection.  Pain responses are shown graphically in Figure 
3-67.  Five participants showed improved measures of effusion though 
these were small (only one of these was an improvement greater than 
2mm, Figure 3-68). Three showed a reduced depth of synovial 
hypertrophy, with two showing improvements greater than 2mm (Figure 
3-69). Popliteal cysts size only improved significantly in 1 of 3 
participants with popliteal cysts (Figure 3-70). PD signal was detected 
in 2 placebo responders at baseline (Table 3-51).One week following 
the placebo injection PD was not detected in the same participants but 
was observed in another participant. At follow-up when pain had 
returned to its pre-injection severity, PD signal could still be observed in 
that same participant and a further two others.  
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Figure 3-67 Pain responders to Placebo: change in Pain VAS scores (mm) after 
placebo injection  
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Figure 3-68 Pain responders to Placebo: change in effusion (mm) after placebo 
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Figure 3-69 Pain responders to Placebo: change in synovial hypertrophy (mm) 
after placebo injection 
Change in synovial hypertrophy following
placebo injection
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Figure 3-70 Pain responders to Placebo: change in popliteal cysts (mm) after 
placebo injection 
Change in popliteal cyst  following
placebo injection
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Table 3-51 Observed PD signal in pain responders following placebo injection  
 
 
Observed PD Signal 
Participant 
id 
Baseline Week 1 Follow-up 
(pain returned) 
2 0 0 0 
6 0 1 1 
15 0 0 0 
24 1 0 0 
30 0 0 0 
36 0 0 1 
38 0 0 0 
51 0 0 1 
61 0 0 0 
114 0 0 0 
164 1 0 0 
(1= PD signal observed, 0= PD signal not observed 
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4 Discussion  
This chapter revisits the objectives of the thesis and the original 
hypotheses are accepted or rejected in light of the study findings. Study 
findings are discussed in the context of previous work and novel 
findings are explored. Caveats of the study are addressed and finally 
the thesis is brought to a close by suggesting directions for future 
research and drawing final conclusions. 
4.1 Study objectives & Hypotheses 
The primary objectives of this thesis were to firstly determine the 
frequency of US features suggestive of joint inflammation (effusion, 
synovial hypertrophy and PD signal) in normal knees, painful knees, 
radiographic OA knees and symptomatic OA knees. Secondly, to 
determine if US features were associated with knee pain, radiographic 
features, and clinical symptoms and signs associated with inflammation 
rest pain, clinical effusion and stiffness) and function.  These objectives 
were achieved by conducting a cross-sectional multiple group 
comparison study in the community. The hypotheses related to this 
study were: 
Hypothesis 1. US features of inflammation will be more 
common in knees with radiographic changes, irrespective of pain 
status, and will be more pronounced in people with knee pain.  
Hypothesis 2. US features of inflammation will be independently 
associated with an increased risk for knee pain.  
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Grey-scale US features (effusion, synovial hypertrophy and popliteal 
cysts) were observed more frequently in participants with radiographic 
OA (regardless of the presence of symptoms) compared to those 
without. Those features were also more pronounced, and for effusion 
and synovial hypertrophy were significantly more pronounced in those 
with SOA compared to ROA. PD signal was only more common in 
those with SOA compared to those without radiographic changes. As a 
result, hypothesis 1 can be accepted. Secondary analysis found 
synovial hypertrophy to be the only US feature that was consistently 
and independently associated with knee pain, and so hypothesis 2 can 
be partly accepted for this feature. 
Secondary objectives for the study were to determine if US features of 
inflammation changed in tandem with fluctuations in knee pain in those 
with symptomatic OA. The hypothesis related to this was: 
Hypothesis 3. Changes in US features of inflammation in SOA 
knees will correlate with changes in reported knee pain over time 
and also following an intervention for knee pain.  
Follow-up observation of control and SOA participants was conducted 
after a period of three months. Only 39% of participants with SOA 
reported a change in pain severity (increased or decreased) and no 
correlation was found between change in pain severity and change in 
US measures. A small intervention study subsequently set out to 
examine US response following pain reduction from an intra-articular 
steroid injection and a placebo saline injection. Pain severity decreased 
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following both the cortico-steroid and placebo injection but no 
correlation was found between change in pain severity and US 
measures. While these findings do not initially support the hypothesis, 
the small number of participants for whom pain changed at follow-up 
and the small sample size of the intervention study suggest that this 
hypothesis should not be rejected outright at this stage. Rather, 
additional work that is adequately powered should be undertaken to 
answer this question definitively. 
 
4.2 Study findings 
4.2.1 Reliability  
When considering the use of an outcome measure there are several 
characteristic to bear in mind. Validity and reliability determine the 
confidence that can be placed in the inferences drawn from their use, 
sensitivity and specificity are important for diagnostic purposes, and 
responsiveness is important for monitoring disease progression or 
treatment. Additionally, an outcome measure should be clinically 
meaningful and easy to use. 
The criterion validity of ultrasound in detecting synovial pathology in 
knee OA has been demonstrated by the comparison with arthroscopy 
findings and histopathological evaluation (Karim, Wakefield et al. 2004) 
whereas construct validity has been demonstrated more widely against 
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clinical and laboratory findings and other imaging techniques such as 
radiographs, bone scans and MRI imaging  
The issue of reliability remains an important consideration for any study 
using ultrasonography.  Though reliability and validity are separate 
issues in terms of metric properties, the validity of an outcome measure 
is dependent on how reliable it is. Issues in the reliability in US 
assessment can be further divided into the acquisition and reading of 
scans. The potential for variation is greater in the acquisition of scans 
due to the nature of the scanning process.  Even with a standardised 
scanning protocol, the choice of image and the optimising of US 
settings remains at the discretion and skill of the sonographer. 
This study has demonstrated good reliability in determining the 
presence or absence, and magnitude of US features and is comparable 
with other studies (Karim, Wakefield et al. 2004; Abraham, Goff et al. 
2011; Iagnocco, Perricone et al. 2012; Wu, Shao et al. 2012). For intra-
observer reliability, kappa values between 0.7 DQG  S ZHUH
reached for detecting the presence or absence of grey-scale features of 
inflammation in 28 knees. Intra class correlation co-efficients of 
between 0.82 and 0.95 (p<.001) were found for continuous US 
measures demonstrating substantial to excellent reliability.  
Inter-observer reliability was tested in ten knee joints and demonstrated 
against an experienced consultant musculoskeletal radiologist. 
Reliability was good for both the presence US features (kappa = 0.62 to 
 S DQG FRQWLQXRXVPHDVXUHV RI86 IHDWXUHV ,&&  0.8 to 
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0.9, p<.001). Similar reliability was also reported for the dichotomous 
scoring of grey-scale features in a comparable study of 17 OA knee 
joints where inter-observer reliability was tested between a senior and a 
junior sonographer (Iagnocco, Perricone et al. 2012).  
However the low number of participants (due to the availability of the 
2nd sonographer (KL)) and the low prevalence of US findings are likely 
to contribute to the high values. Bland-Altman plots did show a small 
but  systematic bias within the reading where by the main study 
sonographer (MH) had higher reading compared to the second 
sonographer (KL) which needs to be borne in mind when interpreting 
the results. 
Reliability for PD signal was statistically also high for both intra and 
inter-observer agreement (kappa = 1.0 and 0.76 respectively)  However 
it is worth noting that the kappa statistic is affected by the prevalence of 
the feature under consideration and for rare findings such as PD signal  
low values may not necessarily reflect low agreement and vice versa. 
Sample sizes for future reliability studies should address this issue.   
Structural US features of osteophytes and depth of femoral articular 
cartilage were not the primary outcome measures of interest in this 
study. However, they were also included in a subset of 10 knees which 
underwent testing for intra- and inter-observer reliability. Intra-observer 
reliability was higher than inter-observer for osteophytes (kappa = 0.80 
and 0.55, respectively). Inter-observer agreement was less than other 
published studies (Abraham, Goff et al. 2011; Iagnocco, Perricone et al. 
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2012). For depth of femoral articular cartilage in the transverse view the 
ICC for intra and inter-observer reliability was 0.71 and 0.52 
respectively, and was comparable to reliability reported by Abraham et 
al (2011).  
The presence of chondrocalcinosis (CC) was not examined in terms of 
reliability as it was not observed in any of the reliability participants. It 
was also not used as a primary outcome measure for this study. Poor 
agreement (kappa = 0.28, p<0.001) was found between US and 
radiographic detected chondrocalcinosis in this study and there are 
several reasons why this might have occurred.  
Firstly, CC was not observed throughout the training period. Therefore it 
cannot be assured that the presence of CC was not missed, particularly 
during the early phases of data collection. Secondly, the detection of 
CC was limited to the appearance within the femoral articular cartilage 
which may lead to an under-reporting of the true US prevalence. 
Thirdly, the assessment of the femoral articular cartilage was 
standardised to 90° knee flexion which may not be the optimal for 
assessing CC. 
The diagnosis of CC is mainly based in radiographic and detection of 
calcium pyrophosphate dihydrate (CPPD) crystals within the joint fluid. 
CPPD crystal deposits in the knee joint can also be observed by US as 
thin hyper-echoic bands within the articular cartilage, as hyper-echoic 
spots within the menisci and fibrocartilage and as hyper-echoic 
aggregates within the synovial fluid and popliteal cysts (Dufauret-
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Lombard, Vergne-Salle et al. 2010). Only a few small studies have 
assessed the agreement between radiography and US in detecting CC. 
In 28 knees with chondrocalcinosis and 46 normal controls, no 
difference was reported between US and  radiography in detecting CC 
within the articular cartilage, but US was less sensitive for detecting 
meniscal calcification (Coari, Iagnocco et al. 1995). A small study of 11 
patients with CPPD and 13 patients with mild OA but without CPPD 
found that plain radiographs confirmed the presence of the US CC in all 
cases. Two cases of CC were identified by US where standard 
radiographs did not confirm the diagnosis, highlighting both sensitivity 
and specificity of US, albeit in a very small group (Frediani, Filippou et 
al. 2005). Further work on the validity and reliability of US in the 
diagnosis of chondrocalcinosis is required but is beyond the scope of 
this current body of work.  
Although good reliability was demonstrated, other technical aspects of 
scanning may also have affected the overall reliability. Assessment of 
the knee joint is largely superficial but scanning was more difficult in 
obese participants. Attenuation of US energy occurs as waves pass 
through the tissues and results in echoes from deeper structures being 
displayed less intensively. While the depth of penetration can be altered 
this is often at the sacrifice of frequency and image resolution. The 
detection of blood flow using Doppler in these participants was also 
more technically challenging.  
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4.2.2 Diurnal variation 
A potential source of variation in US scanning is the time of day that is 
performed. Diurnal variations (daily patterns) in joint pain and stiffness 
are well recognised in inflammatory conditions and have been also 
demonstrated in knee OA in addition to variations in serum levels of 
hyaluronan and other biomarkers of inflammation (Bellamy, Sothern et 
al. 1990; Criscione, Elliott et al. 2005; Kong, Stabler et al. 2006). A 
recent study of hand joints with active RA demonstrated US variations 
in PD signal and semi-quantitative scoring over a 24 hour period, where 
higher scores were awarded during morning scans compared to the 
afternoon and evening (Semerano, Gutierrez et al. 2011). It is plausible 
therefore, that US features of inflammation may also exhibit diurnal 
variations in knee OA. 
This current study found no such diurnal variation within a sample of 
participants with bilateral symptomatic OA. Furthermore pain severity 
showed no significant differences across the three weeks reflecting a 
chronic but stable pain state. Participants with more unpredictable pain 
may show greater variation in US measures and this should be 
considered in future studies. PD signal was not detected in any 
participants and so it is unknown whether diurnal variation may occur in 
this feature in OA. 
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4.2.3 Cross-sectional multiple group comparison study 
4.2.3.1 Primary findings 
The primary objective for this study was to firstly determine the 
frequency of US features of joint inflammation in a community sample 
with normal knees (controls), painful knees (KP), radiographic OA 
knees (ROA) and symptomatic OA knees (SOA), and secondly, to 
determine if US features are associated with pain, structural change or 
clinical symptoms and signs of inflammation. 
US features representative of joint inflammation were not restricted to 
symptomatic OA. Within the control group, a background presence of 
US effusion was observed in 29% and synovial hypertrophy in 8%. The 
size of effusions were small (mean depth <3mm) but some knees 
exhibited effusions up to 10.3mm. Synovial thickening was generally 
minor (mean depth <1mm) but was observed to be as thick as 6.7mm.  
The presence of PD signal was low at around 2%. Popliteal cysts were 
detected in 12.4% in control knees and were mainly small (mean <1 
mm) although the range extended up to 13.5mm. Pes anserine bursae 
were not observed within controls and patellar bursae were infrequent 
(< 3.3% in control knees).  
Previous studies have reported US detected effusions in between 0-
35% of normal and control participants (Tarhan and Unlu 2003; Naredo, 
Cabero et al. 2005; de Miguel Mendieta, Cobo Ibáñez et al. 2006). 
Different cut-off measures used to define effusions can account for 
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some variation in the findings but differences in scanning protocols may 
also yield different findings.  
No previous studies have reported the frequency of US features for 
people with knee pain without structural change. This study found that 
US features were more common in the KP group compared to controls 
but were not statistically different. Effusions were observed in 33% of 
the KP group, synovial hypertrophy in 12%, popliteal cysts in 9% and 
PD signal in around 3.5%. Frequency of popliteal cysts and PD signal 
were also not significantly different from the control group. The 
presence of US effusion and synovial hypertrophy in control and  KP 
groups may reflect pre-clinical and pre-radiographic changes that have 
been observed histologically (Benito, Veale et al. 2005). 
A clear increase in grey-scale features was observed in the ROA group 
compared to control and KP groups. Prevalence of effusions rose to 
81% within index knees, Synovial hypertrophy was observed in 41% 
and PDS in 6% of the group. Popliteal cysts were between 8 and 10 
times more common in ROA (between 17-22%) compared to controls 
(p<.05), and twice as common as those with knee pain alone (though 
not statistically different).   
De Miguel et al (2006) are the only other authors to have reported US 
findings in patients with radiographic OA with and without symptoms as 
independent groups. The frequency of US features in the SOA group, 
were similar to the current findings of this study but there were different 
observations in the ROA group. Effusions were less frequently 
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observed (35%) whereas popliteal cysts and infra-patellar bursitis were 
more common (40% and 15% respectively). The disparity for infra-
patellar bursitis can be explained by the lower cut-off value for defining 
bursitis (>2mm), but is somewhat surprising for US effusion which had 
the same definition. Scanning protocol could account for this as 
effusions were measured in the midline of the supra-patellar pouch and 
therefore may have underestimated the true frequency. Schmidt et al 
(2004) reported fluid not only in the midline longitudinal plane of the 
supra-patellar pouch but also in the lateral recess of the pouch. Criteria 
for popliteal cysts were very similar for both studies (>4mm and   
PPDQGZKLOHWKHREVHUYHGIUHTXHQF\RISRSOLWHDOF\VWVZDVVLPLODU
in the SOA group for both studies, differences in the ROA may be a 
reflection of the sample sizes of the ROA groups.  
US features were most frequently observed in the SOA group.  
Effusions were found in over 90% participants, synovial hypertrophy in 
82% and popliteal cysts in 39%. Mean depth of effusion, synovial 
hypertrophy and size of popliteal cyst were significantly greater than in 
all other groups. PD signal was observed in 16% of SOA group which 
was significantly higher than in control and KP groups but not 
compared to the ROA group. 
Many studies have reported similar observations for US effusion with 
frequencies around 69-86% (Tarhan and Unlu 2003; de Miguel 
Mendieta, Cobo Ibáñez et al. 2006; Kristoffersen, Torp-Pedersen et al. 
2006; Pendleton, Millar et al. 2008; Mermerci, Garip et al. 2011). Others 
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though have reported considerably lower prevalence rates but 
aggregate around 43-47% (D'Agostino, Conaghan et al. 2005; Naredo, 
Cabero et al. 2005; Iagnocco, Meenagh et al. 2010) which is suggestive 
of a systematic difference between these studies.  Observations of 
synovial hypertrophy from other studies  are more varied and range 
from of 16.7% to 100% which makes interpretation difficult (D'Agostino, 
Conaghan et al. 2005)(Kristoffersen, Torp-Pedersen et al. 2006). The 
presence of popliteal cysts showed good consensus with the other 
studies (Tarhan and Unlu 2003; de Miguel Mendieta, Cobo Ibáñez et al. 
2006; Pendleton, Millar et al. 2008). 
PD signal is not a common observation in knee OA, and this is agreed 
by most studies where it has been investigated. Pendleton et al (2008) 
reported PD activity in 5 of 86 (6%) patients with SOA, while Iagnocco 
et al (2010) reported occurrence in only 2 of 82 (3%) and Mermerci et al 
(2011) reported no PD activity in any of 143 patients. However there 
are some studies who have reported it to be more frequent, 
Kristoffersen et al (2006) reported colour Doppler in 51 of 71 
participants with SOA, while Song et al (2008) reported PD in 63% of 
cases.  Reviewing the criteria and methodology for each study there 
appears to be no obvious reason was to why such a wide discordance 
showed be observed. The main inclusion criteria for all studies was 
knee joint OA according to American College of Rheumatology criteria 
(Altman, Asch et al. 1986). Radiographic OA was defined according 
Kellgren & Lawrence (Kellgren and Lawrence 1957), though Mermerci 
et al (2011) included some participants with grade 1 changes.  
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Participants with possible inflammatory pathologies were excluded with 
the possible exception of Song et al (2006) who did not report specific 
exclusion criteria.  
Observed PD signal in this study was 16% and this may reflect 
differences in scanning protocol. Doppler activity was assessed in all 
areas where synovial hypertrophy was found, including the supra-
patellar recesses, medial and lateral joint margins, and within popliteal 
cysts. Studies of hand OA show similar disparity in terms of frequency 
of PD signal, with reported prevalence ranging from 7% (Keen, 
Wakefield et al. 2008) to 86% (Kortekaas, Kwok et al. 2010). While it is 
not the intention to directly compare data from hand and knee studies 
here, it does highlight the major difficulty in using PD for clinical and 
epidemiological studies. 
The largest study of symptomatic OA knees with which to compare 
these findings was carried out in 600 secondary-care patients 
(D'Agostino, Conaghan et al. 2005).  Frequency of US features was 
lower with joint effusion observed in 43.6% of patients and synovial 
hypertrophy in just 16.7%. Mean size and depth of features were also 
smaller. However there are some distinct differences between the 
studies which may account for the disparity. A very conservative 
approach to assessing and defining synovitis was used with 
descriptions of synovitis to be excluded, for example fibrous synovitis 
and ³normal´ hypertrophic synovium. This is at odds with previous 
research where it has been shown that grey-scale US cannot 
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differentiate between synovial hypertrophy and synovitis (Schmidt, 
Volker et al. 2000; Walther, Harms et al. 2001). Tissue debris, blood 
clots and fibrosis are known to mimic some US features of synovial 
proliferation but these feature do not exhibit PD signal (Fiocco, Cozzi et 
al. 1996) and it is unfortunate that PD signal was not utilised in the 
EULAR study. Observation was also restricted to its appearance in the 
supra-patellar region which can result in hypertrophy being missed from 
the medial and lateral recess of the supra-patellar pouch and joint 
margins (Song, Burmester et al. 2008; Hayashi, Roemer et al. 2011). 
Wu et al reported a  higher prevalence of synovial hypertrophy (63% in 
ROA and 93% in SOA patients ) in a study where the joint was scanned 
not just the median longitudinal plane of the suprapatellar pouch but 
also the medial and lateral recesses, where focal synovitis has been 
previously observed on arthroscopy (Ayral, Pickering et al. 2005). 
Further possible explanations for the wide variation reported are the 
study populations. The EULAR population was derived from hospital 
out-patient clinics and although they were younger and had less severe 
x-ray changes they reported more severe pain. This probably reflects 
differences between those referred to secondary centres because of 
their knee pain and community participants who are more successfully 
managing their symptoms. Secondly, it has been shown that prescribed  
stable doses of non-steroidal anti-inflammatory drugs can have a 
significant effect on the detection and grading of ultra-sound detected 
synovitis in the hands of  patients with rheumatoid arthritis (Zayat, 
Conaghan et al. 2011). Whilst it has not been demonstrated whether 
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this is also true for osteoarthritic joints, this study had a washout period 
for NSAIDs of 48 hours prior to ultrasound assessment which is a 
sufficient period to ensure the washout of most short-life NSAIDs such 
as ibuprofen and diclofenac. Other studies of knee OA did not specify 
whether a wash-out period for NSAIDs (D'Agostino, Conaghan et al. 
2005; Naredo, Cabero et al. 2005; Mermerci, Garip et al. 2011) or 
specified that drugs were not altered for the study (de Miguel Mendieta, 
Cobo Ibáñez et al. 2006) which may have led to an under-estimating of 
frequency and severity of US features.  Finally, reliability is always a 
consideration for large multi-centre studies. Whilst training was 
undertaken for the EULAR study to ensure standardisation, no formal 
assessment of inter-reliability was performed. 
4.2.3.2  Secondary findings 
This study found that synovial hypertrophy was the only US feature 
independently associated with knee pain. The adjusted risk for knee 
pain was 6.6 times greater in those with US detected synovial 
hypertrophy than in those without.  
Pain at rest (at night) or pain of a constant nature is commonly thought 
to reflect the pain of inflammation. Synovial hypertrophy was associated 
with both though the association was stronger for constant knee pain 
(aOR 8.34 (95% CI 3.56, 19.52)) compared to night pain (aOR 4.93 
(95% CI 2.28, 10.63)). Intermittent knee pain which can be more 
mechanical in nature was associated with both US detected effusion 
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(aOR 2.67 (95% CI 1.46, 4.92)) and synovial hypertrophy (aOR 6.30 
(95%CI 3.03, 13.08)). 
Wu et al (2012) found a dose dependent relationship between synovial 
hypertrophy (mm) and pain severity on moWLRQ PP ȕ  &,
  SDLQ DW UHVW ȕ   &,   DQG
EHWZHHQHIIXVLRQDQGSDLQRQPRWLRQ ȕ &I (6.14, 39.92)), 
but not for popliteal cysts. Linear regression modelling was not 
performed in this study but we found that pain severity was weakly 
correlated continuous US measures (r = 0.3 for effusion and synovial 
hypertrophy) and remained weak or insignificant even when the 
relationship was examined in the SOA group.  Popliteal cysts were not 
found to be independently associated with knee pain or correlate with 
pain severity.  
US features were themselves were related. A strong correlation was 
found between depth effusion and synovial thickness (r=0.79, p<0.01), 
though this was not as strong within the SOA group (r= 0.55, p<0.01). 
This finding is similar to that reported by the EULAR study (r= 0.51) 
(D'Agostino, Conaghan et al. 2005). Popliteal cyst size was also 
correlated with synovial thickening (r=0.35, p<0.01) but there was no 
relationship with effusion.  
The association between US features of inflammation and ROA and 
was very strong. Even after adjusting for age, sex, BMI and knee pain, 
the risk for ROA was high (aOR 14.39 (95% CI 6.28, 32.94)  for 
synovial hypertrophy, 13.39 (95% CI 6.14, 29.02) for effusion and 3.19 
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(95% CI 1.42, 7.17) for popliteal cyst). PD signal was not independently 
associated with ROA after adjusting for knee pain.  
Significant relationships were also observed between severity of 
radiographic OA using summated scores from the Nottingham LDA and 
continuous measures of US features. The strongest relationship 
observed was between synovial hypertrophy and the global score 
(r=0.71, p<0.01) whereas US effusion showed a more moderate 
relationship (r=0.57, p<0.01). Popliteal cyst size was weakly correlated 
but remained highly significant (r= 0.33, p<0.01). Though direct 
correlations with radiographic severity have not been previously 
UHSRUWHG'¶$JRVWLQRHWDOUHSRUWHGWKDWPRUHVHYHUHUDGLRJUDSKLF
VFRUHV .	/  JUDGH  ZDV DVVRFLDWHG ZLWK D -fold increased 
probability of synovitis. These findings demonstrate that although there 
is a clear association between synovial hypertrophy and the presence 
of knee pain, US features are more strongly associated with 
radiographic OA.  
4.2.4 Follow-up and intervention studies 
Secondary objectives for the study were concerned with the 
responsiveness of US measures. The ability to demonstrate change 
and the extent to which change correlates with other outcome 
measures, is a fundamental consideration if US is to be employed as a 
clinical outcome measure but this has not yet been fully demonstrated 
(Keen, Mease et al. 2011).  
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No longitudinal studies of US features in knee OA over time have been 
reported.  This study carried out follow-up evaluations in participants 
who self-reported a change in symptoms (increase or decrease in knee 
pain) and routinely after 3 months in control and symptomatic OA 
participants. Follow-up analysis was carried out in 116 participants, only 
3 of whom self-reported a change in knee pain.   
Pain severity remained stable for most people and did not change for 
over 60% of participants with OA and 77% of controls. Change in knee 
pain was not associated with a gross change in the presence or 
absence of US features. Additionally, change in pain VAS scores did 
not correlate with changes in measure of effusion, hypertrophy or 
popliteal cyst size.  Change in the depth of effusion was correlated with 
change in synovial hypertrophy and was stronger for those with OA 
(r=0.66, p<.01), reinforcing the relationship between these two features 
that was previously observed in the cross-sectional study.  
The relative stability of knee-pain and symptoms observed during the 
follow-up evaluations prompted the inclusion of an intervention study to 
observe the effects of pain relief following a cortico-steroid injection and 
a placebo injection on US features.  Corticosteroid injections are a safe 
and effective intervention in knee OA. They reduce the symptoms of 
pain within a few days and the effects may last several weeks and in 
some case several months. Though not firmly established, the 
mechanism of action is thought to be mediated in part by an anti-
inflammatory effect on the synovium which may be detected by US 
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examination (Creamer 1999). Corticosteroid injections are a well-
established treatment for pain in OA and are recommended in all 
current guidelines including those by NICE (NICE 2008). Although 
many may not expect an objective change following placebo, there is 
good evidence that placebo produces a marked improvement in pain 
though this is not generally thought to relate to a direct biological effect 
on the synovium (Doherty and Dieppe 2009; Zhang, Nuki et al. 2010). 
However it has been  theorised  that changes to the synovium may 
occur via a central effect whereby increased endogenous 
glucocorticoids are released via the hypothalamic-pituitary-adrenal 
(HPA) axis), resulting in a reduction of local inflammation (Guess, 
Kleinman et al. 2002).  
At present there is a paucity of research to demonstrate change in US 
features following therapeutic interventions in knee OA. A degree of 
responsiveness has been demonstrated for measures of synovial 
hypertrophy and  effusion (Jan, Chai et al. 2006) and popliteal cyst size 
(Acebes, Sánchez-Pernaute et al. 2006) though the measures used 
were somewhat atypical. Song et al (2009) reported no significant 
change in grey-scale US, PD signal, contrast enhanced US or MRI 
measures  following a series of intra-articular injections of Icatibant (a 
bradykinin receptor 2 antagonist) despite a significant pain response.  
The authors suggest that this may be due to Icatibant having an 
analgesic mechanism of action as opposed to an anti-inflammatory 
mechanism.  
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In this current study, significant pain improvements were demonstrated 
following both cortico-steroid and placebo injections.  A response 
FULWHULRQ IRU WKHVWXG\ZDVVHWDW DQDEVROXWH FKDQJHRI PPRQD
100mm VAS. Although this is more generous that the treatment 
response defined by the Osteoarthritis Research Society International 
criteria (Pham, van der Heijde et al. 2004) retrospective examination of 
the data showed that this amounted to only one additional participant 
being classified as responder. 
Synovial hypertrophy was the only US feature to show a statistical 
significant difference from baseline but this was not statistically different 
to change following the placebo injection. As was observed in the 
follow-up evaluation at 3 months, change in pain did not correlate with 
change in US measures, though once again change in effusion was 
strongly correlated with change in synovial hypertrophy (r=0.77, p<.01). 
The presence of US features at baseline was not found to predict 
response following injection. However, it is important to recognise that 
though the size of the sample used was sufficient to detect significant 
change in pain, it may not have been adequately powered to detect 
significant changes in US measures.  
Individual examination of responders to the steroid injection showed 
that more than half showed improved measures of effusion, 
hypertrophy and popliteal cysts size most of which deteriorated again 
when pain returned, indicating some degree of internal responsiveness.  
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When this was examined in the eleven responders to the placebo 
injection, US response was not as evident. Less than half showed an 
improvement in effusion size, around 1 quarter showed an improvement 
in synovial hypertrophy and only 1 out of 3 popliteal cysts improved.   
Change in PD signal was not significant for steroid or placebo 
responders and when it was examined within individuals it had an 
unpredictable occurrence.  
Though it was not the intention of this study to evaluate the efficacy of 
the steroid over the placebo injection, it was of interest to find no 
significant difference in pain response between them. Clinical response 
to placebo is well recognised for patient-reported subjective outcome 
such as OA pain (Zhang, Robertson et al. 2008; Doherty and Dieppe 
2009). Determinants of response to placebo include blinding, effect size 
of the active treatment and invasive route of delivery all of which are 
relevant to this study.  Pooled effect size of intra-articular cortico-steroid 
injection on pain in knee OA is 0.58 (95% CO 0.34, 0.75) and for a 
placebo comparison is 0.39 (0.18, 0.59). However there are other 
contextual considerations which may account for the high placebo 
response observed in this study.  
Response expectancy has demonstrated physiological changes even to 
the point of reversing the pharmacological effect of a drug (Doherty and 
Dieppe 2009). Participants in this study were told that they could expect 
an improvement in their symptoms with both the placebo and steroid 
injection which may last for several weeks or months, added to this, 
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most if not all of the participants were naive to intra-articular injection 
which may well have enhanced their expectancy further.  
In addition to pain response, the length of maintained response was 
also considerably greater in this study. Effect sizes for pain response 
following intra-articular steroid injections in published trials mainly peak 
at 1-2 weeks after injection and decrease considerably after four weeks 
(Zhang, Robertson et al. 2008). In this study, however, mean time from 
injection to pain returning was in the order of 10-12 weeks with no 
significant difference between placebo and steroid. 
The on-going relationship between the participants and the researcher 
is also likely to have a contextual effect on the outcome. Positive 
consultations where patients are given a confident diagnosis following a 
thorough examination, where clinicians are positive about treatment 
outcomes and where outcomes are monitored are all proposed to 
improve response (Doherty and Dieppe 2009). The same is likely to 
apply to research participants, especially when seen in a less hurried 
research setting. 
4.3 Novel findings 
As an adjunct to the analysis of radiographic OA, the presence of 
chondrocalcinosis (CC) was examined as a separate radiological 
feature. CC is usually due to calcium pyrophosphate (CPP) crystal 
deposition (CPPD) within the cartilage and most commonly affects the 
knee joint. Acute inflammatory synovitis secondary to CPP crystal 
shedding from cartilage is well recognised but lower degrees of 
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persistent inflammation may also associate with CC and CPPD.  The 
community prevalence of CC is estimated at 4.5% after adjusting for 
age, knee pain and sex (Neame, Carr et al. 2003). For this study, CC 
was most commonly observed in knees with SOA and was found in  
13% of left and index knees but as many as 18.5% of right knees. CC 
was observed around in 5% of controls knees with no statistical 
difference between controls, knee pain and ROA groups.  
The presence of grey-scale US features were not associated with CC 
but the presence of PD signal conferred a more than 6-fold increase in 
the risk of CC on x-ray (aOR 6.57, 95% CI 1.66, 25.94) after adjusting 
for age, sex, BMI and knee pain. Additional adjustment for the presence 
of ROA did not appreciably alter the risk. 
CPPD can lead to acute CPP crystal synovitis in 10-20% of cases. 
CPPD is typically diagnosed from radiographs but can also be 
visualised using grey-scale US though the accuracy and sensitivity of 
this has not been established. The association observed here between 
PD signal and CC on radiographs suggests that US may be useful in 
identifying not only CC but also the associated inflammation in some 
patients. 
A novel aspect of this thesis was the consideration of knee joint 
stiffness (self-reported as a symptom and as objective biomechanical 
measurements). This is the first to look at associations between self-
reported stiffness, biomechanically assessed stiffness, radiographic OA 
and knee pain. Self-reported stiffness of at least moderate intensity was 
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reported by over 80% of participants with SOA, though prolonged 
stiffness (>30 minutes) was less common (27.3%). Self-reported 
stiffness in ROA (6.3%) was not significantly different to control 
participants (12.2%). Of interest though was how frequently stiffness 
was reported in those with knee pain without structural change (69.5%). 
This was not significantly different to those with symptomatic OA and 
would suggest that self-reported stiffness is more associated with the 
presence of knee pain than radiographic OA. The same patterns were 
also observed for the WOMAC subscale for stiffness. 
Correlations between self-reported stiffness and pain severity showed a 
strong relationship (r=0.80, p<.001). The association was confirmed by 
logistic regression which showed that the odds of knee pain were 
increased 25 fold in those self-reporting moderate knee joint stiffness 
compared to those reporting none or mild stiffness, after adjusting for 
age, sex, BMI and radiographic OA.  
A passive pendulum test was used to calculate 2 biomechanical 
measures of joint stiffness: a stiffness co-efficient and a damping co-
efficient. However a large number of participants were unable to 
perform the passive pendulum test (n=89, 36.6%). Valid testing was 
most successful in control participants where 70% were able to 
complete the test. Smaller numbers of participants with knee pain 
(n=34, 58%), ROA (n=21, 66%) and SOA (n=36, 58%) completed the 
testing successfully but this was not statistically different. Where valid 
testing was conducted the reliability of the testing was shown to be very 
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high (ICC >0.85) and only those participants were included in the 
analysis.  
Stiffness co-efficients were significantly higher in the SOA group 
compared to controls, but there were no other statistical differences 
between groups. Damping and stiffness co-efficients were not 
associated with knee pain, though pain severity had a modest 
correlation with biomechanical stiffness in the SOA group (r=0.39, 
p=.02). Change in pain VAS scores over time did not however correlate 
with change in stiffness co-efficients. 
Radiographic severity was weakly correlated with self-reported stiffness 
(r= 0.23, p<0.01) and stiffness co-efficients (r= 0.19, p<0.05). 
Additionally correlations between self-reported stiffness and stiffness 
and damping co-efficients were weak indicating that they may not be 
measuring the same thing.  
This poses an interesting question, that if biomechanical measures of 
joint stiffness show only a weak relationship with knee pain and 
radiographic OA at best, what are the factors which contribute to 
biomechanically measures of joint stiffness? US and clinical features 
were explored using correlations to identify possible explanatory 
variables.   
The variance observed in the stiffness co-efficients was largely 
explained by BMI and gender, local factors such as radiographic 
severity and knee pain did not contribute significantly. Synovial 
hypertrophy contributed to about 1% of the overall variance in line with 
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previous estimates by Wright and Johns (1960). Caution must be 
applied when interpreting these results, given the number of 
participants who were unable to successfully complete the test, its 
validity as a clinically useful test is questionable.  
 
4.4 Study caveats 
There are several caveats to this study which need to be considered 
when interpreting the reported findings. 
Recruitment to the study was not random; participants were 
purposefully recruited to each study group with the aim of comparing 
four groups with a balanced number of 50 participants. Participants 
were drawn from previous community studies of knee pain for whom a 
variable amount of time (between 3 and 10 years) had passed between 
participation in the original and current study (Limer, Tosh et al. 2009; 
Doherty, Hawkey et al. 2011; Ingham, Zhang et al. 2011). As such, 
previous radiographic and pain status could not predict current x-ray 
and pain status i.e. it would be expected that there would an incidence 
of new radiographic OA and new knee pain, as well as knee pain 
having resolved in others.  Consequently, recruitment to each group 
was unbalanced, with the ROA group under represented and SOA 
group over represented in the final analysis. Estimates suggest that the 
prevalence of ROA lies between 27-44% of the population (Felson, 
Naimark et al. 1987; Dillon, Rasch et al. 2006; Jordan, Helmick et al. 
2007) but identifying those participants is inherently difficult as they are 
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asymptomatic and require radiographs to confirm their status. 
Recruitment was ceased after all previously identified ROA participants 
had been approached, and 183 participants with and without ROA were 
screened for knee pain, in order to prevent further over recruiting of 
control and SOA participants. 
Recruited participants were largely representative of their original 
studies in terms of age though slightly more females than males were 
recruited, and participants in the KP only group were younger than 
other groups by around 15 years. 
The population for the study was drawn from individuals from the 
community which limited the comparison that could be made with 
hospital-based studies.  This was most obvious when comparing the 
UHVXOWV WR WKH ILQGLQJV RI '¶$JRVWLQR HW DO  ZKHUH WKH KRVSLWDO-
based sample was younger, has less severe radiographic changes but 
reported higher levels of pain.  
Comparison with other studies is also limited by variations in definitions 
of US pathology and protocols for scanning and scoring US features. 
This study used the definitions developed by the OMERACT 
ultrasonography and current EULAR guidance which is leading the way 
in terms of developing US as an imaging tool that is useful for both 
clinical trials and clinical practice. It is hoped that in utilising these 
definitions and guidelines that direct comparison with future studies will 
be easier. 
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The allocation of study participants to the four comparison groups was 
not without problems, notably the Kellgren & Lawrence grading to 
classify participants as controls or cases. It has been suggested that 
studies should classify K&L grade 1 as a case rather than a control as it 
has been shown that progression to GHILQLWH2$.	/*UDGHRFFXUV
in 62% of women graded K&L 1 at baseline compared with only 22% of 
controls with K&L Grade 0 (Hart and Spector 2003).  Because this 
study was concerned with the prevalence and association of US 
features with current symptoms and radiographic features participants 
with K&L grade 1 were allocated to the control group. 
The allocation to study groups was also challenging with regards to the 
presence of knee pain. The issue of screening for pain in knee OA is 
old but one that still causes difficulties for researchers especially when 
severity of pain is also considered. Most studies of knee pain require 
symptoms on most days of the previous month and a VAS score of 
FPRQDVFDOH,QLWLDOVFUHHQLQJRISDWLHQWVLQWKLVVWXG\IRXQGWKDW
participants would describe infrequent episodes of moderate knee pain 
(usually related to specific activities) or regular pain (on most days of 
the last month) but of very low severity when scored on the VAS. Not 
wanting to exclude these participants from the analysis,  classification 
of knee pain used a method previously reported in an MRI study of 
synovitis and knee pain (Baker, Grainger et al. 2010). Those reporting 
at least moderate knee pain in any of the five questions within the pain 
subscale were classified as pain positive. Those reporting none or mild 
pain were classified as pain negative.  
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The consequence of this is that the comparison groups are not 
completely ³FOHDQ´ DQG WKDW VRPH FRQWURO DQG 52$ SDUWLFLSDQWV KDYH
mild or infrequent knee pain and the control and KP groups have some 
participants with K&L grade 1 structural change.  
Outcomes from the secondary analysis should be interpreted with 
caution as the analysis was undertaken irrespective of the study 
design. For example, the association between pain and US features in 
all 243 participants was assembled from 4 different groups: control, 
knee pain, radiographic knee OA and symptomatic knee OA. The 
association from such mixed groups may not be representative to the 
true association in the general population. 
A further limitation of the analysis of this study was the use of an overall 
pain VAS score which could only be attributed to the index knee. A 
discrete pain score for each knee would have allowed a separate 
analysis of US features with respect to pain to be carried out in each 
knee.   
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4.5 Future research & Conclusions 
This study represents a significant contribution to the current research 
on the prevalence of US features of inflammation and its association 
with pain and radiographic features. Within the community, US detected 
effusion and synovial hypertrophy were significantly  more common and 
profuse in those with knee pain, ROA and SOA. Popliteal cysts were 
more frequent and larger in those with OA regardles of pain.   
The findings confirm that US detected synovial hypertrophy is an 
independent predictor of knee pain, conferring over a six-fold increase 
in the risk of pain but highlights the stronger associations between 
greyscale features and the presence of ROA.  PD signal which was 
most common observed in SOA knees was not found to be associated 
with pain.  These findings may be a reflection of the community nature 
of the participants who have not yet sought secondary care for their 
knee symptoms and may differ in hospital population. 
However, the nature of these findings question the general assumption 
that 86 IHDWXUHV DUH ³LQIODPPDWRU\´ LQ QDWXUH DQG DUH UHVSRQVLEOH IRU
driving pain in OA, and suggest rather that they are part of the overall 
structural pathology.  
Further research still needs to be carried out before ultrasound findings 
can be used as a primary outcome to measure clinical response or  
guide clinical decisions. 
250 
 
Longitudinal observational studies are required to demonstrate 
temporal changes and associations between US features and the 
development and progression of radiographic OA and symptoms.  This 
has been carried out with some success in MRI studies (Felson 2011) 
and the incorporation of US imaging into a sub-group within an MRI 
study would have the additional benefits of demonstrating external 
validity and allow bony MRI lesions (which strongly associate with 
symptoms) to be considered in the analysis. Additional analysis of 
biochemical biomarkers of inflammation may help substantiate or refute 
any association between US features and inflammation. 
Whether US measures are sensitive to flares in pain is yet to be 
determined. MRI studies have shown that effusion and synovial 
hypertrophy may be sensitive to increasing, but not decreasing knee 
pain (Zhang, Nevitt et al. 2011). The follow-up period for this study was 
limited to 3 months due to time restrictions on the study.  Replication in 
a larger sample over a longer time period may show greater fluctuations 
of pain over time which can address this question.  
The prognostic value of US in knee OA remains uncertain. US features 
were not found to be predictors of response to intra-articular steroid 
injection by this and previous studies (Pendleton, Millar et al. 2008) and 
for longer term-prognosis only effusion was found to be an independent 
predictor of total knee replacement (Conaghan, D'Agostino et al. 2009).  
These results have been based on the dichotomous presence or 
absence of US findings (themselves based on arbitrary cut-off 
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measures). The development and validation of joint based scoring 
systems may better facilitate this and other studies. An adequately 
powered study, which also addresses optimal doses of cortico-steroid 
would help clarify if US features exhibit change following a cortico-
steroid or are prognostic indicator to response.  
In conclusion, this cross-sectional study has shown that grey-scale US 
features which are considered of be suggestive of inflammation are not 
unique to those with painful knee OA but are also frequently found in 
those with ROA. PD signal which is generally regarded as a surrogate 
for inflammation was significantly higher in SOA but was not 
independently associated with pain. US detected synovial hypertrophy 
is an important predictive factor of knee and longitudinal studies are 
required to better understand its contribution to the pain in OA. 
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Ultrasound detected inflammation in knee joints 
Chief Investigator: Prof Michael Doherty,  
Michelle Hall, Dr Weiya Zhang ,  
 
Participant Information Sheet 
Version 5.0 24/11/2010 
 
You are being invited to take part in a research study.  Before you 
decide, it is important for you to understand why the research is being 
done and what it will involve.  Please take time to read the following 
information carefully.  Talk to others about the study if you wish.  Ask us 
if there is anything that is not clear or if you would like further 
information.  Take time to decide whether or not you wish to take part. 
 
Background to the study 
Knee pain and knee OA are both very common in older people and 
often associate with disability.  X-rays have been the most common 
method of assessing the knee joints in people with OA. However x-rays 
only show changes to the bony structure of the joint, and changes to 
VRIWWLVVXHVRIWKHMRLQWVXFKDVWKHMRLQWOLQLQJRU³V\QRYLXP´PD\DOVR
contribute to knee pain, stiffness and the loss of physical function.  
 
Ultrasound scanning is a relatively new way of examining the soft 
tissues of the joint. It allows the measurement of increased joint fluid or 
³HIIXVLRQ´WKLFNHQLQJRIWKHMRLQWOLQLQJDQGLQFUHDVHGEORRGIORZZLWKLQ
the synovium ± all of which reflect joint inflammation. Ultrasound also 
can show changes in ligaments and tendons, the thickness of cartilage 
and the presence of joint osteophytes (bony outgrowths). 
 
Inflammation of the joint lining has been found in about half the people 
with painful OA who are under hospital care for their knee OA. However 
only people with marked symptoms and severe OA tend to get referred 
to hospital clinics, and we have no information on how common 
inflammation is present in the broader spectrum of knee pain and OA 
present in the community.  
 
Also, it is not clear whether inflammation only occurs in knees with OA 
and whether this inflammation contributes directly to pain, stiffness or 
impaired function of the knee.  Nevertheless, it has been suggested 
that people who show inflammation may develop more severe and 
progressive OA and experience greater pain and disability. The 
presence of inflammation therefore could be important in terms of 
diagnosis and management of knee pain and OA. 
 
In this current study we will be using Ultrasound to measure features of 
inflammation in the knees of 200 people some of whom will have OA 
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and or Knee pain and some without to compare groups and re-testing 
some groups and individuals to see how these features change.  
We hope that the results of this study will lead to a better understanding 
of role of inflammation in people with knee pain and knee OA, and how 
useful Ultrasound is in detecting signs of inflammation.  
 
Why have I been chosen? 
We are asking you to take part because we know from the 
investigations that were undertaken on you in the past that you are 
suitable for inclusion into this new study, and that you have agreed to 
for us to keep your details on a database and contact you for this 
reason.   We will need to recruit approximately 200 people in total.   
 
However if any of the following apply to you, then you may not be 
suitable for the study. 
x You have been diagnosed with an inflammatory arthritis e.g. 
rheumatoid arthritis 
x You have been diagnosed with osteoarthritis in the Hip 
x You have had a steroid injection in either of your knees in the 
past 3 months 
x You have had a knee joint replacement 
x You have a neurological condition eg a Stroke or Parkinsons 
disease 
x You have widespread body pain 
x You are confined to a wheel chair 
 
If you are unsure if you are suitable for the study for any other reason, 
please ring us so we can discuss it with you. 
 
Do I have to take part? 
You should only take part in this study if you want to.  It is entirely up to 
you whether or not you wish to take part.  If you do, you will be given 
this information sheet to keep and be asked to sign a consent form.  
You are free to withdraw at any time, without having to give a reason.  
This in no way will influence the medical care you receive at the 
Nottingham University Hospitals NHS Trust.   
 
What does the study involve? 
If you return your reply slip indicating that you are happy to take part in 
this study, you will be contacted by telephone by a researcher to 
arrange an appointment to see you. You will be given an initial 
appointment to see Michelle Hall in Academic Rheumatology at the City 
Hospital which will last around 3.5 hours. We can arrange for prepaid 
taxi transport to bring you to the City Hospital or we can reimburse your 
travel expenses incurred as a result of participating. 
 
You will be asked to not take any anti-inflammatory medication e.g. 
³1HXURIHQ´³,EXSURIHQ´RU³$VSULQ´IRUKRXUVSULRUWRDWWHQGLQJ<RX
make take Paracetamol if needed the night before your appointment, 
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but not on the morning itself. You should bring a list of your current 
medication with you. 
 
You will have a chance to further discuss the study and before you are 
asked to sign and date a consent form and this will be stored in a 
secure office within Academic Rheumatology.  You will also receive a 
copy of the consent form and the information sheet for your own 
records. 
 
During your visit you will have the following assessments taken: 
 
x X-rays of your both your knees (unless you have had previous x-
rays taken in the past year) 
x You will be asked about any knee pain or symptoms that you 
might have, and complete 2 questionnaires about the pain that 
you may have in your knee(s) and your ability to carry out day to 
day activities. 
x Your knees will be examined for swelling and stability of the 
ligaments, the strength of your thigh muscles will be measured 
and your height and weight measured. 
x An Ultrasound scan of both your knees will be taken 
x Knee joint stiffness will be measured by a special camera which 
can track the movement of your knee during a swinging motion. 
This is a system of cameras which track the movement of infra-
UHGPDUNHUVDWWDFKHGWRWKHLQGLYLGXDO¶VOHJXVLQJWDSH7KH
system does not video or take images of the individual 
themselves. You will need to wear loose fitting shorts for this. 
x You will carry out a physical performance test where you will be 
timed while you get up from a chair and walk 50 feet, and while 
you get up from a chair, walk 3 meters, turn around, walk back 
and sit down. 
 
Depending on the outcome of these tests you may also be asked to 
attend for a 3 months later (this repeat assessment will not include x-
rays). In addition if you experience a significant change in your knee 
symptoms, either an increase or decrease in your knee pain that lasts 3 
days or more, in the next 3 months then we would like you to contact us 
so we can repeat the Ultrasound scan and tests on your knees. 
 
As Ultrasound is a relatively new way of assessing OA we need to 
evaluate how reliable it is. To do this some participants will undergo 
repeat ultrasound testing in the afternoon following their initial 
assessment.  This will be repeated (morning and afternoon) on a further 
2 days, one week apart. 
Some participants will also be asked to return at 3 days where they will 
have a repeat ultrasound scan carried out by an expert radiologist. 
 
What are the side effects of any treatment or procedures received 
when taking part? 
There are no side-effects associated with this study. 
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This study involves radiation exposure from a knee x-ray. As part of 
everyday living, everyone is exposed to small amounts of background 
radiation that comes from soil, rocks and outer space (3mSv each 
year). The absorbed radiation dose you will receive in this study 
(0.003mSv) is about the amount you receive in less than one day from 
background radiation. This risk from this dose is small. The radiation 
exposure is not necessary for your medical care but is necessary to 
obtain the research information required. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to taking part in this study. 
 
What are the potential benefits of taking part in this study? 
There is no direct benefit to you in taking part in this study. However, 
the information we obtain might help improve the treatment of people 
with knee OA and knee pain in the future. 
 
Will my taking part in this study be kept confidential? 
Your GP will be informed of your participation in this study and the 
results of any x-rays taken.  
Your details will be kept strictly confidential and you will be given a 
unique identification number if you agree to participate in this study.  
Your personal and medical details will be linked to this number, but this 
link will be held in a secure file within Academic Rheumatology and will 
only be accessed by study personnel. The x-rays of your knees will be 
stored electronLFDOO\ RQ WKH &LW\ +RVSLWDO¶V V\VWHP 3$&6 7KHVH
images would be available for review for clinical purposes in the future 
by other doctors and clinicians based at the City Hospital and QMC 
Campus.   
 
:KDWZLOOKDSSHQLI,GRQ¶WZDQWWRFDUU\RQZLWKWKHstudy? 
Your participation in the study is voluntary and you are free to withdraw 
at any time, without giving reason, and without your legal rights being 
affected. If you withdraw the information collected so far cannot be 
erased and this information may still be used in the project analysis. 
 
What will happen to my information once the study has finished? 
All data will remain confidential and only be linked by your unique ID 
number. It will be stored within Academic Rheumatology, Clinical 
Sciences Building, Nottingham City Hospital. Only study personnel will 
have access to this information. 
 
Who has reviewed the study? 
All medical research is looked at by an independent group of people 
called a Research Ethics Committee to protect your interests. This 
study has been reviewed and given a favourable opinion by Derbyshire  
Research Ethics Committee. 
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Will I be paid for participation in this study? 
Participation in this study is entirely voluntary. You will receive no 
payment for your participation. However we will reimburse the travel 
expenses you incur as a result of visiting the City Hospital to participate 
in the study. 
 
Who is organising and funding the research? 
This study is being organized by Academic Rheumatology, who are a 
department of the University of Nottingham and who are based at the 
City Hospital.   
The study is being funded by the Arthritis Research Campaign UK, a 
charity who gives grants for research into arthritis. 
 
What will happen to the results of the study? 
We hope that the results of this study will lead to a better understanding 
of role of inflammation in people with knee pain and knee OA, and how 
useful Ultrasound is in detecting signs of inflammation.   Results from 
the study will be published in scientific and medical journals. 
 
Contact for Further Information 
If you have any concerns or questions about any aspect of the study, 
you should ask to speak to Michelle Hall, who will do her best to answer 
your questions (telephone number 0115-8231761).   
 
What if there is a problem? 
If you are unhappy or wish to complain about any aspect of this study, 
you should ask to speak to Professor Michael Doherty, Chief 
Investigator, who will do his best to answer your questions. 
 
University of Nottingham, 
Division of Academic Rheumatology 
Clinical Sciences Building 
Nottingham City Hospital 
Nottingham  
NG5 1PB 
Tel 0115 8231756 
 
If you remain unhappy, and wish to complain formally, the Patient 
Advice and Liaison Service provide a confidential service and can 
advise you regarding the NHS Complaints Procedure. 
 
NUH NHS Trust 
c/o PALS 
Freepost 
NEA 14614 
Nottingham 
NG7 1BR 
Freephone: 0800 183 0204 
 
Thank you for taking the time to read this information sheet. 
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CONSENT FORM 
(Version 5.0 24/11/2010) 
 
Ultrasound detected inflammation in knee joints 
Chief Investigator: Prof Michael Doherty Academic Rheumatology 
Michelle Hall, Prof Weiya Zhang 
  
REC ref: 09/H0401/83 
       
 
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet 
Version  5.0 dated 24/11/2010 for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, and without 
my medical care or legal rights being affected. I understand 
that should I withdraw then the information collected so far 
cannot be erased and that this information may still be used in 
the project analysis. 
 
3. I understand that relevant sections of my medical notes and data 
collected in the study may be looked at by authorised 
individuals from the University of Nottingham, the research 
group and regulatory authorities where it is relevant to my 
taking part in this study. I give permission for these individuals 
to have access to these records and to collect, store, analyse 
and publish information obtained from my participation in this 
study. I understand that my personal details will be kept 
confidential. 
 
4. I understand and agree that an x-ray of both my knees at 
Nottingham University Hospital NHS Trust (City Hospital) will 
be taken to determine the severity of osteoarthritis in the joints. 
 
5. I understand and agree that an Ultrasound scan of both my knees 
will be taken to evaluate inflammation in the joints. 
 
6. I understand that my details will be kept on a database in Academic 
Rheumatology so that I may be contacted for future studies 
(optional). 
 
7. I agree to take part in the above study. 
 
 
Name of Participant   Date          Signature 
 
Name of Person taking consent           Date          Signature 
 
 
Please initial box 
ID 
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Response of knee pain and Ultrasound findings 
following intra-articular injection in painful knee 
osteoarthritis. 
 
Chief Investigator: Prof Michael Doherty,  
Sally Doherty, Michelle Hall, Dr Weiya Zhang . 
 
Participant Information Sheet 
Version 6.0 10/05/2011 
 
You are being invited to take part in a research study.  Before you 
decide, it is important for you to understand why the research is being 
done and what it will involve.  Please take time to read the following 
information carefully.  Talk to others about the study if you wish.  Ask us 
if there is anything that is not clear or if you would like further 
information.  Take time to decide whether or not you wish to take part. 
 
Background to the study 
Painful knee osteoarthritis (OA) is a very common and disabling 
condition. X-rays are the usual way of assessing the knee joints in OA 
but the pain people experience is not always matched by the severity of 
the disease on x-ray. We know from previous studies and our ongoing 
Ultrasound study, which you kindly participated in, that people with 
painful knee OA often have swelling and synovitis (inflammation of 
synovium or joint lining), which may contribute to the severity of knee 
pain and disability experienced. For the next phase of this study we are 
looking at the effects of two different intra-articular injections on knee 
pain and ultrasound findings in people with painful knee osteoarthritis. 
 
Intra-articular injections are injections into a joint. Corticosteroid 
injections are commonly given to reduce inflammation, swelling and 
pain within a joint. The injection should give relief within a few days and 
may last for 2 months or longer. Corticosteroids are thought to work by 
acting on synovium so may reduce the swelling and synovitis seen on 
Ultrasound. Saline (placebo) injections can also significantly relieve 
pain in knee OA but they do not contain an active ingredient and so are 
unlikely to have an effect on the synovium.  
 
The study is a randomised cross-over study which means that you will 
receive both the corticosteroid injection and the saline injection in turn, 
but in a random order. Neither you nor the ultrasound assessor will 
know which order you receive the injections (though we can find out if 
we need to). This is because sometimes if participants or the research 
team know the order of the treatments it may affect the results. 
 
Why have I been chosen? 
We are asking you to take part because we know from the 
investigations in the Ultrasound study that you have painful knee OA 
and are suitable, and that you have agreed to for us to contact you to 
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take part in further research. However if any of the following apply to 
you, then you may not be suitable for this part of the study. 
 
x You have had a steroid injection in either of your knees in the 
past 3 months 
x You have had any knee joint surgery in the past 3 months 
x You have had a knee injury in the past 3 months 
 
If you are unsure if you are suitable for the study for any other reason, 
please ring us so we can discuss it with you. 
 
Do I have to take part?  
You should only take part in this study if you want to.  It is entirely up to 
you whether or not you wish to take part.  If you do, you will be given 
this information sheet to keep and be asked to sign a consent form.  
You are free to withdraw at any time, without having to give a reason.  
This in no way will influence the medical care you receive at the 
Nottingham University Hospitals NHS Trust.   
 
What does the study involve? 
If you return your reply slip indicating that you are happy to take part in 
this study, you will be contacted by telephone to arrange an 
appointment with the research team in Academic Rheumatology at the 
City Hospital.  
 
You will have a chance to further discuss the study before you are 
asked to sign and date a consent form. This will be stored in a secure 
office within Academic Rheumatology. You will also receive a copy of 
the consent form and the information sheet for your own records. 
 
During your initial visit you will be asked about your current knee 
symptoms, pain severity and current medication. You will be asked to 
identify which knee is the most painful. We will then ask you to 
complete two questionnaires about your knee pain and an Ultrasound 
examination of both your knees will be carried out. 
 
You will then receive an injection to your most painful knee from Prof 
Doherty. If neither knee is more painful than the other, a knee will be 
randomly chosen (this is like tossing a coin). The injection you receive 
will either contain 1ml (40mg) of a corticosteroid called methyl 
prednisolone or 1ml of 0.9% saline. The order of the injections will be 
randomised and you will not know which injection you receive and 
neither will the person scanning your knee.  
 
You will return for a follow-up visit one week after the initial injection 
and again when your pain severity returns close to the level before your 
injection. This may be several weeks later so we will arrange to 
telephone you on a weekly basis to monitor this.  
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You will then receive a second injection, and return for a follow-up visit 
one week after the injection and again when your pain severity returns 
close to your baseline level.  
 
Each visit should last no longer than 1½ hours. There are five visits in 
total which may be spread over three to six months depending on how 
long your pain-relief lasts. 
 
The following flow chart shows the pathway of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following each injection you can continue with your normal day to day 
activities. You may continue to take your usual knee pain medication if 
required and you should continue with any other usual medication. 
 
You will be asked to not take any anti-inflammatory medication e.g. 
³1HXURIHQ´ ³,EXSURIHQ´ RU ³$VSLULQ´ IRU  KRXUV EHIRUH HDFK
assessment. You may take Paracetamol if needed the night before your 
appointment, but not on the morning itself. 
 
What are the side effects of any treatment or procedures received 
when taking part? 
Side-effects are very unlikely but occasionally people notice a 
worsening in their knee pain within the first 24 hours of the injection. 
This usually settles with a couple of days without treatment.  
Visit 1 
(Baseline) 
Visit 2  
(1 week later) 
 
Visit 3 
(when knee pain returns 
to baseline level) 
Visit 4  
(1 week after 2nd  
injection) 
  Visit 5 
(when knee pain returns 
 to baseline level) 
Ultrasound scan, Pain 
Questionnaires 
& 
1st Injection 
Ultrasound scan & Pain 
Questionnaires 
 
Ultrasound scan, Pain 
Questionnaires 
& 
2nd Injection 
Ultrasound scan & Pain 
Questionnaires 
 
Ultrasound scan & Pain 
Questionnaires 
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Facial flushing may occur in small number of people. 
Some people can feel faint when having an injection, but these will be 
given on a reclined couch by a trained medical doctor. 
There is a negligible (very rare) risk of infection being introduced to the 
joint at the time of an injection. This is the same risk as giving a blood 
sample. The injection will be given using an aseptic (sterile) technique 
to minimise this risk. 
There are no contra-indications for either the cortico-steroid or saline 
injections. You may take other medicines along with both. 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to taking part in this study. 
 
What are the potential benefits of taking part in this study? 
Both the steroid and saline injection are likely to improve your knee 
pain. 
 
Will my taking part in this study be kept confidential? 
Your GP will be informed of your participation in this study.  
Your details will be kept strictly confidential and you will be given a 
unique identification number if you agree to participate in this study.  
Your personal and medical details will be linked to this number, but this 
link will be held in a secure file within Academic Rheumatology and will 
only be accessed by study personnel.  
 
:KDWZLOOKDSSHQLI,GRQ¶WZDQWWRFDUU\RQZLWKWKHVWXG\" 
Your participation in the study is voluntary and you are free to withdraw 
at any time, without giving reason, and without your legal rights being 
affected. If you withdraw the information collected so far cannot be 
erased and this information may still be used in the project analysis. 
 
What will happen to my information once the study has finished? 
All data will remain confidential and only be linked by your unique ID 
number. It will be stored within Academic Rheumatology, Clinical 
Sciences Building, Nottingham City Hospital. Only study personnel will 
have access to this information. 
 
Who has reviewed the study? 
All medical research is looked at by an independent group of people 
called a Research Ethics Committee to protect your interests. This 
study has been reviewed and given a favourable opinion by Derbyshire 
Research Ethics Committee. 
 
Will I be paid for participation in this study? 
Participation in this study is entirely voluntary. You will receive no 
payment for your participation. However we will reimburse the travel 
expenses you incur as a result of visiting the City Hospital to participate 
in the study. 
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Who is organising and funding the research? 
This study is being organised by Academic Rheumatology, who are a 
department of the University of Nottingham and who are based at the 
City Hospital.   
The study is being funded by  Arthritis Research UK, a charity who 
gives grants for research into arthritis. 
 
What will happen to the results of the study? 
We hope that the results of this study will lead to a better understanding 
of role of inflammation in people with knee pain and knee OA, and how 
useful Ultrasound is in monitoring signs of inflammation after intra-
articular injections. Results from the study will be published in scientific 
and medical journals. 
 
Contact for Further Information 
If you have any concerns or questions about any aspect of the study, 
you should ask to speak to Michelle Hall, who will do her best to answer 
your questions (telephone number 0115-8231761).   
 
What if there is a problem? 
If you are unhappy or wish to complain about any aspect of this study, 
you should ask to speak to Professor Michael Doherty, Chief 
Investigator, who will do his best to answer your questions. 
 
University of Nottingham, 
Division of Academic Rheumatology 
Clinical Sciences Building 
Nottingham City Hospital 
Nottingham  
NG5 1PB 
Tel 0115 8231756 
 
If you remain unhappy, and wish to complain formally, the Patient 
Advice and Liaison Service provide a confidential service and can 
advise you regarding the NHS Complaints Procedure. 
 
NUH NHS Trust 
c/o PALS 
Freepost 
NEA 14614 
Nottingham 
NG7 1BR 
Freephone: 0800 183 0204 
 
Thank you for taking the time to read this information sheet. 
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CONSENT FORM 
(Version 6.0 10/05/2011) 
 
Response of knee pain and Ultrasound findings following  
intra-articular injection in  painful knee osteoarthritis 
REC ref: 09/H0401/83 
Chief Investigator: Prof Michael Doherty,  
Sally Doherty, Michelle Hall, Dr Weiya Zhang .  
     
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet 
Version 6.0 dated 10/05/2011 for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, and without 
my medical care or legal rights being affected. I understand 
that should I withdraw then the information collected so far 
cannot be erased and that this information may still be used in 
the project analysis. 
 
3. I understand that relevant sections of my medical notes and data 
collected in the study may be looked at by authorised 
individuals from the University of Nottingham, the research 
group and regulatory authorities where it is relevant to my 
taking part in this study. I give permission for these individuals 
to have access to these records and to collect, store, analyse 
and publish information obtained from my participation in this 
study. I understand that my personal details will be kept 
confidential. 
 
4. I understand and agree that an Ultrasound scan of both my knees 
will be taken to evaluate inflammation in the joints. 
 
5. I understand and agree that I will receive two separate intra-
articular injections of a corticosteroid and a saline placebo in a 
random order. 
 
6. I understand that my details will be kept on a database in Academic 
Rheumatology so that I may be contacted for future studies 
(optional). 
 
7. I agree to take part in the above study. 
 
 
Name of Participant   Date          Signature 
 
Name of Person taking consent           Date          Signature 
 
 
Please initial box 
ID 
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7 APPENDIX 2   
Study questionnaires 
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WOMAC OSTEOARTHRITIS INDEX 
 
SECTION 1: PAIN 
 
The following questions concern the amount of pain you have 
experienced in your knees over the last week. (Please tick one box 
for each item) 
How much pain do you have? 
  None Mild    Moderate Severe Extreme 
1 Walking on a flat 
surface 
     
 None Mild    Moderate Severe Extreme 
2 Going up or down stairs 
     
 None Mild    Moderate Severe Extreme 
3 At night while in bed 
     
 None Mild    Moderate Severe Extreme 
4 Sitting or Lying 
     
 None Mild    Moderate Severe Extreme 
5 Standing upright 
     
 
                                                                                            
SECTION 2: STIFFNESS 
 
The following questions concern the amount of stiffness  (not 
pain) you have experienced in your knees over the last week. 
Stiffness is a sensation of restriction or slowness in the ease with 
which you move your joints. (Please tick one box for each item) 
 
6. How severe is your stiffness after first waking in the morning? 
   
None  Mild Moderate Severe Extreme 
     
7. How severe is your stiffness after sitting, lying or resting later in the 
day? 
   
None  Mild Moderate Severe Extreme 
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SECTION 3: PHYSICAL FUNCTION 
 
The following questions concern your physical function. By this 
we mean your ability to move around and look after your self. For 
each of the following activities, please indicate the degree of 
difficulty you have experienced over the last week due to 
problems with your knees. (Please tick one box for each item) 
 
What degree of difficulty do you have with: 
 
  None Mild    Moderate Severe Extreme 
8. Descending stairs 
     
 None Mild    Moderate Severe Extreme 
9. Ascending stairs 
     
 None Mild    Moderate Severe Extreme 
10. Rising from sitting 
     
 None Mild    Moderate Severe Extreme 
11. Standing 
     
 None Mild    Moderate Severe Extreme 
12. Bending to the floor 
     
  None Mild    Moderate Severe Extreme 
13. Walking on the flat 
     
  None Mild    Moderate Severe Extreme 
14. Getting in/out of car 
 
     
  None Mild    Moderate Severe Extreme 
15. Going shopping 
     
  None Mild    Moderate Severe Extreme 
16. Putting on 
socks/stockings 
     
  None Mild    Moderate Severe Extreme 
17. Rising from bed 
     
  None Mild    Moderate Severe Extreme 
18. Taking off 
socks/stockings 
     
  None Mild    Moderate Severe Extreme 
19. Lying in bed 
     
  None Mild    Moderate Severe Extreme 
20. Getting in/out bath 
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None 
 
 
Mild    
 
 
Moderate 
 
 
Severe 
 
 
Extreme 
21. Sitting 
 
     
  None Mild    Moderate Severe Extreme 
22. Getting on/off toilet 
     
  None Mild    Moderate Severe Extreme 
23. Heavy domestic duties 
     
  None Mild    Moderate Severe Extreme 
24. Light domestic duties 
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Clinical History  
 
Current Knee Pain status 
³+DYH \RX HYHU KDG SDLQ LQ RU DURXQG WKH NQHH RQPRVW GD\V IRU DW
least a month?          Y  /  N 
,IVRKDYH\RXH[SHULHQFHGDQ\SDLQGXULQJWKHODVW\HDU"´    Y  /  N 
Most symptomatic joint             L  /  R / Neither 
Knee Joint Stiffness 
Do you experience knee joint stiffness first thing in the morning?  
          Y  /  N 
If so how long does it usually last?   ___ minutes 
Do you experience knee joint stiffness after rest during the day?   
         Y  /  N 
If so how long does it usually last?  ___ minutes 
Drugs History 
What medication do you usually take? 
 
 
How do you take medication for pain relief?   
Every day  
When pain gets too bad  
Depends on how bad pain is  
Every day when having a bad patch,    
otherwise only as needed 
 
Before bed  
Before exercise  
When did you last take any NSAIDs drugs?  ____________________ 
When did you last take any Paracetamol?     ____________________ 
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Clinical Examination 
Height cm 
 
   
Weight kg 
 
   
  Left Right 
Joint effusion 
 
zero/trace/1/2/3   
Warmth Y/N 
 
   
Clinical 
instability 
Y/N 
ACL   
 PCL 
 
  
 MCL 
 
  
 LCL 
 
  
Deformity  Very bowlegged/bow 
legged/normal/knock-
knee/very knock-
knee 
  
ROM (degrees) Ext 
 
  
 Flex 
 
  
Muscle strength 
(kg) 
Quads   
 H/S 
 
  
Lower leg length  
 
mm mm 
Functional performance  
Get Up and Go  
(GUG) tests 
OQWKHFRPPDQG³*R´from a chair 
without  arm rests,  ask participant 
to stand up and walk as fast as they 
can to a mark 50 feet from the chair. 
  
OQWKHFRPPDQG³*R´from a chair 
without  arm rests,  ask participant 
to stand up and walk as to a mark 
3m from the chair, turn and return to 
the chair and sit down. 
 
Secs 
 
 
Secs 
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Knee Pain Map 
 
Pain Right 
knee 
Left knee 
Localised Use of 1 or 2 fingers to point (patellar, 
superior-medial, inferior-medial, medial joint line, 
superior-lateral, inferior-lateral, lateral joint line, or 
back of knee). 
  
Regional Use of all fingers/hand to show(medial, 
lateral, patellar, or back of the knee). 
 
  
Diffuse unable to identify pain as localized or 
regional in nature. Pain all over. 
 
 
  
 
 
R R L L 
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 Knee Joint Tenderness 
    
 
R R L L 
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Pain VAS 
 
Thinking about the pain you experience in your knee(s) over the 
past 48 hours, put an X on the line below where you think the 
severity of your pain lies. 
 
If you put an X at the left hand end of the line you are indicating that 
you have no pain. 
If you put an X at the right hand end of the line you are indicating that 
your pain is extreme. 
 
NO PAIN  EXTREME PAIN 
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8 APPENDIX 3   
Ultrasound Scanning proforma 
Radiographic scoring sheet 
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US Scanning Proforma 
 LEFT KNEE  RIGHT KNEE 
Suprapatellar   
Effusion Absent  
<4mm  
Present  
>4mm 
mm Absent  
<4mm  
Present  
>4mm 
mm 
Synovial hypertrophy Absent  
<4mm 
Present  
>4mm 
mm Absent  
<4mm 
Present  
>4mm 
mm 
Doppler Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Comments 
 
 
 
 
 
 
Medial joint line 
      
Osteophytes    Femoral Absent  Present  
 
mm Absent  Present  
 
mm 
                        Tibial Absent  Present  
 
mm Absent  Present  
 
mm 
MCL thickness 
 
mm   mm   
Doppler signal Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Comments 
 
 
  
 
Lateral joint Line 
      
Osteophytes    Femoral Absent  Present  
 
mm Absent  Present  
 
mm 
                        Tibial Absent  Present  
 
mm Absent  Present  
 
mm 
LCL thickness 
 
mm   mm   
Doppler signal Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Comments 
 
 
  
 
 
Infrapatellar 
      
Pat tendon thickness 
 
mm   mm   
Bursitis Absent  
 
Present mm Absent  Present mm 
Pes Ans Bursitis Absent  
 
Present mm Absent  Present mm 
Doppler signal Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Comments 
 
 
  
 
Fem Cartilage 
    
Transverse view medial  
mm 
lateral  
mm 
medial  
mm 
lateral  
mm 
Longitudinal view medial  
mm 
lateral  
mm 
medial  
mm 
lateral  
mm 
Comments 
 
 
 
 
 
Posterior 
      
Popliteal cyst Absent 
 <4mm 
Present  
>4mm 
 
mm Absent  
<4mm 
Present  
>4mm 
 
mm 
Doppler signal Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Absent 0 
Mild 1 
Moderate 2 
Marked 3 
Comments 
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Radiographic Scoring Proforma 
 
